KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
kolの履歴書 Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller：統計に影響を与えます
レポートを実行します
| Concept | World rank |
|---|---|
| einstein dvt patients | #1 |
| diagnostic strategies patients | #1 |
| 53 amputations | #1 |
| clinical decision rule | #1 |
| aptt org 10172 | #1 |
| treatment cumulative incidence | #1 |
| women factor leiden | #1 |
| extensive screening cancer | #1 |
| fxainhibitors vka recipients | #1 |
| unexplained dvt patients | #1 |
| respondents lmwh | #1 |
| reduceddose noacs | #1 |
| rnapc2 groups | #1 |
| departments pharmacological prophylaxis | #1 |
| ddimer test | #1 |
| intestinal microbiota coagulation | #1 |
| treatment experimental thrombosis | #1 |
| respondents 60 | #1 |
| simple diagnostic strategy | #1 |
| failure cip | #1 |
| initial heparin edoxaban | #1 |
| probabilityscan | #1 |
| strategies diagnostic management | #1 |
| vitamin anticoagulants | #1 |
| variable d‐dimer thresholds | #1 |
| lmwh delivery | #1 |
| tinaquant assay comparison | #1 |
| tb402 12 kg1 | #1 |
| ddimer levels cdr | #1 |
| uesvt median | #1 |
| clinical probability risk | #1 |
| 97 compression ultrasonography | #1 |
| acenocoumarol heparin | #1 |
| undvt | #1 |
| safety clinical utility | #1 |
| hokusai‐vte cancer study | #1 |
| safety 60 dose | #1 |
| predefined outcomes | #1 |
| cancer patients cdr | #1 |
| clinically relevant disease | #1 |
| 3633 patients edoxaban | #1 |
| early discharge strategies | #1 |
| wellsrule | #1 |
| presentation category | #1 |
| prevention topic guidelines | #1 |
| fxainhibitors | #1 |
| abelacimab | #1 |
| anticoagulant treatment patients | #1 |
| ventilation lung scanning | #1 |
| riskstroponin | #1 |
| ctscanreading | #1 |
| combination cdrscore | #1 |
| quantitative ddimer tests | #1 |
| carriers relative risks | #1 |
| ifngamma pselectin | #1 |
| method factor | #1 |
| cancer patients cancer | #1 |
| acenocoumarol initial treatment | #1 |
| cdr dimer | #1 |
| evaluable patients apixaban | #1 |
| therapeutic doses lmwh | #1 |
| followup overt cancer | #1 |
| uesvt mortality | #1 |
| avidin idrabiotaparinux | #1 |
| cdrscore combination | #1 |
| reduceddose noacs warfarin | #1 |
| matisse clinical trials | #1 |
| heparins vitamin antagonists | #1 |
| dose response apixaban | #1 |
| easier monitoring | #1 |
| s1p1activation | #1 |
| timeperiod | #1 |
| dvt costs | #1 |
| relevant major | #1 |
| hokusaivte trial patients | #1 |
| combined training gps | #1 |
| extended anticoagulation apixaban | #1 |
| guideline adherence justification | #1 |
| ventilation scan chest | #1 |
| double heterozygous carriers | #1 |
| cancer cdr | #1 |
| ldf diagnosis | #1 |
| hokusai‐vte trial | #1 |
| relatives antithrombin | #1 |
| timerequirement | #1 |
| endotoxemia tests | #1 |
| analysis hokusai | #1 |
| oral apixaban treatment | #1 |
| oral anticoagulants phase | #1 |
| patients examiner | #1 |
| 95 intracranial | #1 |
| patients reduceddose noacs | #1 |
| combination cdrs | #1 |
| beneficial lmwh | #1 |
| pulmonary angiography strategies | #1 |
| controlledstudy | #1 |
| subcutaneous length life | #1 |
| idraparinux vitamin antagonist | #1 |
| 9 incidence | #1 |
| severity clinical presentation | #1 |
| monoclonal antibodies apc | #1 |
| pulmonary embolism carriers | #1 |
| travellers thrombosis | #1 |
| ankle brachial prevalence | #1 |
| 0·2 3633 patients | #1 |
| wells clinical | #1 |
| nadroparin patients | #1 |
| coagulation clinical | #1 |
| acenocoumarol efficacy | #1 |
| clinically suspected uedvt | #1 |
| efficiency subgroups | #1 |
| thrice daily gentamicin | #1 |
| cancer patients cvcs | #1 |
| diagnosis deepvein thrombosis | #1 |
| wells simplified | #1 |
| pulmonary embolism fondaparinux | #1 |
| probability normal | #1 |
| 2630 pilots | #1 |
| reported incidence vte | #1 |
| idraparinux recurrent thromboembolism | #1 |
| recurrent dvt dvt | #1 |
| matisse dvt | #1 |
| travel venous thromboembolism | #1 |
| placebo 25mg apixaban | #1 |
| incidence venous | #1 |
| milliliter enoxaparin | #1 |
| dvt symptomatic | #1 |
| lowmolecularweight heparin treatment | #1 |
| tests prevalence abi | #1 |
| coagulation fibrinolytic proteins | #1 |
| cstatistic major bleeding | #1 |
| vte addition | #1 |
| lowmolecularweight heparin category | #1 |
| intravenous injections lmwh | #1 |
| lmwh plasma levels | #1 |
| outpatients symptomatic dvt | #1 |
| ldf cus | #1 |
| khorana | #1 |
| rule dimer | #1 |
| cancer clinical presentation | #1 |
| original wells | #1 |
| uesvt | #1 |
| antithrombotic prescriptions adherence | #1 |
| 393 patients warfarin | #1 |
| vitamin antagonists treatment | #1 |
| 500 org | #1 |
| survival fondaparinux | #1 |
| anticoagulants chemotherapy | #1 |
| embolism sensitivity | #1 |
| edoxaban dalteparin | #1 |
| lmwhmediated | #1 |
| laalleles | #1 |
| pvo ctscan | #1 |
| subcutaneous nadroparin placebo | #1 |
| level loss patency | #1 |
| outcome recurrent | #1 |
| patients advanced malignancy | #1 |
| standard therapy months | #1 |
| lmwh venous thrombosis | #1 |
| anticoagulants probability | #1 |
| venography tests | #1 |
| clinically suspected cancer | #1 |
| oral administration bsf | #1 |
| ili score | #1 |
| pulmonary embolism idraparinux | #1 |
| noncarriers annual incidence | #1 |
| selective ddimer thresholds | #1 |
| vte occurred | #1 |
| crptest | #1 |
| sensitivity 100 percent | #1 |
| lmwh users incidence | #1 |
| dvt 3 | #1 |
| death venous thromboembolism | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| progression svt | #1 |
| polyethylenglycolhirudin | #1 |
| preferred oral anticoagulant | #1 |
| coagulation factors markers | #1 |
| 0·2 edoxabantreated | #1 |
| single‐detector row | #1 |
| revascularisation procedures patients | #1 |
| guidelines abi | #1 |
| anticoagulant treatment vte | #1 |
| ufh grade 1a | #1 |
| referral basis | #1 |
| compression ultrasonography presentation | #1 |
| 95ci tb402 | #1 |
| embolism randomized | #1 |
| fviii venous thromboembolism | #1 |
| clinical presentation category | #1 |
| 8h flight | #1 |
| quantitative ddimer testing | #1 |
| prevalence coagulation | #1 |
| prophylaxis idraparinux | #1 |
| cancer edoxaban | #1 |
| patients uedvt uesvt | #1 |
| dvt impedance plethysmography | #1 |
| questionnaires thrombosis | #1 |
| falsenormal | #1 |
| 95 elevated ctni | #1 |
| flebography | #1 |
| cdr ddimer test | #1 |
| cdr physicians | #1 |
| single dose tb402 | #1 |
| lmwh immobilization | #1 |
| platelets iqr | #1 |
| smoking graft patency | #1 |
| relevant bleeding | #1 |
| study centre duration | #1 |
| advanced malignancy | #1 |
| pvo qscan | #1 |
| symptomatic recurrent vte | #1 |
| wells rule primary | #1 |
| fviii homocysteine | #1 |
| reocclusion antithrombotic drug | #1 |
| baseline characteristics duration | #1 |
| doacs anatomical extent | #1 |
| local radiologist | #1 |
| messages justification | #1 |
| lowmolecularweight heparin 95 | #1 |
| tb402 enoxaparin | #1 |
| compression ultrasound dvt | #1 |
| double reports | #1 |
| standalone ddimer testing | #1 |
| rnapc2 inhibition | #1 |
| acute recurrent patients | #1 |
| avws prevalence | #1 |
| warfarin cstatistic | #1 |
| netherlands vka | #1 |
| prediction models recurrence | #1 |
| malignancy achieved inr | #1 |
| heparins cancer spread | #1 |
| presentation major | #1 |
| acquired atiii deficiency | #1 |
| submassive elevated ctni | #1 |
| symptomatic recurrent | #1 |
| 2479 relatives | #1 |
| selective beta‐blocker treatment | #1 |
| 023 relatives | #1 |
| rabinovpaulin | #1 |
| topic thrombophlebitis | #1 |
| graft patency patency | #1 |
| 5395 patients | #1 |
| 20210a mutation | #1 |
| dose daily edoxaban | #1 |
| doacs factor | #1 |
| pulmonary embolism tests | #1 |
| einsteinextension | #1 |
| simplified geneva score | #1 |
| p0424 | #1 |
| 3633 patients edoxabantreated | #1 |
| avidin placebo | #1 |
| subcutaneous idraparinux | #1 |
| elderly outpatients combination | #1 |
| fxiaso enoxaparin | #1 |
| ventricular dysfunction edoxaban | #1 |
| elevated ctni patients | #1 |
| tsh antitpo | #1 |
| relatives tafi levels | #1 |
| major bleeding cancer | #1 |
| obese controls difference | #1 |
| pioped study study | #1 |
| departments orthopedic surgery | #1 |
| 15 lmwh | #1 |
| longhaul flight | #1 |
| current practise | #1 |
| crp test patients | #1 |
| calf dvt ultrasound | #1 |
| normal ddimer result | #1 |
| carriers recurrence | #1 |
| chest perfusion scintigraphy | #1 |
| 208791 | #1 |
| 0·620·74 | #1 |
| recurrent vte immobilization | #1 |
| fibrinolysis levels | #1 |
| apixaban randomized patients | #1 |
| excluded pulmonary | #1 |
| threemonth incidence | #1 |
| 95 3633 patients | #1 |
| fetal loss carriers | #1 |
| fviii hyperhomocysteinemia | #1 |
| randomized studies efficacy | #1 |
| vte fatal | #1 |
| patients treatment duration | #1 |
| vte procoagulant activity | #1 |
| pyridines recurrence | #1 |
| vte difference | #1 |
| efficacy heparin therapy | #1 |
| severe presentation patients | #1 |
| risk homozygous women | #1 |
| patients unexplained dvt | #1 |
| dimer test | #1 |
| hokusaivte trial | #1 |
| initial heparin patients | #1 |
| edoxaban cancer patients | #1 |
| comparison vidas assay | #1 |
| recommendations dvt | #1 |
| patients ivte | #1 |
| patients advanced prostate | #1 |
| elevated fviii age | #1 |
| mutation arg506 | #1 |
| cancer 145 patients | #1 |
| fviii women | #1 |
| 5‐snp scores | #1 |
| dalteparin major bleeding | #1 |
| proximal extent ipe | #1 |
| wellscdrscore | #1 |
| proximal location ipe | #1 |
| tb402 prevention | #1 |
| ultrasound compression ultrasound | #1 |
| screening carriers | #1 |
| vka recipients | #1 |
| bleeding risk treatment | #1 |
| local radiologist experts | #1 |
| factor viii relatives | #1 |
| vte airline pilots | #1 |
| —brachial | #1 |
| proportion pulmonary embolism | #1 |
| phase doacs | #1 |
| patients mismatched scan | #1 |
| 5mg apixaban | #1 |
| patients inherited thrombophilia | #1 |
| mdct expert radiologist | #1 |
| failure rate efficiency | #1 |
| vitamin antagonist patients | #1 |
| pulmonary embolism basis | #1 |
| dvt anticoagulants | #1 |
| p0001 saline | #1 |
| category fxainhibitors | #1 |
| elevated fviii patients | #1 |
| placebo rnapc2 | #1 |
| age multiple comorbidities | #1 |
| nonhigh cdr | #1 |
| fondaparinux rfviia injection | #1 |
| vte arterial | #1 |
| tests venography | #1 |
| protein resistance control | #1 |
| studies ttr | #1 |
| study ecq | #1 |
| thrombophlebitis tomography | #1 |
| standardintensity vkas doacs | #1 |
| patients antithrombotic prescriptions | #1 |
| specificity pulmonary embolism | #1 |
| diagnostic management patients | #1 |
| duration heparin treatment | #1 |
| age recurrent vte | #1 |
| venous thromboembolism edoxaban | #1 |
| cus strategies | #1 |
| rfviia 3 | #1 |
| abnormal vaginal bleeding | #1 |
| botticelli dvt dose‐ranging | #1 |
| normal dimer | #1 |
| failure diagnostic management | #1 |
| dose rnapc2 | #1 |
| extended treatment edoxaban | #1 |
| scenarioanalysis | #1 |
| achieved inr patients | #1 |
| apixaban extended treatment | #1 |
| lmwh acute treatment | #1 |
| association travel | #1 |
| 560 pharmacies | #1 |
| venous thrombosis vwf | #1 |
| noacs prevention | #1 |
| incidence ctni | #1 |
| false normal | #1 |
| standard treatment idraparinux | #1 |
| rfviia fondaparinux | #1 |
| baseline pvo | #1 |
| older patients cdr | #1 |
| perfusion scan | #1 |
| enoxaparin vkas | #1 |
| conventional therapy enoxaparin | #1 |
| suspected perfusion scan | #1 |
| thromboembolism treated | #1 |
| relative risks carriers | #1 |
| prothrombin individuals | #1 |
| molecular weight fondaparinux | #1 |
| models development studies | #1 |
| thrombophilia patients doacs | #1 |
| idraparinux versus | #1 |
| realtime bmode ultrasonography | #1 |
| treated vka | #1 |
| doses 75 microg | #1 |
| org aptt | #1 |
| ml1 ctpa | #1 |
| vka treatment treatment | #1 |
| 65±9years | #1 |
| rule cdr | #1 |
| popliteal veins sensitivity | #1 |
| crt cvc | #1 |
| upper extremity uedvt | #1 |
| simplified wells rule | #1 |
| venous thromboembolism episode | #1 |
| vkas lmwh | #1 |
| 6 months avidin | #1 |
| diagnostic strategy primary | #1 |
| clinical probability exclusion | #1 |
| probability categories | #1 |
| studies 3 months | #1 |
| wound haematoma | #1 |
| patients protein deficiencies | #1 |
| pulmonary embolism cdr | #1 |
| cdrscore | #1 |
| idraparinux 25 | #1 |
| bleeding rates quality | #1 |
| aged venous | #1 |
| deficiency proteins | #1 |
| efficacy outcome | #1 |
| months standard therapy | #1 |
| adjunct thrombolysis | #1 |
| oral rivaroxaban treatment | #1 |
| normal lung scan | #1 |
| ccus 4 | #1 |
| cancer patients uedvt | #1 |
| 5 years lmwh | #1 |
| cip diagnostic management | #1 |
| patients wells rule | #1 |
| abdominal pelvic strategies | #1 |
| impedance thrombophlebitis | #1 |
| puerperium diagnostic suspicion | #1 |
| 50 rivaroxaban | #1 |
| prospective management study | #1 |
| protein levels mortality | #1 |
| enoxaparin heparin treatment | #1 |
| scores occult cancer | #1 |
| embolism suspected | #1 |
| idraparinux | #1 |
| rfviia idraparinux | #1 |
| venous thrombosis recurrence | #1 |
| residual thrombotic mass | #1 |
| vte trial | #1 |
| ambulatory computers | #1 |
| heparinoid | #1 |
| extended anticoagulation doacs | #1 |
| uedvt terms | #1 |
| time recombinant | #1 |
| international thrombosis experts | #1 |
| lmwh rtap | #1 |
| heparin vitamin antagonist | #1 |
| deepvein thrombosis incidence | #1 |
| clinical uedvt | #1 |
| rnapc2 groups placebo | #1 |
| levels procoagulant factors | #1 |
| subsequent symptomatic cancer | #1 |
| rabinov | #1 |
| plateletactivating antibodies risk | #1 |
| doacs cirrhosis patients | #1 |
| exclusion pulmonary | #1 |
| ecq ankle brachial | #1 |
| smoking patency | #1 |
| proportion 75 years | #1 |
| edoxaban risk factors | #1 |
| mutation relatives | #1 |
| bleeding risk lmwh | #1 |
| leg veins patients | #1 |
| elevated levels fviii | #1 |
| rivaroxaban replacement | #1 |
| combination cdr | #1 |
| uedvt recurrent vte | #1 |
| heparins cancer patients | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| 12 kg1 enoxaparin | #1 |
| doac recipients | #1 |
| feasibility venography | #1 |
| apc resistance tests | #1 |
| recurrence bleeding risk | #1 |
| death category | #1 |
| practiceassistants | #1 |
| fondaparinux unfractionated | #1 |
| treat thrombosis | #1 |
| current comprehensions | #1 |
| cart lower levels | #1 |
| hemorrhage heparin | #1 |
| preference doacs | #1 |
| management study | #1 |
| thrombophilia late loss | #1 |
| relatives elevated levels | #1 |
| warfarin cancer patients | #1 |
| heparin org 10172 | #1 |
| anticoagulation period | #1 |
| sgs pretest probability | #1 |
| recurrent vte doacs | #1 |
| age∗10μg | #1 |
| venous thrombosis hyperglycemia | #1 |
| cdrs patients | #1 |
| influenza case patients | #1 |
| patients normal tests | #1 |
| ldfr symptomatic legs | #1 |
| einsteindvt | #1 |
| decisions duration | #1 |
| sspe proximal | #1 |
| 50 years combination | #1 |
| ddimer test patients | #1 |
| heparins data | #1 |
| coagulationinhibiting | #1 |
| bleeding clinically | #1 |
| consensus strategy strategy | #1 |
| elderly patients dvt | #1 |
| increasing levels ft4 | #1 |
| rivaroxaban acute dvt | #1 |
| qscan 3 weeks | #1 |
| rhir lmwh | #1 |
| ft4 level patients | #1 |
| lmwhs 95 | #1 |
| included patients study | #1 |
| clinically suspected dvt | #1 |
| uesvt recurrent vte | #1 |
| hokusaivte study | #1 |
| ddimer result | #1 |
| superficial thrombophlebitis incidence | #1 |
| deep vein thrombosis | #1 |
| oral edoxaban dose | #1 |
| 123362 | #1 |
| vte risk day | #1 |
| dvt 69 | #1 |
| relatives normal levels | #1 |
| gastrointestinal cancer edoxaban | #1 |
| replacement vka | #1 |
| ivte | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| presenting vte location | #1 |
| elevated biomarkers hospital | #1 |
| patients clinical probability | #1 |
| daily dalteparin treatment | #1 |
| rivaroxaban dvt treatment | #1 |
| presenting location vte | #1 |
| patients compression ultrasonography | #1 |
| nadroparin therapeutic dose | #1 |
| rnapc2 united states | #1 |
| rnapc2 patients | #1 |
| heparin acenocoumarol | #1 |
| protein mortality | #1 |
| absolute thrombotic risk | #1 |
| carriers pulmonary embolism | #1 |
| studies doac treatment | #1 |
| standardintensity vkas | #1 |
| procoagulant factors levels | #1 |
| gogh dvt trial | #1 |
| patients artificial graft | #1 |
| treatment venous | #1 |
| intravenous unfractionated | #1 |
| acute treatment lmwh | #1 |
| low levels ft4 | #1 |
| pulmonary embolism metaanalysis | #1 |
| ivte clinical practice | #1 |
| xainhibitors | #1 |
| fviii normal levels | #1 |
| gentamicin patients netilmicin | #1 |
| dvt 56 | #1 |
| edoxabantreated | #1 |
| ultrasonography leg veins | #1 |
| axa activity 5 | #1 |
| loss subsequent pregnancy | #1 |
| major bleeds vka | #1 |
| thrombosis vte | #1 |
| year prophylaxis | #1 |
| risk percentage points | #1 |
| clinical probability patients | #1 |
| 12 months edoxaban | #1 |
| 378 patients edoxaban | #1 |
| atherosclerosis hemophilia patients | #1 |
| individualized duration | #1 |
| pulmonary embolism role | #1 |
| subsequent diagnosis malignancy | #1 |
| absolute annual incidences | #1 |
| evaluable patients 95 | #1 |
| vkas efficacy | #1 |
| tomography angiography vte | #1 |
| wells rule exclusion | #1 |
| somittrial | #1 |
| cdr ddimer levels | #1 |
| obese hemophilic patients | #1 |
| echocardiography normotensive patients | #1 |
| pvoq | #1 |
| patients khorana | #1 |
| hellp syndrome mutations | #1 |
| wells cdr | #1 |
| prothrombin 20210a mutation | #1 |
| ipe expert radiologists | #1 |
| normal levels fviii | #1 |
| prescriptionbased | #1 |
| presence venous thrombosis | #1 |
| death vte studies | #1 |
| scan pulmonary embolism | #1 |
| thromboembolism 3 | #1 |
| reduceddose noacs stroke | #1 |
| 2 diagnostic management | #1 |
| vka share | #1 |
| laalleles platelets | #1 |
| inr studies | #1 |
| scores riete score | #1 |
| dalteparin vte treatment | #1 |
| positive vte | #1 |
| idraparinux patients | #1 |
| perelated death classification | #1 |
| rivaroxaban lmwh vka | #1 |
| 5 avidin infusion | #1 |
| edoxaban warfarin groups | #1 |
| pulmonary angiography ultrasonography | #1 |
| test venography | #1 |
| tb402 50 | #1 |
| annual incidence patients | #1 |
| equinox study | #1 |
| constans score | #1 |
| distal clots | #1 |
| excluding pulmonary | #1 |
| survival lmwh | #1 |
| xageneration | #1 |
| adjusted dose ufh | #1 |
| cstatistic model discrimination | #1 |
| carriers thrombophilic defects | #1 |
| recurrent vte statin | #1 |
| strategies abdominal pelvic | #1 |
| calfvein thrombi | #1 |
| limited screening 95 | #1 |
| initial treatment patients | #1 |
| vka netherlands | #1 |
| uesvt uedvt | #1 |
| ctscan qscan | #1 |
| successful attenuation | #1 |
| frequency venous thromboembolism | #1 |
| idraparinux standard therapy | #1 |
| patients laalleles | #1 |
| aged nadroparin | #1 |
| matisse trials | #1 |
| elevated cardiac troponins | #1 |
| symptomatic venous | #1 |
| incidental symptomatic vte | #1 |
| enoxaparin primary efficacy | #1 |
| venous thrombosis mutations | #1 |
| compression ultrasonography patients | #1 |
| suspected cdr | #1 |
| cancer patients ufh | #1 |
| combination nonhigh cdr | #1 |
| elevated fviii | #1 |
| compression ultrasonography detection | #1 |
| nondiagnostic lung scan | #1 |
| intracranial clinical presentation | #1 |
| thrombo‐embolic events | #1 |
| infections gentamicin | #1 |
| anticoagulants double | #1 |
| factor viii homocysteine | #1 |
| orthopedic surgery netherlands | #1 |
| withheld | #1 |
| aptt org | #1 |
| pulmonary embolism studies | #1 |
| 250 patients cancer | #1 |
| svt lmwh | #1 |
| vitamin antagonists time | #1 |
| vivo coagulation factor | #1 |
| simplified rule proportion | #1 |
| presenting location women | #1 |
| alternative diagnoses patients | #1 |
| beta thromboglobulin org | #1 |
| fviii vte | #1 |
| obstetric complications relatives | #1 |
| 547253 | #1 |
| total vte patients | #1 |
| apixaban conventional therapy | #1 |
| pulmonary embolism | #1 |
| relatives mutation | #1 |
| long haul flights | #1 |
| control anticardiolipin antibodies | #1 |
| chromogenic endotoxin | #1 |
| rule exclusion | #1 |
| controlled trials thrombophilia | #1 |
| lmwh replacement | #1 |
| abnormal ipg | #1 |
| anticoagulant fondaparinux | #1 |
| perelated death category | #1 |
| women elevated levels | #1 |
| pharmacological methods prophylaxis | #1 |
| individuals air travel | #1 |
| symptomatic legs dvt | #1 |
| fetal loss miscarriage | #1 |
| wellscdr | #1 |
| patients deep | #1 |
| 69 conclusions | #1 |
| idraparinux 6 months | #1 |
| vte study | #1 |
| 7268 patients suspected | #1 |
| plasma concentration fviii | #1 |
| antidote vitamin | #1 |
| idraparinux vte | #1 |
| desogestrelcontaining coagulation factors | #1 |
| pulmonary angiography study | #1 |
| patients malignancy | #1 |
| leg ultrasonography patients | #1 |
| pregnancyrelated complications relatives | #1 |
| non‐invasive diagnostic work‐up | #1 |
| dalteparin 6 months | #1 |
| org heparin | #1 |
| neoplasms heparin | #1 |
| quantitative ddimer test | #1 |
| strategies ultrasonography | #1 |
| casedescription | #1 |
| patients initial heparin | #1 |
| lmwh departments | #1 |
| uesvt patients | #1 |
| vte location | #1 |
| fviii concentration | #1 |
| rivaroxaban standard therapy | #1 |
| d‐dimer level | #1 |
| qscan | #1 |
| venous thrombus growth | #1 |
| 36 papers | #1 |
| vte risk coc | #1 |
| pulmonary embolism life | #1 |
| netherlands 5 years | #1 |
| association protein levels | #1 |
| diagnostic strategies strategies | #1 |
| category death | #1 |
| thromboembolism relatives | #1 |
| early time recurrence | #1 |
| lmprovement | #1 |
| heparin survival | #1 |
| cvc crt | #1 |
| netherlands lmwh | #1 |
| ufh grade | #1 |
| rtap lmwh | #1 |
| heparin initial treatment | #1 |
| combination ddimer testing | #1 |
| 750 μg l1 | #1 |
| efficacy vte | #1 |
| cdr normal | #1 |
| administration lmwh | #1 |
| bleeding einstein | #1 |
| orthopedic thromboprophylaxis | #1 |
| tests pulmonary embolism | #1 |
| prophylaxis crt | #1 |
| enoxaparin tb402 | #1 |
| ddimer test result | #1 |
| previous surveys netherlands | #1 |
| initial treatment dvt | #1 |
| patients retropubic prostatectomy | #1 |
| doacs initial heparin | #1 |
| 00515 | #1 |
| standard therapy rivaroxaban | #1 |
| weight heparinoid | #1 |
| edoxaban east asian | #1 |
| chest perfusion scan | #1 |
| progression vte | #1 |
| role exclusion | #1 |
| normotensive patients studies | #1 |
| 3 rfviia | #1 |
| patients tb402 | #1 |
| thrombosis vitamin | #1 |
| outcome clinically | #1 |
| thiazoles venous | #1 |
| hokusai vte cancer | #1 |
| united states rnapc2 | #1 |
| idrabiotaparinux idraparinux | #1 |
| systematic search cteph | #1 |
| ultrasonography diagnostic | #1 |
| poc test patients | #1 |
| synthetic selective factor | #1 |
| isolated deficiencies proteins | #1 |
| rate recurrent | #1 |
| safety idraparinux | #1 |
| embolism radionuclide | #1 |
| strategy abdominal pelvic | #1 |
| safety outcome | #1 |
| protecht shr | #1 |
| enoxaparin initial treatment | #1 |
| category perelated death | #1 |
| normal venogram | #1 |
| probability cdr | #1 |
| efficacy conventional treatment | #1 |
| types major bleeding | #1 |
| dimer clinical | #1 |
| cancer patients patients | #1 |
| nadroparin aspirin | #1 |
| doubleheterozygotes | #1 |
| enoxaparin vkas treatment | #1 |
| predefined outcomes vte | #1 |
| treatment idraparinux | #1 |
| normal ddimer concentration | #1 |
| relatives normal fviii | #1 |
| amplify trial apixaban | #1 |
| heparin vitamin | #1 |
| probability ventilation | #1 |
| idraparinux placebo | #1 |
| fetal loss stillbirth | #1 |
| lmwh edoxaban | #1 |
| inr range ttr | #1 |
| principal safety | #1 |
| 25mg apixaban | #1 |
| 7268 patients | #1 |
| ddimer test combination | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| segmental subsegmental | #1 |
| amplify trial | #1 |
| embolism wells | #1 |
| patients enoxaparin vkas | #1 |
| vte day | #1 |
| hyperhomocysteinemia relatives | #1 |
| ultrasonography dvt | #1 |
| uedvt clinical | #1 |
| symptomatic pts | #1 |
| probability lung scan | #1 |
| members symptomatic carriers | #1 |
| asymptomatic extension | #1 |
| patency smokers | #1 |
| patients acute recurrent | #1 |
| prolactin venous thrombosis | #1 |
| silent dvt | #1 |
| patients tests prevalence | #1 |
| factual hemorrhage heparin | #1 |
| d‐dimer test | #1 |
| mortality postthrombotic symptoms | #1 |
| wells rules | #1 |
| activecontrol placebo | #1 |
| bmi fondaparinux | #1 |
| heparins inhibition | #1 |
| postthrombotic symptoms patients | #1 |
| extra hospital visits | #1 |
| inherited thrombophilia patients | #1 |
| venous thrombosis pregnancy | #1 |
| suspected symptomatic | #1 |
| 3 idraparinux | #1 |
| intrinsic coagulation vivo | #1 |
| heparin initial | #1 |
| patients idraparinux | #1 |
| recurrence major bleeding | #1 |
| recurrent thrombosis pts | #1 |
| sustained antithrombotic effects | #1 |
| travel‐related venous thrombosis | #1 |
| venous thromboembolism idraparinux | #1 |
| intensity vkas doacs | #1 |
| women edoxaban | #1 |
| avidin vte | #1 |
| ultrasound strategies patients | #1 |
| compression ultrasonography | #1 |
| iii plg | #1 |
| risk pulmonary embolism | #1 |
| dimer result | #1 |
| presentation 1 week | #1 |
| submassive incidence | #1 |
| venography feasibility | #1 |
| suspected deep | #1 |
| idraparinux months | #1 |
| apc resistance factor | #1 |
| quantitative dimer | #1 |
| unexplained dvt | #1 |
| animal female heparin | #1 |
| suspected upper | #2 |
| efficiency original score | #2 |
| interleukin‐10 response | #2 |
| relevant patient subgroups | #2 |
| months 25 | #2 |
| exclusion pulmonary embolism | #2 |
| embolism primary | #2 |
| venographically | #2 |
| endogenous activated protein | #2 |
| surgical casts | #2 |
| nct00633893 | #2 |
| rivaroxaban thiazoles | #2 |
| enoxaparin warfarin | #2 |
| duration anticoagulant treatment | #2 |
| resource utilisation treatment | #2 |
| measurement ankle brachial | #2 |
| healthcare settings findings | #2 |
| diagnostic lung | #2 |
| computerized impedance | #2 |
| plasma d‐dimer concentration | #2 |
| venous | #2 |
| exposure flights | #2 |
| common alternative diagnoses | #2 |
| mutations cleavage sites | #2 |
| vte elevated fviii | #2 |
| death vte | #2 |
| cha2ds2vasc nri | #2 |
| analysis venous | #2 |
| arterial thrombotic disease | #2 |
| recombinant hirudin cgp | #2 |
| pravastatin therapy children | #2 |
| embolism safely | #2 |
| clinical pretest probability | #2 |
| n832 | #2 |
| central localization | #2 |
| cdr wells cdr | #2 |
| quality warfarin treatment | #2 |
| ufh 6 months | #2 |
| subsegmental emboli | #2 |
| antagonists vka | #2 |
| thrombophilic disorders | #2 |
| vte svt | #2 |
| efficiency diagnostic strategies | #2 |
| clinically suspected | #2 |
| lowmolecularweight heparin women | #2 |
| safety pravastatin therapy | #2 |
| performance constans rule | #2 |
| coagulation fibrinolytic | #2 |
| patients prior vte | #2 |
| fvl carriers carriers | #2 |
| oral direct inhibitors | #2 |
| thyroid hormone coagulation | #2 |
| recurrent vte risk | #2 |
| rivaroxaban 30 bid | #2 |
| dimer thresholds | #2 |
| plasmin activity inhibition | #2 |
| women therapeutic doses | #2 |
| c1173t dimorphism | #2 |
| amuse strategy | #2 |
| 95 comparator individuals | #2 |
| exclude pulmonary | #2 |
| received edoxaban | #2 |
| treatment deep | #2 |
| efficiency strategy | #2 |
| employees longhaul flight | #2 |
| mutation 35 | #2 |
| f5 r506q | #2 |
| uedvt cancer patients | #2 |
| n1423 | #2 |
| current clinical challenges | #2 |
| wells cdr patients | #2 |
| extended constans score | #2 |
| fibrinolysis influenza | #2 |
| embolism deep | #2 |
| treated anticoagulants | #2 |
| prolactin relation | #2 |
| blood coagulation rnapc2 | #2 |
| 95 0·2 | #2 |
| bleeding edoxaban | #2 |
| apixaban lmwh vka | #2 |
| statins recurrent vte | #2 |
| major bleeding cindexes | #2 |
| referred patients secondary | #2 |
| uedvt efficiency | #2 |
| risk deep | #2 |
| beta‐receptor blockade | #2 |
| intrinsic cascade | #2 |
| nematode anticoagulant | #2 |
| enoxaparin difference | #2 |
| idraparinux vitamin | #2 |
| clinical probability estimate | #2 |
| hospitalbased strategies | #2 |
| fviii increased risk | #2 |
| angioplasty clopidogrel | #2 |
| vitamin antagonist rivaroxaban | #2 |
| lmwh efficacy | #2 |
| global public awareness | #2 |
| major clinically | #2 |
| regression pravastatin | #2 |
| rfviia injection rfviia | #2 |
| 95 dvt | #2 |
| coumarin sensitivity | #2 |
| crnm bleeds | #2 |
| 17 apixaban | #2 |
| subcutaneous length | #2 |
| bleeding rate patients | #2 |
| vitamin antagonists quality | #2 |
| 3306 patients | #2 |
| lmwh users | #2 |
| khorana protecht | #2 |
| heparin treatment influenza | #2 |
| major bleeding edoxaban | #2 |
| fibrinolysis pentoxifylline | #2 |
| adapted ddimer thresholds | #2 |
| 8292 patients | #2 |
| euro138 | #2 |
| biomarkers casecontrol studies | #2 |
| sspe patients patients | #2 |
| hyperglycemia diagnosis | #2 |
| sr34006 | #2 |
| cdr variables cdr | #2 |
| gcpg | #2 |
| suspected pulmonary | #2 |
| scan normal | #2 |
| recurrence thromboembolism | #2 |
| hokusai vte | #2 |
| administration rviia | #2 |
| ddimer determination | #2 |
| low‐molecular‐weight heparin | #2 |
| normohomocysteinemic relatives | #2 |
| major bleeding intermediate | #2 |
| hmb primary outcome | #2 |
| vte 1000 personyears | #2 |
| pregnancy coc | #2 |
| limits cancer | #2 |
| impedance plethysmography patients | #2 |
| intermediate phenotype vte | #2 |
| travel venous | #2 |
| vte 12 | #2 |
| levels coagulation factors | #2 |
| rnapc2 | #2 |
| patients low probability | #2 |
| venous thrombophlebitis | #2 |
| comparator individuals 95 | #2 |
| ageadjusted ddimer testing | #2 |
| recombinant nematode | #2 |
| thrombosis normal | #2 |
| compression doppler | #2 |
| prothrombin pulmonary embolism | #2 |
| factor iia | #2 |
| influenza coagulation | #2 |
| graft occlusion patients | #2 |
| test cancer | #2 |
| patients oral factor | #2 |
| acquired antithrombin | #2 |
| vidas assay | #2 |
| patients hemorr2hages | #2 |
| negative ageadjusted ddimer | #2 |
| uedvt performance | #2 |
| 20210a mutations | #2 |
| hellp syndrome prevalence | #2 |
| raskob | #2 |
| life treatment duration | #2 |
| endotoxininduced activation coagulation | #2 |
| mutations propeptide | #2 |
| amadeus study | #2 |
| single administration tb402 | #2 |
| 8 wk risk | #2 |
| score dimer | #2 |
| sustained antithrombotic | #2 |
| computed venous | #2 |
| secondary efficiency | #2 |
| suspected pulmonary embolism | #2 |
| events severe | #2 |
| rnapc2 doses | #2 |
| primary hospitalbased strategies | #2 |
| rule proportion | #2 |
| concomitant thrombophilic | #2 |
| mild risk factor | #2 |
| secondary strategies | #2 |
| heparin effective | #2 |
| age‐adjusted d‐dimer testing | #2 |
| bleeding complications treatment | #2 |
| incidence recurrent | #2 |
| presentation dvt | #2 |
| vte orthopedic surgery | #2 |
| pulmonary embolism efficacy | #2 |
| hasbled score hemorr2hages | #2 |
| inflammation neutrophils thrombosis | #2 |
| thromboinflammation cardiovascular disease | #2 |
| ate cancer patients | #2 |
| ultrasonography patients | #2 |
| blood coagulation inhibition | #2 |
| apixaban enoxaparin warfarin | #2 |
| hemorr2hages atria scores | #2 |
| incidental vte | #2 |
| ventilation scanning | #2 |
| simplired test | #2 |
| hokusai vtecancer study | #2 |
| levothyroxine exposure | #2 |
| coagulation factors prolactin | #2 |
| risk khorana | #2 |
| primary healthcare secondary | #2 |
| patients abi measurement | #2 |
| relation coagulation factors | #2 |
| patients peripheral graft | #2 |
| crd42017056309 | #2 |
| normal ddimer test | #2 |
| duration anticoagulant | #2 |
| clinical prediction model | #2 |
| recurrent deep | #2 |
| 6 months scores | #2 |
| annual incidences | #2 |
| treated edoxaban | #2 |
| standardised time intervals | #2 |
| thromboembolism thrombophilia | #2 |
| outcome symptomatic | #2 |
| gauge plethysmography | #2 |
| ddimer assay | #2 |
| risk anticoagulation therapy | #2 |
| absolute incidence | #2 |
| uptake noacs | #2 |
| composite scores area | #2 |
| ufh survival | #2 |
| screening fvl | #2 |
| tinaquant vidas | #2 |
| medscape | #2 |
| wells cdr cdr | #2 |
| decision rule | #2 |
| bleeding occurred | #2 |
| anticoagulated patients permanent | #2 |
| impedance plethysmography diagnosis | #2 |
| major bleeding recurrent | #2 |
| heparin compounds | #2 |
| pregnancy venous thrombosis | #2 |
| incidental venous | #2 |
| 95 cancer patients | #2 |
| pulmonary embolism asthma | #2 |
| rule combined | #2 |
| patients khorana score | #2 |
| protein rnapc2 | #2 |
| thrombophilic defects risk | #2 |
| simplified wells | #2 |
| undiagnosed malignancy | #2 |
| mdct reference standard | #2 |
| pharmacological strategies | #2 |
| brain metastases doacs | #2 |
| cancer recurrent vte | #2 |
| venous thromboembolism enoxaparin | #2 |
| deficiencies proteins | #2 |
| model cancer patients | #2 |
| plasma concentrations endotoxin | #2 |
| vein compressibility | #2 |
| lower clinical utility | #2 |
| serum tnf activity | #2 |
| primary efficacy outcome | #2 |
| fibrinolytic proteins | #2 |
| heparin nadroparin | #2 |
| pentasaccharide fondaparinux | #2 |
| years 36 | #2 |
| influenza prothrombotic state | #2 |
| heparin administered | #2 |
| treatment ttr | #2 |
| warfarintreated | #2 |
| cancer addition | #2 |
| pulmonary embolism purpose | #2 |
| nonpermanent heart failure | #2 |
| failure rate strategy | #2 |
| alife study | #2 |
| symptomatic outpatients | #2 |
| principal safety outcome | #2 |
| age annual incidence | #3 |
| crt cancer patients | #3 |
| single diagnostic | #3 |
| recurrence thrombophlebitis | #3 |
| ddimer assays | #3 |
| extensive screening | #3 |
| cancer randomised trials | #3 |
| antithrombin iii concentrate | #3 |
| dimer blood | #3 |
| discontinuation ufh | #3 |
| low probability models | #3 |
| presenting location | #3 |
| sensitivity compression | #3 |
| venous thrombosis positive | #3 |
| composite stroke | #3 |
| safety acenocoumarol | #3 |
| dvt hip | #3 |
| patients 6575 years | #3 |
| venous arterial | #3 |
| prevalence hemostatic abnormalities | #3 |
| dalteparin difference | #3 |
| prolactin controls | #3 |
| fxiaso | #3 |
| pulmonary embolism models | #3 |
| placebo n4 | #3 |
| patients ultrasonography | #3 |
| subcutaneous fondaparinux | #3 |
| approaches primary | #3 |
| female hemorrhage humans | #3 |
| safely exclude | #3 |
| lowmolecularweight heparin placebo | #3 |
| venous thromboembolism thrombophilia | #3 |
| pulmonary embolism gestalt | #3 |
| intravenous loading dose | #3 |
| ddimer threshold | #3 |
| pph lmwh | #3 |
| female humans inhibitors | #3 |
| prevalence avws | #3 |
| treatment vka | #3 |
| healthy donor fmt | #3 |
| gestalt 95 | #3 |
| einstein studies | #3 |
| venous thromboembolism apixaban | #3 |
| studies cus strategies | #3 |
| hasbled | #3 |
| lmwh | #3 |
| outpatients dvt | #3 |
| bleeding major | #3 |
| impedance predictive | #3 |
| tinaquant assay | #3 |
| baseline values placebo | #3 |
| safely excluded | #3 |
| death clinical studies | #3 |
| patients ft4 level | #3 |
| thrombophlebitis treatment | #3 |
| hf severity risk | #3 |
| venous thrombosis travel | #3 |
| cardiac troponine | #3 |
| 12month study period | #3 |
| ipe cancer patients | #3 |
| thombosis | #3 |
| apc protective | #3 |
| 3month vte incidence | #3 |
| recombinant hirudin rhir | #3 |
| treatment lowmolecularweight heparin | #3 |
| warfarin subgroup | #3 |
| enoxaparin follow | #3 |
| activecontrol | #3 |
| vte major burden | #3 |
| dvt primary | #3 |
| capillary blood sample | #3 |
| chemotherapy prophylaxis | #3 |
| products follow | #3 |
| protein thrombophilia | #3 |
| factor viiic | #3 |
| mechanisms heparin | #3 |
| time venous thrombosis | #3 |
| pulmonary embolism primary | #3 |
| treatment vte recurrence | #3 |
| 3month incidence | #3 |
| administration rnapc2 | #3 |
| endogenous apc | #3 |
| pad smokers | #3 |
| rnapc2 fviia | #3 |
| nadroparin placebo | #3 |
| “gestalt | #3 |
| nct00643201 | #3 |
| 20210ga | #3 |
| vte venous thrombosis | #3 |
| axa activity | #3 |
| tfindependent | #3 |
| topic heparin heparin | #3 |
| recurrent thromboembolic | #3 |
| idiopathic venous | #3 |
| definition perelated death | #3 |
| 02011 | #3 |
| standard therapy treatment | #3 |
| dvt major | #3 |
| thrombophilic defect | #3 |
| safely | #3 |
| coagulation influence | #3 |
| negative predictive proportion | #3 |
| patients proximalvein thrombosis | #3 |
| coagulation air travel | #3 |
| venous thrombosis cancer | #3 |
| users incidence | #3 |
| adult patients vte | #3 |
| heparins cancer | #3 |
| primary rule | #3 |
| desogestrelcontaining | #3 |
| vte denmark | #3 |
| mutation venous | #3 |
| favour lmwh | #3 |
| idrabiotaparinux warfarin | #3 |
| incidental pulmonary embolism | #3 |
| knee factor | #3 |
| multiple comorbidities polypharmacy | #3 |
| lmwh pph | #3 |
| studies hemorrhage | #3 |
| vte low | #3 |
| 3633 patients | #3 |
| combination wells score | #3 |
| dvt systematic differences | #3 |
| revised geneva efficiency | #3 |
| dose reduction edoxaban | #3 |
| thiophenes venous | #3 |
| patients 6 months | #3 |
| subcutaneous lmwh | #3 |
| failurerate | #3 |
| efficacy heparin | #3 |
| patients wells | #3 |
| ventilation scan | #3 |
| treatment vitamin antagonists | #3 |
| vte performance | #3 |
| atria hemorr2hages | #3 |
| dip placebo | #3 |
| 6575 years | #3 |
| primary wells rule | #3 |
| incidence total vte | #3 |
| cancer active cancer | #3 |
| probability dimer | #3 |
| factors prothrombin | #3 |
| einstein patients | #3 |
| compensated dic | #3 |
| outcome venous | #3 |
| proximalvein thrombosis | #3 |
| lowmolecularweight humans length | #3 |
| bleeding 3 | #3 |
| einstein dvt | #3 |
| iii deficiency | #3 |
| alternative diagnoses | #3 |
| ctnt risk stratification | #3 |
| diagnosis pulmonary | #3 |
| thromboembolism low | #3 |
| incidence enoxaparin | #3 |
| stable acute | #3 |
| thromboembolism background | #3 |
| cancer patients ate | #3 |
| tb‐402 | #3 |
| patients venous | #3 |
| travel venous thrombosis | #3 |
| pulmonary embolism‐related death | #3 |
| ultrasonography strategies | #3 |
| svt vte | #3 |
| 100 years year | #3 |
| plethysmography impedance | #3 |
| idrabiotaparinux | #3 |
| hokusai‐vte | #3 |
| older children vte | #3 |
| gestalt probability | #3 |
| patients incidental vte | #3 |
| clinical models patients | #3 |
| simplified wells specificity | #3 |
| monoclonal replacement | #3 |
| deep vein | #3 |
| treatment low | #3 |
| platelet agents | #3 |
| introduction mdct | #3 |
| normal result | #3 |
| inhibition blood coagulation | #3 |
| patients gastrointestinal cancer | #3 |
| vte 3 | #3 |
| normal ctnt presentation | #3 |
| wells rule dvt | #3 |
| selectine | #3 |
| patients venography | #3 |
| oral hormonal cross | #3 |
| dvt einstein | #3 |
| embolism‐related | #3 |
| ft4 risk | #3 |
| vein thrombosis | #3 |
| detection dvt | #3 |
| diagnosis deep | #3 |
| outpatient treatment dvt | #3 |
| diagnosis pulmonary embolism | #3 |
| cohort study employees | #3 |
| venous thromboembolism | #3 |
| heparin edoxaban | #3 |
| influence heparins | #3 |
| cdr combination | #3 |
| predictable pharmacokinetics | #3 |
| strategies efficiency | #3 |
| cancer patients ipe | #3 |
| wells rule gestalt | #3 |
| 95 wells rule | #3 |
| therapy venous | #3 |
| heparin heparin | #3 |
| noacs netherlands | #4 |
| 150 microg levonorgestrel | #4 |
| questionnaires venous | #4 |
| chemotherapy vte prophylaxis | #4 |
| clot lysis patients | #4 |
| 335 patients | #4 |
| patients clinically | #4 |
| disease vte | #4 |
| chemotherapy shr | #4 |
| risk vkas | #4 |
| embolism dimer | #4 |
| lowmolecular weight heparins | #4 |
| vte total | #4 |
| patients alternative diagnosis | #4 |
| ageadjusted cutoff patients | #4 |
| refuted | #4 |
| vte treatment patients | #4 |
| population rivaroxaban | #4 |
| rfviia injection | #4 |
| thrombosis uedvt | #4 |
| vte highincome countries | #4 |
| preexisting heparin | #4 |
| disease burden vte | #4 |
| patients edoxaban | #4 |
| 35±4 | #4 |
| received warfarin | #4 |
| criteria dose reduction | #4 |
| women apc resistance | #4 |
| cleavage sites apc | #4 |
| embolism tomography | #4 |
| treatment unfractionated heparin | #4 |
| patients nonpermanent | #4 |
| 3587 | #4 |
| abdomen relationship | #4 |
| enoxaparin female humans | #4 |
| symptomatic deep | #4 |
| thromboembolism factor | #4 |
| episode venous | #4 |
| lowmolecularweight heparin | #4 |
| ddimer assay patients | #4 |
| travel thrombosis | #4 |
| vitamin antagonists patients | #4 |
| patients fondaparinux | #4 |
| cancer vwf | #4 |
| patients submassive | #4 |
| patients crcl 60 | #4 |
| protecht | #4 |
| hemostatic profile | #4 |
| leiden carriers | #4 |
| vte netherlands | #4 |
| idiopathic venous thrombosis | #4 |
| diagnostic management strategies | #4 |
| lmwh cancer patients | #4 |
| “reversal | #4 |
| primary pulmonary embolism | #4 |
| serial impedance plethysmography | #4 |
| oral rivaroxaban | #4 |
| apixaban efficacy | #4 |
| chromogenic compounds | #4 |
| coagulation endotoxin | #4 |
| thrombosis deep | #4 |
| measurement abi | #4 |
| series venograms | #4 |
| thromboembolism study | #4 |
| serial impedance | #4 |
| control anticoagulation | #4 |
| fibrin generation test | #4 |
| global burden vte | #4 |
| recurrent vte months | #4 |
| vitamin antagonist treatment | #4 |
| hyperhomocysteinemic relatives | #4 |
| proximal patients | #4 |
| dimer assays | #4 |
| thromboembolism arterial | #4 |
| dutch orthopedic | #4 |
| venous thrombosis levels | #4 |
| patients dimer | #4 |
| daily netilmicin | #4 |
| estrogen therapy patients | #4 |
| clinically relevant bleeding | #4 |
| venography patients | #4 |
| thrombophilic families | #4 |
| arterial thrombotic | #4 |
| 6 months prophylaxis | #4 |
| enoxaparin day | #4 |
| death survey | #4 |
| rivaroxaban 20 | #4 |
| levels ft4 | #4 |
| chinese korean ethnicity | #4 |
| thromboembolism systematic | #4 |
| life duration | #4 |
| vitamin antagonists | #4 |
| noacs cancer patients | #4 |
| rviia thrombin generation | #4 |
| patients venous thromboembolism | #4 |
| global disease burden | #4 |
| 0651 | #4 |
| diagnostic management | #4 |
| advanced cancer 95 | #4 |
| embolism background | #4 |
| vka treatment | #4 |
| predilution postdilution | #4 |
| negative point | #4 |
| rule pulmonary | #4 |
| point dimer | #4 |
| total vte | #4 |
| thrombosis symptomatic | #4 |
| contraindications treatment | #4 |
| diagnosis uedvt | #4 |
| venous thromboembolism patients | #4 |
| patient education treatment | #4 |
| gramnegative bacteria humans | #4 |
| thromboembolism vitamin | #4 |
| thrombophilia 95 | #4 |
| clot resolution | #4 |
| warfarin 3 months | #4 |
| chads2 p0001 | #4 |
| amadeus trial | #4 |
| risk occult cancer | #4 |
| activation fibrinolytic | #4 |
| netherlands pulmonary | #4 |
| dose noacs | #4 |
| doac studies | #4 |
| mbe patients | #4 |
| edoxaban patients | #4 |
| thromboembolism treatment | #4 |
| prophylaxis lmwh | #4 |
| probability prospective | #4 |
| patient category | #4 |
| thrombosis air | #4 |
| pregnancies carriers | #4 |
| ultrasonography venous | #4 |
| hemorr2hages | #4 |
| women normal levels | #4 |
| 10172 | #4 |
| extended treatment | #4 |
| embolism roc | #4 |
| primary failure rate | #4 |
| thrombosis ischemic stroke | #4 |
| postthrombotic symptoms | #4 |
| impedance plethysmography | #4 |
| tinaquant | #4 |
| procoagulant factors | #4 |
| vte global burden | #4 |
| lmwh female heparin | #4 |
| 150 microg desogestrel | #4 |
| thromboembolism occurred | #4 |
| patients primary healthcare | #4 |
| coagulation factors risk | #4 |
| sankyo | #4 |
| bleeding anticoagulants | #4 |
| lmwhs standard heparin | #4 |
| diagnostic prediction models | #4 |
| vte global | #4 |
| safety pravastatin | #4 |
| nct00571649 | #4 |
| specificity thrombophlebitis | #5 |
| efficiency patients | #5 |
| recurrent dvt patients | #5 |
| treatment fondaparinux | #5 |
| pad smoking | #5 |
| thromboembolism idraparinux | #5 |
| thrombosis primary | #5 |
| bleeding cancer | #5 |
| cancer strategy | #5 |
| cgp 39393 | #5 |
| southern latin america | #5 |
| preschool contraceptives | #5 |
| antithrombotic drug treatment | #5 |
| elevated plasma level | #5 |
| patients recurrent dvt | #5 |
| secondary venous thrombosis | #5 |
| asymptomatic carriers mutation | #5 |
| low‐molecular‐weight | #5 |
| diagnosis questionnaire | #5 |
| 2 rules | #5 |
| isolated calfvein thrombosis | #5 |
| thromboembolism | #5 |
| phlebography plethysmography | #5 |
| suspected uedvt | #5 |
| pregnancy pph | #5 |
| dvt prevalence | #5 |
| daiichi sankyo | #5 |
| clinical presentation clinical | #5 |
| 8292 | #5 |
| patients pulmonary embolism | #5 |
| ventricular dysfunction echocardiography | #5 |
| thrombosis leg | #5 |
| hirudin treatment | #5 |
| patients wells score | #5 |
| severe pph women | #5 |
| endotoxin testing | #5 |
| secondary dvt | #5 |
| endotoxin chimpanzees | #5 |
| thrombophlebitis ultrasonography | #5 |
| thrombosis upper | #5 |
| inhibition plasminogen activation | #5 |
| transfusion blood loss | #5 |
| treatment acute dvt | #5 |
| patients subtherapeutic | #5 |
| compression ultrasound | #5 |
| normal ctpa | #5 |
| predilution | #5 |
| vte factor | #5 |
| fviia rnapc2 | #5 |
| deepvein thrombosis | #5 |
| adjusted dimer | #5 |
| venous thromboembolism studies | #5 |
| panwards | #5 |
| women warfarin | #5 |
| pulmonary embolism patients | #5 |
| 8491 | #5 |
| outpatients hospital | #5 |
| thromboembolism studies | #5 |
| patients parenteral anticoagulants | #5 |
| cdr patients | #5 |
| vte patients cancer | #5 |
| rivaroxaban enoxaparin vka | #5 |
| upper extremity thrombosis | #5 |
| clinical probability assessment | #5 |
| thromboembolism thrombosis | #5 |
| lmwh recommended | #5 |
| day rivaroxaban | #5 |
| fviii families | #5 |
| heparin compared | #5 |
| outcome major | #5 |
| risk prediction scores | #5 |
| hokusai | #5 |
| fh patients cvd | #5 |
| low molecularweight humans | #5 |
| incidence prognostic significance | #5 |
| factor leiden 95 | #5 |
| patients superficial thrombophlebitis | #5 |
| molecularweight heparin | #5 |
| sensitivity negative predictive | #5 |
| netilmicin patients | #5 |
| vte 6 | #5 |
| ft4 level | #5 |
| gestalt | #5 |
| coronary angioplasty angioplasty | #5 |
| vka patients | #5 |
| exclusion venous thromboembolism | #5 |
| diagnostic strategies | #5 |
| burden vte | #5 |
| consensus strategy | #5 |
| dimer combination | #5 |
| endogenous activated | #5 |
| iii plasminogen | #5 |
| clinical probability | #5 |
| coc pregnancy | #5 |
| previous venous thromboembolism | #5 |
| repeated ultrasonography | #5 |
| lmwh incidence | #5 |
| medea study | #5 |
| embolism reproducibility | #5 |
| standardized morbidity ratio | #6 |
| vka | #6 |
| effects ufh | #6 |
| patients uedvt | #6 |
| vte anticoagulant treatment | #6 |
| dabigatran etexilate dabigatran | #6 |
| leiden | #6 |
| prevalence vte | #6 |
| treatment pulmonary embolism | #6 |
| patients anticoagulation clinic | #6 |
| arterial cardiovascular | #6 |
| assay fibrin | #6 |
| simplired dimer | #6 |
| vte cancer | #6 |
| pembqol questionnaire | #6 |
| patients suspected | #6 |
| rate major bleeding | #6 |
| endotoxin assays | #6 |
| risk khorana score | #6 |
| venograms | #6 |
| neoplasms pulmonary embolism | #6 |
| grade 1a ufh | #6 |
| patients pulmonary angiography | #6 |
| pulmonary embolism presence | #6 |
| blood coagulation mechanism | #6 |
| severe dic | #6 |
| c1173 | #6 |
| dimer cut | #6 |
| low absolute risk | #6 |
| subcutaneous low | #6 |
| probability pulmonary | #6 |
| thrombophilic defects | #6 |
| fixeddose regimen | #6 |
| synthetic pentasaccharides | #6 |
| recurrent pulmonary | #6 |
| ft4 patients | #6 |
| anticoagulant treatment | #6 |
| symptoms intermittent claudication | #6 |
| embolism pulmonary | #6 |
| symptomatic legs | #6 |
| perioperative blood loss | #6 |
| patients lowmolecularweight heparin | #6 |
| duration rivaroxaban | #6 |
| stressinduced hyperglycaemia | #6 |
| incidence recurrence | #6 |
| levonorgestrel desogestrel | #6 |
| thrombosis guidelines | #6 |
| ultrasonography normal | #6 |
| dalteparin dose | #6 |
| edoxaban efficacy | #6 |
| treatment ufh | #6 |
| daily gentamicin | #6 |
| lmwh users users | #6 |
| compression stockings patients | #6 |
| wells rule | #6 |
| diagnostic workup | #6 |
| 39393 | #6 |
| subjects vte | #6 |
| elisapositive | #6 |
| apixaban treatment dose | #6 |
| combined utility | #6 |
| 12month cumulative incidence | #6 |
| repeatedly normal | #6 |
| isolated deficiencies | #6 |
| patients proximal | #6 |
| oral anticoagulants dabigatran | #6 |
| treatment intermittent claudication | #6 |
| enoxaparin incidence | #6 |
| lmwh cancer | #6 |
| effects levonorgestrel | #6 |
| patients diagnostic | #6 |
| severe antithrombin | #6 |
| endotoxininduced activation | #6 |
| anticoagulants hemorrhage | #6 |
| outcome occurred | #6 |
| thromboembolism bleeding | #6 |
| treatment svt | #6 |
| patients tests | #6 |
| warfarin venous thromboembolism | #6 |
| oral edoxaban | #6 |
| amplify | #6 |
| subcutaneous nadroparin | #6 |
| embolism ventricular | #6 |
| funding bayer | #6 |
| initial heparin treatment | #6 |
| fviia inhibition | #6 |
| selective beta | #6 |
| antagonists treatment | #6 |
| patients factor mutation | #6 |
| 049 95 | #6 |
| dvt trial | #6 |
| efficiency proportion | #6 |
| conventional therapy treatment | #6 |
| myocardial infarction ctni | #6 |
| proportion cancer patients | #6 |
| risk increasing levels | #6 |
| factor leiden carriers | #6 |
| d‐dimer testing | #6 |
| 10±4 | #6 |
| patients iohexol | #6 |
| vte controls | #6 |
| 393 patients | #6 |
| clinically relevant subgroups | #6 |
| svt extension | #6 |
| anticoagulants female | #6 |
| cancer primary patients | #6 |
| women hyperhomocysteinemia | #6 |
| anticoagulant parameters | #7 |
| recurrent dvt | #7 |
| venous thrombosis treatment | #7 |
| heparin org | #7 |
| embolism prospective | #7 |
| diagnosis venous thrombosis | #7 |
| vka therapy | #7 |
| carriers venous thromboembolism | #7 |
| primary dvt | #7 |
| incidence recurrent vte | #7 |
| tb402 | #7 |
| coagulation humans | #7 |
| inhibitor apixaban | #7 |
| vte cancer diagnosis | #7 |
| diagnostic suspicion | #7 |
| thrombophlebitis adolescent | #7 |
| noncompressibility | #7 |
| proportion older patients | #7 |
| carriers defects | #7 |
| silent pulmonary embolism | #7 |
| factor female humans | #7 |
| day initial treatment | #7 |
| perelated death | #7 |
| antithrombin protein | #7 |
| nondiagnostic lung scans | #7 |
| presence cteph | #7 |
| tnf injection | #7 |
| arterial cardiovascular disease | #7 |
| negative ddimer test | #7 |
| ufh treatment | #7 |
| ottawa score | #7 |
| rivaroxaban 10 | #7 |
| 597939 | #7 |
| aspirin combined | #7 |
| stockings control | #7 |
| negative predictive npv | #7 |
| levels factor viii | #7 |
| phenprocoumon polymorphism | #7 |
| thromboembolism vte | #7 |
| protein protein deficiencies | #7 |
| vitamin antagonists vka | #7 |
| treatment doac | #7 |
| etexilate oral | #7 |
| thromboembolism adult | #7 |
| plasma levels ifngamma | #7 |
| administration bsf | #7 |
| doppler skin | #7 |
| specific antidotes | #7 |
| deepvein thrombosis patients | #7 |
| pulmonary embolism sensitivity | #7 |
| dvt ipg | #7 |
| general practitioners guideline | #7 |
| statin treatment risk | #7 |
| relation prolactin levels | #7 |
| lung scan | #7 |
| mutations factor viii | #7 |
| thromboembolism total | #7 |
| unselected women | #7 |
| primary efficacy | #7 |
| combination ipg | #7 |
| placebo rivaroxaban | #7 |
| rates edoxaban | #7 |
| spiral sensitivity | #7 |
| patients standard heparin | #7 |
| mpc1609 | #7 |
| leg ultrasonography | #7 |
| prothrombin risk | #7 |
| major bleeding rate | #7 |
| 680 | #7 |
| blood coagulation humans | #7 |
| major bleeding vkas | #7 |
| major bleeding | #7 |
| neoplasms pulmonary | #7 |
| relation levels | #7 |
| thrombophilia pregnancy loss | #7 |
| 220 dabigatran | #7 |
| dimer concentration | #8 |
| dimer tests | #8 |
| international organisations | #8 |
| inherited thrombophilic | #8 |
| discontinuation anticoagulant treatment | #8 |
| thrombosis adolescent | #8 |
| deficiency antithrombin | #8 |
| compression surveys | #8 |
| optimal intensity | #8 |
| v617f jak2 | #8 |
| fxi aso | #8 |
| contrast venography | #8 |
| increased fibrinolytic | #8 |
| objectively confirmed | #8 |
| aged phlebography | #8 |
| recurrent vte mb | #8 |
| tests pulmonary | #8 |
| 0·2 | #8 |
| p0001 hasbled score | #8 |
| duration treatment | #8 |
| patients excluded | #8 |
| risks dvt | #8 |
| pvoct | #8 |
| severe preeclampsia patients | #8 |
| vitamin antagonists vkas | #8 |
| leiden prothrombin | #8 |
| proximal deep | #8 |
| agnelli | #8 |
| products humans | #8 |
| recurrent vte bleeding | #8 |
| ufh initial treatment | #8 |
| normal computed | #8 |
| risk employees | #8 |
| vte score | #8 |
| nafronyl | #8 |
| point ultrasonography | #8 |
| current approach | #8 |
| 97 95 | #8 |
| oral glucocorticoids risk | #8 |
| oral apixaban | #8 |
| thrombosis prophylaxis | #8 |
| enoxaparin vka | #8 |
| lmwh grade 1a | #8 |
| unprovoked vte patients | #8 |
| patients symptomatic vte | #8 |
| anticoagulants antineoplastic | #8 |
| inr values patients | #8 |
| 1599 patients | #8 |
| initial heparin | #8 |
| proximal deepvein thrombosis | #8 |
| homocysteine markers | #8 |
| administration low | #8 |
| arg506 factor | #8 |
| heparin vitamin antagonists | #8 |
| consecutive outpatients | #8 |
| xii deficient | #8 |
| occult cancer patients | #8 |
| years cumulative incidence | #8 |
| ageadjusted ddimer cutoff | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| treatment venous thrombosis | #8 |
| carriers fvl | #8 |
| chemotherapy low risk | #8 |
| patients extended anticoagulation | #8 |
| 150 enoxaparin | #8 |
| low clinical probability | #8 |
| funding daiichi | #8 |
| anticoagulation unprovoked vte | #8 |
| bnp ctnt | #8 |
| warfarin hazard ratio | #8 |
| wells scores | #8 |
| persistent risk factors | #8 |
| testing rule | #8 |
| symptomatic deepvein thrombosis | #8 |
| vka lmwh | #8 |
| cancer pulmonary embolism | #8 |
| probability lung | #8 |
| acute symptomatic vte | #8 |
| comorbidity polypharmacy | #8 |
| vascular endothelial barrier | #8 |
| overt cancer | #8 |
| apixaban enoxaparin | #8 |
| prospective management | #8 |
| euro55 | #8 |
| levonorgestrelcontaining | #8 |
| physicians stockings | #8 |
| nondiagnostic scan | #8 |
| structured algorithm | #8 |
| oac adherence | #8 |
| analysis apixaban | #8 |
| inr determination | #8 |
| prevention vte | #8 |
| cofact | #9 |
| thrombosis thromboinflammation | #9 |
| cancer cell extravasation | #9 |
| combination stroke | #9 |
| thrombosis venous thromboembolism | #9 |
| patients fxa inhibitors | #9 |
| edoxaban major bleeding | #9 |
| characteristics severity | #9 |
| incidental pulmonary | #9 |
| concomitant cancer | #9 |
| hemorr2hages atria | #9 |
| postdilution | #9 |
| diagnosis mdct | #9 |
| vte relatives | #9 |
| vte rcts | #9 |
| lmwh mortality | #9 |
| serotonin platelet | #9 |
| diagnostic prediction model | #9 |
| acute medical illnesses | #9 |
| bled bleeding | #9 |
| thrombosis compared | #9 |
| months efficacy | #9 |
| apixaban oral factor | #9 |
| placebo plasma levels | #9 |
| enoxaparin factor | #9 |
| male oligosaccharides | #9 |
| atiii concentrates | #9 |
| nonpermanent | #9 |
| strategies dimer | #9 |
| fondaparinux cancer patients | #9 |
| discontinuing anticoagulation | #9 |
| cancer episode | #9 |
| fxa inhibitor | #9 |
| treatment edoxaban | #9 |
| weight heparin | #9 |
| tafi levels | #9 |
| anticoagulant pathways | #9 |
| comorbidities polypharmacy | #9 |
| cancer factor | #9 |
| treatment prophylaxis | #9 |
| longterm treatment vte | #9 |
| thromboembolism cancer | #9 |
| generation pill | #9 |
| iii concentrate | #9 |
| prothrombin 20210a | #9 |
| abnormal vaginal | #9 |
| büller | #9 |
| oral contraceptive pregnancy | #9 |
| incidence postthrombotic syndrome | #9 |
| major bleeding treatment | #9 |
| ultrasonogram | #9 |
| lipoproteina women | #9 |
| carriers factor leiden | #9 |
| daiichisankyo | #9 |
| method enoxaparin | #9 |
| therapeutic dose patients | #9 |
| compression stockings prevention | #9 |
| independent committee | #9 |
| heparin therapy patients | #9 |
| homocysteine women | #9 |
| patients active cancer | #9 |
| crcl 60 | #9 |
| embolism venous | #9 |
| normal ddimer | #9 |
| factors thrombophlebitis | #9 |
| oral antithrombins | #9 |
| deficiencies antithrombin | #10 |
| 1215 patients | #10 |
| thrombosis background | #10 |
| fondaparinux risk | #10 |
| incidence major bleeding | #10 |
| rabbits administration | #10 |
| major bleeding crnmb | #10 |
| magellan study | #10 |
| cancer patients lmwh | #10 |
| snp scores | #10 |
| venous thrombosis | #10 |
| nadroparine | #10 |
| factor prevention | #10 |
| embolism patients | #10 |
| wells | #10 |
| oral thrombin inhibitor | #10 |
| vnv | #10 |
| venous thromboembolic event | #10 |
| gramnegative septicemia | #10 |
| factor levels patients | #10 |
| leg veins | #10 |
| 100 years discontinuation | #10 |
| bled scores | #10 |
| protein dic | #10 |
| rates recurrent vte | #10 |
| embolism clinical | #10 |
| subcutaneous metaanalysis | #10 |
| cus diagnosis | #10 |
| anticoagulants | #10 |
| patients venous thrombosis | #10 |
| inherited thrombophilic factors | #10 |
| aged antithrombin | #10 |
| crp test | #10 |
| ddimer concentration | #10 |
| thrombophlebitis adult | #10 |
| patients endotoxemia | #10 |
| magellan trial | #10 |
| retrospective study efficacy | #10 |
| treatment aprotinin | #10 |
| induced coagulation | #10 |
| single loss | #10 |
| simplified geneva | #10 |
| treatment vitamin | #10 |
| 598 patients | #10 |
| intimamedia thickness imt | #10 |
| fii mutation | #10 |
| cvd fh patients | #10 |
| probability pulmonary embolism | #10 |
| asymptomatic pulmonary embolism | #10 |
| animal heparin | #10 |
| lmwh studies | #10 |
| thr incidence | #10 |
| treatment uedvt | #10 |
| year years | #10 |
| incidence 1000 personyears | #10 |
| severity clinical | #10 |
| hypocoagulable state | #10 |
| dvt lower extremity | #10 |
| cancer patients vte | #10 |
| injection avidin | #10 |
| 4470 | #10 |
| heparin nomogram | #10 |
| schedule heparin | #10 |
| normohomocysteinemic | #10 |
| pregnancy carriers | #10 |
| ageadjusted cutoff | #10 |
| oral administration dabigatran | #10 |
| rfviia blood loss | #10 |
| extremity deep | #10 |
| vte efficacy | #10 |
| inr cases | #10 |
| levels prolactin | #11 |
| pyridines thiazoles | #11 |
| 30 microg ethinylestradiol | #11 |
| cancer patients evidence | #11 |
| ufh studies | #11 |
| dabigatran enoxaparin | #11 |
| clinical pretest | #11 |
| adult anticoagulants | #11 |
| endotoxin assay | #11 |
| ldfr | #11 |
| weight humans | #11 |
| combination dimer | #11 |
| 880 patients | #11 |
| medical conferences | #11 |
| pcc dabigatran | #11 |
| heparinoid org | #11 |
| embolism prevalence | #11 |
| pulmonary angiography venography | #11 |
| embolism recurrence | #11 |
| previous venous | #11 |
| lmwh pregnancy | #11 |
| hospital lmwh | #11 |
| inhibitors hemorrhage | #11 |
| mutations prevalence | #11 |
| recombinant human tnf | #11 |
| crnmb 95 | #11 |
| reference testing | #11 |
| cancer patients dvt | #11 |
| screening cancer | #11 |
| haemophilia vwd | #11 |
| carriers factor | #11 |
| oral dabigatran | #11 |
| org 10172 | #11 |
| gps training | #11 |
| d‐dimer levels | #11 |
| incidence major | #11 |
| thromboembolism major | #11 |
| endotoxin pentoxifylline | #11 |
| variation inr | #11 |
| gentamicin treatment patients | #11 |
| sulfates dermatan | #11 |
| knee clinical trials | #11 |
| dvt | #11 |
| patients anticoagulant treatment | #11 |
| pulmonary embolism incidence | #11 |
| air travel | #11 |
| pregnancyrelated complications | #11 |
| patients cvcs | #11 |
| 750 μg | #11 |
| patients probability | #11 |
| fondaparinux hemorrhage | #11 |
| factor venous | #11 |
| vte vwf | #11 |
| patients cancer vte | #11 |
| intensity anticoagulation | #11 |
| edoxaban | #11 |
| lmwh pregnancies | #11 |
| 9702 | #12 |
| patients lmwhs | #12 |
| humanized arthroplasty | #12 |
| topic venous | #12 |
| thrombophilic | #12 |
| risk venous | #12 |
| perelated | #12 |
| control metaanalysis | #12 |
| women factor | #12 |
| noacs vka | #12 |
| geneva score | #12 |
| pioped study | #12 |
| subsegmental pulmonary emboli | #12 |
| 9295 | #12 |
| bnp cardiac troponin | #12 |
| anticoagulation unprovoked | #12 |
| fondaparinux unfractionated heparin | #12 |
| safety efficiency | #12 |
| hirulog1 | #12 |
| recurrent vte anticoagulation | #12 |
| bayer schering pharma | #12 |
| prevention venous thrombosis | #12 |
| outcomes venous thromboembolism | #12 |
| patients lupus anticoagulant | #12 |
| ageadjusted ddimer | #12 |
| factor leiden prothrombin | #12 |
| paulin | #12 |
| hemodynamically stable | #12 |
| anticoagulant factor | #12 |
| nephro | #12 |
| treatment crt | #12 |
| female heparin humans | #12 |
| vte recurrence risk | #12 |
| livebirth rate | #12 |
| peghirudin | #12 |
| dvt treatment | #12 |
| months primary | #12 |
| recurrent vte | #12 |
| outpatient management patients | #12 |
| observation risk | #12 |
| venous thromboembolism incidence | #12 |
| event recurrence | #12 |
| deficient women | #12 |
| stopping anticoagulation | #12 |
| thrombin generation fibrinolysis | #12 |
| patients incidental | #12 |
| proximal vein | #12 |
| warfarin recurrent vte | #12 |
| crd42013003526 | #12 |
| vka noacs | #12 |
| warfarin therapy inr | #12 |
| proximal veins | #12 |
| 72 children | #12 |
| doseadjustment | #12 |
| warfarin treated | #12 |
| annual incidence vte | #12 |
| thrombosis dvt | #12 |
| concomitant disorders | #12 |
| heparin low | #13 |
| arterial thromboembolism ate | #13 |
| vte recurrence 95 | #13 |
| continuous intravenous heparin | #13 |
| vte groups | #13 |
| 86 percent | #13 |
| thrombosis young | #13 |
| vte female humans | #13 |
| bayer healthcare | #13 |
| safety oral | #13 |
| groups inr | #13 |
| inferiority efficacy | #13 |
| rivaroxaban thiophenes | #13 |
| dvt lower | #13 |
| dabigatran vte | #13 |
| safety doacs | #13 |
| patients anticoagulant | #13 |
| dimer threshold | #13 |
| factor leiden mutation | #13 |
| hematologic pregnancy trimester | #13 |
| vte | #13 |
| category studies | #13 |
| selective testing | #13 |
| thrombosis acute | #13 |
| randomized cross | #13 |
| plethysmography | #13 |
| arixtra | #13 |
| concomitant antiplatelet therapy | #13 |
| levels factor | #13 |
| ufh dalteparin | #13 |
| daily subcutaneous | #13 |
| pselectin patients | #13 |
| prevention venous thromboembolism | #13 |
| recombinant hirudin rhirudin | #13 |
| 95 carriers | #13 |
| bleeding events edoxaban | #13 |
| treatment venous thromboembolism | #13 |
| dabigatran 220 | #13 |
| clinical decision rules | #13 |
| patients thrombophilia | #13 |
| obesity haemophilia patients | #13 |
| deepvein thrombosis dvt | #13 |
| indication anticoagulation | #13 |
| major hip | #13 |
| vte 64 | #13 |
| inhibition tnf | #13 |
| antithrombin iii activity | #13 |
| plethysmograms | #13 |
| uedvt | #13 |
| time prothrombin | #13 |
| occult cancer | #13 |
| conventional anticoagulants | #13 |
| superficial thrombophlebitis | #13 |
| nct00986154 | #13 |
| factor viii apc | #13 |
| spiral computed tomography | #13 |
| dimer testing | #13 |
| association venous thrombosis | #13 |
| marder score | #13 |
| vte major | #13 |
| strain gauge plethysmography | #13 |
| unprovoked vte vte | #14 |
| effects hyperthyroidism | #14 |
| patients vka therapy | #14 |
| edoxaban oral factor | #14 |
| thrombosis | #14 |
| safety edoxaban | #14 |
| vte months | #14 |
| 12 kg1 | #14 |
| edoxaban warfarin | #14 |
| awareness pad | #14 |
| patients acute vte | #14 |
| obstetric complications women | #14 |
| doseranging study | #14 |
| factor viii levels | #14 |
| low molecular | #14 |
| cadherins endothelium | #14 |
| revised geneva | #14 |
| lmwh vka | #14 |
| vte statin | #14 |
| standard heparin | #14 |
| bolus intravenous injection | #14 |
| 17 placebo | #14 |
| atiii deficiency | #14 |
| limited screening | #14 |
| dvt lower extremities | #14 |
| patients dvt | #14 |
| recurrent venous | #14 |
| pregnancy venous | #14 |
| costs dvt | #14 |
| ultrasound strategies | #14 |
| experimental endotoxaemia | #14 |
| recurrent venous thromboembolism | #14 |
| fvl carriers | #14 |
| anticoagulant rivaroxaban | #14 |
| conventionaltherapy | #14 |
| incidence severe pph | #14 |
| aged plethysmography | #14 |
| female fibrin | #14 |
| thromboembolism age | #14 |
| acute deep | #14 |
| plasminogen apoa | #14 |
| riete score | #14 |
| treatment duration patients | #14 |
| placebo rfviia | #14 |
| loss women | #14 |
| thrombophilia patients | #14 |
| gastrointestinal bleeding patients | #14 |
| crnm | #14 |
| aspirin women | #14 |
| higher ddimer levels | #14 |
| aged anticoagulants | #14 |
| treated lmwh | #14 |
| patients outpatients | #14 |
| symptomatic pulmonary | #14 |
| cancer patients anticoagulation | #14 |
| inr patient | #15 |
| antagonist vka | #15 |
| 500 pg | #15 |
| generation oral | #15 |
| edoxaban treatment | #15 |
| clinically relevant endpoints | #15 |
| vitaminkantagonists | #15 |
| symptomatic events | #15 |
| thyroid hormone excess | #15 |
| probability assessment | #15 |
| doacs aspirin | #15 |
| pregnancy outcome pregnancy | #15 |
| fondaparinux efficacy | #15 |
| subcutaneous enoxaparin | #15 |
| activation contact | #15 |
| khorana score | #15 |
| established vte | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| lmwh ufh | #15 |
| thrombinography | #15 |
| cteph incidence | #15 |
| thrombus growth | #15 |
| inr range | #15 |
| primary safety outcome | #15 |
| thrombosis diagnosis | #15 |
| prior venous thromboembolism | #15 |
| subcutaneous regimen | #15 |
| coc vte | #15 |
| enoxaparin vte | #15 |
| recombinant factor viia | #15 |
| diagnosis venous | #15 |
| control subjects prevalence | #15 |
| oral direct factor | #15 |
| studies pulmonary | #15 |
| arg562 | #15 |
| arg506 | #15 |
| anticoagulants patients | #15 |
| coagulation | #15 |
| lomoparan | #15 |
| prophylaxis venous thromboembolism | #15 |
| experimental thrombosis | #15 |
| abdominal pelvic | #15 |
| cardiovascular diseases thrombosis | #15 |
| patients vitamin antagonists | #15 |
| patients ctpa | #15 |
| factor leiden | #15 |
| treatment 12 months | #15 |
| postthrombotic syndrome children | #16 |
| test clinical | #16 |
| occult cancer detection | #16 |
| cancer screening patients | #16 |
| abdomino | #16 |
| 6 months placebo | #16 |
| thrombosis adult | #16 |
| thromboembolism time | #16 |
| dvt lmwh | #16 |
| 100 95 | #16 |
| arterial vascular events | #16 |
| vterelated death | #16 |
| thrombosis haemostasis | #16 |
| viia activity | #16 |
| analysis rivaroxaban | #16 |
| cancer cancer patients | #16 |
| vte khorana score | #16 |
| thrombosis low | #16 |
| recurrent symptomatic | #16 |
| factor inhibitor | #16 |
| subsequent pregnancy loss | #16 |
| ddimer levels patients | #16 |
| positivity threshold | #16 |
| warfarin acenocoumarol | #16 |
| deep venous thrombosis | #16 |
| bleeding aged | #16 |
| women unexplained | #16 |
| risk clinically | #16 |
| venous thrombosis warfarin | #16 |
| thrombosis association | #16 |
| combination clinical | #16 |
| avws patients | #16 |
| patients acenocoumarol | #16 |
| major bleeding anticoagulation | #16 |
| major bleeding events | #16 |
| factors major | #16 |
| netilmicin gentamicin | #16 |
| impaired fibrinolysis | #16 |
| anticoagulants clinical | #17 |
| patients impedance | #17 |
| thrombosis clinical | #17 |
| anticoagulants drug | #17 |
| lmwhs patients | #17 |
| scan classification | #17 |
| women mutation | #17 |
| mutation women | #17 |
| endotoxemia bacteremia | #17 |
| factor monoclonal | #17 |
| excessive blood loss | #17 |
| fragment f1 | #17 |
| hematoma heparin | #17 |
| fibrinolysis treatment | #17 |
| 2688 | #17 |
| ctscans | #17 |
| dvt prevention | #17 |
| recurrent vte events | #17 |
| 12 months patients | #17 |
| topic hemorrhage humans | #17 |
| management crt | #17 |
| patients overt hypothyroidism | #17 |
| vkorc1 gene | #17 |
| anticoagulant therapy patients | #17 |
| diagnosis svt | #17 |
| prohemostatic | #17 |
| 516 patients | #17 |
| dimer assay | #17 |
| lower specificity | #17 |
| compared enoxaparin | #17 |
| permanent patients | #17 |
| vte edoxaban | #17 |
| incidence pts | #17 |
| thromboembolism patients | #17 |
| pharmo record linkage | #17 |
| female humans vte | #17 |
| rivaroxaban oral factor | #17 |
| factors venous | #17 |
| gentamicin netilmicin | #17 |
| flight hours | #18 |
| 023 | #18 |
| venous thromboembolism rivaroxaban | #18 |
| stable anticoagulation | #18 |
| prothrombin g20210a | #18 |
| outcome events | #18 |
| commercial airline pilots | #18 |
| patients strategy | #18 |
| aptt heparin | #18 |
| weight adjusted | #18 |
| intravenous heparin therapy | #18 |
| lmwh doacs | #18 |
| warfarin hazard | #18 |
| sanofi aventis | #18 |
| cancer vte | #18 |
| apc thrombin generation | #18 |
| favor lmwh | #18 |
| women pregnancy loss | #18 |
| proximal vein thrombosis | #18 |
| vka vte | #18 |
| thrombosis total | #18 |
| treatment vkas | #18 |
| annual incidence | #18 |
| thrombosis pulmonary | #18 |
| combined form | #18 |
| hivinfected patients cart | #18 |
| poc test | #18 |
| diagnostic strategy | #18 |
| relevant nonmajor | #18 |
| thromboembolism venous | #18 |
| edoxaban vte | #18 |
| antithrombotic treatment patients | #18 |
| vka edoxaban | #18 |
| 4 clinical | #18 |
| simplired | #18 |
| ipdma | #19 |
| venography sensitivity | #19 |
| local angiogenesis | #19 |
| recurrent venous thrombosis | #19 |
| fibrinolytic response | #19 |
| doubleblinding | #19 |
| patients major bleeding | #19 |
| symptomatic dvt | #19 |
| coagulation studies | #19 |
| objective testing | #19 |
| endogenous fibrinolysis | #19 |
| increased risk relatives | #19 |
| vwf vte | #19 |
| systemic activation coagulation | #19 |
| edoxaban dose | #19 |
| dvt rivaroxaban | #19 |
| studies factor | #19 |
| fondaparinux enoxaparin | #19 |
| ufh lmwh | #19 |
| adjusted dose | #19 |
| versions version | #19 |
| oral dabigatran enoxaparin | #19 |
| retropubic prostatectomy | #19 |
| patients sspe | #19 |
| venous thromboembolism relatives | #19 |
| lmwh patients | #19 |
| patients derivation | #19 |
| increased fibrinolytic activity | #19 |
| abnormal ultrasound | #19 |
| treatment heparin | #19 |
| 35 women | #19 |
| recurrence vte | #19 |
| vitamin antagonist | #19 |
| acute recurrent | #19 |
| 56 95 | #19 |
| thromboembolism administration | #19 |
| extended oral | #19 |
| antibodynegative | #19 |
| ddimer tests | #19 |
| prognostic echocardiography | #19 |
| patients elevated biomarkers | #19 |
| low platelets | #19 |
| subcutaneous dalteparin | #19 |
| active search | #19 |
| patients prevalence | #19 |
| new agent | #20 |
| symptomatic venous thrombosis | #20 |
| standardtherapy hazard ratio | #20 |
| excluded patients | #20 |
| portola | #20 |
| proteins thrombin | #20 |
| blindly | #20 |
| thrombosis ultrasonography | #20 |
| carriers prothrombin | #20 |
| warfarin edoxaban | #20 |
| nadroparin | #20 |
| impedance plethysmography ipg | #20 |
| abi risk factors | #20 |
| established atherosclerosis | #20 |
| intravenous injections | #20 |
| abi measurement | #20 |
| subsegmental | #20 |
| patients ddimer testing | #20 |
| dabigatran 150 | #20 |
| prothrombin mutation | #20 |
| malignancy time | #20 |
| single criterion | #20 |
| incidences death | #20 |
| versions questionnaire | #20 |
| synthetic cross | #20 |
| risk thrombophilia | #20 |
| antagonists vkas | #20 |
| therapy rivaroxaban | #20 |
| compared ufh | #20 |
| diagnostic workup patients | #20 |
| life venous thrombosis | #20 |
| distance treatment | #20 |
| injections subcutaneous | #20 |
| shr 95 | #20 |
| treatment vte | #20 |
| pregnancyrelated vte | #20 |
| anticoagulation clinic | #20 |
| cancer severity | #20 |
| residual venous | #20 |
| calf veins | #20 |
| recurrence bleeding | #20 |
| thrombophilia vte | #20 |
| statin vte | #20 |
| guidance ssc | #20 |
| ctnt bnp | #20 |
| antitpo | #20 |
| control situation | #20 |
| absolute risk | #20 |
| concomitant anti | #21 |
| hemodynamically stable patients | #21 |
| treatment apixaban | #21 |
| d‐dimer | #21 |
| doacs lmwhs | #21 |
| treatment acenocoumarol | #21 |
| thrombosis anticoagulants | #21 |
| hemostatic abnormalities | #21 |
| risk cohort study | #21 |
| disease ischemic | #21 |
| outcome incidence | #21 |
| discriminatory performance | #21 |
| vte patients | #21 |
| venogram | #21 |
| thromb | #21 |
| patients 3 months | #21 |
| fibrinolysis inflammation | #21 |
| distance quality | #21 |
| occult malignancy | #21 |
| ddimer concentrations | #21 |
| major bleeding patients | #21 |
| carriers noncarriers | #21 |
| internists cardiologists | #21 |
| prothrombin 20210 | #21 |
| current standard treatment | #21 |
| deep venous | #21 |
| ttr inr | #22 |
| anticoagulants humans | #22 |
| vascular endotoxins | #22 |
| dimer age | #22 |
| patients immobilization | #22 |
| public awareness | #22 |
| riskbenefit ratio | #22 |
| cttr | #22 |
| daily enoxaparin | #22 |
| safety treatment | #22 |
| anticoagulants heparin | #22 |
| venous thromboembolic | #22 |
| cmax ctrough | #22 |
| dichotomously | #22 |
| recurrent thromboembolism | #22 |
| time inr | #22 |
| acute vte | #22 |
| hormonal cross | #22 |
| dose subcutaneous | #22 |
| treatment dvt | #22 |
| lpa plasminogen | #22 |
| patients recurrent symptoms | #22 |
| patients severe hf | #22 |
| patientyears | #22 |
| thrombophilia screening | #22 |
| bleeding treatment | #22 |
| doppler venous thrombosis | #22 |
| alternative anticoagulation | #22 |
| host defense response | #22 |
| time platelet | #23 |
| vte studies | #23 |
| thromboembolism anticoagulants | #23 |
| direct factor inhibitors | #23 |
| life pulmonary embolism | #23 |
| prevalence venous thromboembolism | #23 |
| elevated ctni | #23 |
| lower extremity amputation | #23 |
| fondaparinux | #23 |
| 5392 | #23 |
| bidirectional relation | #23 |
| kakkar | #23 |
| 2 investigators | #23 |
| recurrence venous | #23 |
| clotbound thrombin | #23 |
| standardduration | #23 |
| rivaroxaban dosing | #23 |
| development dic | #23 |
| gentamicin patients | #23 |
| percentage increase | #23 |
| venous arterial thrombosis | #23 |
| 011 | #23 |
| enoxaparin 40 | #23 |
| hasbled score | #23 |
| ambulatory cancer patients | #23 |
| odis | #23 |
| cancer patients risk | #23 |
| normal angiogram | #23 |
| n1157 | #23 |
| patients coagulation disorders | #23 |
| followup incidence | #24 |
| rates venous thromboembolism | #24 |
| levels fviii | #24 |
| bleeding complication | #24 |
| prevalence deficiencies | #24 |
| thrombosis carriers | #24 |
| desogestrel levonorgestrel | #24 |
| years episode | #24 |
| patients abnormal perfusion | #24 |
| predefined criteria | #24 |
| therapy heparin | #24 |
| subtherapeutic | #24 |
| ufh patients | #24 |
| patients acute treatment | #24 |
| patients severe bleeding | #24 |
| presence dvt | #24 |
| 049 | #24 |
| food drugs | #24 |
| fondaparinux placebo | #24 |
| overt hyperthyroidism | #24 |
| independent external validation | #24 |
| parameters fibrinolysis | #24 |
| month incidence | #24 |
| recurrent pulmonary embolism | #24 |
| viiic | #24 |
| ddimer testing | #24 |
| safety fondaparinux | #24 |
| lowmolecularweight humans | #24 |
| a21gly | #24 |
| specific antidote | #24 |
| recurrent thromboembolism patients | #24 |
| treatment symptomatic | #25 |
| perfusion lung scan | #25 |
| fatima | #25 |
| vte clinical | #25 |
| patients gastrointestinal bleeding | #25 |
| studies lmwh | #25 |
| sepsis intravascular coagulation | #25 |
| lmwh treatment | #25 |
| cha2ds2vasc chads2 | #25 |
| expert radiologists | #25 |
| suggestions improvement | #25 |
| f1 2 levels | #25 |
| specificity efficiency | #25 |
| anatomical extent | #25 |
| thromboembolism acute | #25 |
| amadeus | #25 |
| fibrinogen degradation | #25 |
| willebrand factor adamts13 | #25 |
| xii activity | #25 |
| influence smoking | #25 |
| middeldorp | #25 |
| factors anticoagulants | #25 |
| viia complex | #26 |
| patients essential thrombocythaemia | #26 |
| asymptomatic carriers | #26 |
| ecq | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| rate recurrent vte | #26 |
| dalteparin ufh | #26 |
| events year | #26 |
| miscarriage stillbirth | #26 |
| treatment lmwh | #26 |
| hormonal manipulation | #26 |
| unprovoked vte | #26 |
| homozygous carriers | #26 |
| major bleeding bleeding | #26 |
| venous thromboemboli | #26 |
| patients cdr | #26 |
| doacs vitamin antagonists | #26 |
| 9715 | #26 |
| edoxaban versus | #26 |
| specificity negative predictive | #26 |
| patients symptomatic dvt | #26 |
| failure rate | #26 |
| edoxaban vka | #26 |
| parameters risk | #26 |
| rethoracotomy | #26 |
| training gps | #27 |
| combined training | #27 |
| months studies | #27 |
| lowmolecularweight heparin patients | #27 |
| female heterozygote | #27 |
| low molecularweight heparin | #27 |
| patients major hemorrhage | #27 |
| enoxaparin female | #27 |
| patients elevated levels | #27 |
| unprovoked venous | #27 |
| day 35 | #27 |
| thrombocytopenia antibodies | #27 |
| thrombosis venous | #27 |
| extremity venous | #27 |
| perfusion lung | #27 |
| cancer spread | #27 |
| anticoagulants factor | #27 |
| treating physician | #27 |
| vte doacs | #27 |
| current guidance | #27 |
| nonmajor | #27 |
| noncarriers 95 | #27 |
| venous thromboembolism carriers | #27 |
| airline pilots | #27 |
| lmwh prophylaxis | #27 |
| anticoagulants blood | #27 |
| patients 50 | #27 |
| vte thr | #27 |
| thrombophlebitis | #27 |
| npv patients | #27 |
| 0·63 | #27 |
| 4650 | #28 |
| anticoagulants compared | #28 |
| tests diagnostic | #28 |
| apc plasma | #28 |
| pph severe pph | #28 |
| specific reversal agent | #28 |
| rfviia placebo | #28 |
| receiving rivaroxaban | #28 |
| objective tests | #28 |
| vitamin aged | #28 |
| anticoagulation women | #28 |
| vte 6 months | #28 |
| therapeutic doses | #28 |
| acutely medical patients | #28 |
| cancer venous thromboembolism | #28 |
| factors recurrent | #28 |
| presentation followup | #28 |
| pembqol | #28 |
| coagulation tissue factor | #28 |
| 2½ | #28 |
| patients unprovoked | #28 |
| monitoring therapy | #28 |
| hirudin therapy | #28 |
| embolism retrospective | #28 |
| unexplained | #28 |
| pulmonary angiography | #29 |
| oral glucocorticoids | #29 |
| aged morpholines | #29 |
| diagnosis dvt | #29 |
| pbac score | #29 |
| bleeding increased | #29 |
| dabigatran pcc | #29 |
| authors incidence | #29 |
| septicemia | #29 |
| 1000 individuals | #29 |
| cindexes | #29 |
| pulmonary embolism death | #29 |
| thrombosis treatment | #29 |
| dutch famine | #29 |
| current management strategies | #29 |
| aspirin placebo | #29 |
| g20210a mutation | #29 |
| heparin versus | #29 |
| dvt pulmonary embolism | #29 |
| patients standard therapy | #29 |
| 8240 | #29 |
| direct oral anticoagulants | #29 |
| patients avws | #29 |
| sex‐specific differences | #29 |
| thrombo | #29 |
| acenocoumarol patients | #29 |
| pulmonary embolism recurrence | #29 |
| spread cancer | #29 |
| major bleeding rivaroxaban | #29 |
| years year | #29 |
| aminoglycoside therapy | #29 |
| prediction scores | #29 |
| recurrence svt | #29 |
| blind trials | #29 |
| resistance activated protein | #29 |
| thrombosis 95 | #29 |
| plateletactivating antibodies | #29 |
| support techniques | #30 |
| 95 risk | #30 |
| direct oral factor | #30 |
| embolism risk | #30 |
| rule patients | #30 |
| vte coc | #30 |
| administration pentoxifylline | #30 |
| xii factor | #30 |
| markers coagulation activation | #30 |
| subcutaneous heparin | #30 |
| thromboembolism warfarin | #30 |
| costs diagnosis | #30 |
| ufh vte | #30 |
| 1000 personyears incidence | #30 |
| f1 2 | #30 |
| prevention venous | #30 |
| residual thrombosis | #30 |
| cancer venous | #30 |
| new anticoagulants | #30 |
| patients vte | #30 |
| doac vka | #30 |
| pharmacological prophylaxis | #31 |
| recurrent patients | #31 |
| imaging sensitivity specificity | #31 |
| events 95 | #31 |
| vte ufh | #31 |
| thromboembolism adolescent | #31 |
| rhir | #31 |
| 2 antiplasmin | #31 |
| patients deepvein thrombosis | #31 |
| antithrombotic therapies | #31 |
| bled | #31 |
| activation blood coagulation | #31 |
| recurrent vte patients | #31 |
| iii activity | #31 |
| dimer cutoff | #31 |
| term risk | #31 |
| incidence cteph | #31 |
| incidence pph | #31 |
| placebo observation | #31 |
| prevalence probability | #31 |
| analysis reviewers | #31 |
| rfviia novoseven | #31 |
| apixaban placebo | #31 |
| women recurrent miscarriage | #31 |
| experimental endotoxemia | #31 |
| thromboprophylaxis risk | #31 |
| recurrent episode | #31 |
| dvt pulmonary | #31 |
| inhibitor edoxaban | #31 |
| 0206 | #31 |
| ufh fondaparinux | #31 |
| ventilation scintigraphy | #31 |
| extended prophylaxis | #31 |
| 8755 | #31 |
| standardtherapy | #31 |
| khorana score patients | #32 |
| suspected patients | #32 |
| negative dimer | #32 |
| leiden mutation | #32 |
| normal genotype | #32 |
| negative septicemia | #32 |
| factors thrombolytic | #32 |
| resistance activated | #32 |
| age adjusted | #32 |
| year 95 | #32 |
| factor female | #32 |
| treatment anticoagulants | #32 |
| low clinical | #32 |
| parenteral anticoagulation | #32 |
| ufh | #32 |
| international society thrombosis | #32 |
| parenteral anticoagulants | #32 |
| varicosis | #32 |
| warfarin vte | #32 |
| generation patients | #32 |
| netherlands predictive | #32 |
| rhirudin | #33 |
| active implementation | #33 |
| thromboembolism young | #33 |
| warfarin risks | #33 |
| subcutaneous male | #33 |
| factor viii patients | #33 |
| apixaban treatment | #33 |
| chapter patients | #33 |
| additional tests | #33 |
| cancer patients diagnosis | #33 |
| anticoagulant protein | #33 |
| mega study | #33 |
| activation factors | #33 |
| low probability | #33 |
| nephrotoxicity gentamicin | #33 |
| unitage | #33 |
| prophylaxis vte | #33 |
| data meta | #33 |
| heparin lmwh | #33 |
| pulmonary angiogram | #33 |
| thrombosis lower | #34 |
| grade 1a | #34 |
| bilateral venography | #34 |
| compare efficacy | #34 |
| control trials | #34 |
| subsegmental pulmonary embolism | #34 |
| 10 95 | #34 |
| anticoagulant | #34 |
| vte compared | #34 |
| reocclusion patients | #34 |
| hemorrhage heparin humans | #34 |
| lmwh unfractionated heparin | #34 |
| 9241 | #34 |
| phytonadione | #34 |
| plasmin alpha | #34 |
| warfarin adult | #34 |
| pregnancy loss women | #34 |
| vte thrombophilia | #34 |
| apcsr | #34 |
| 590 | #34 |
| 3 months treatment | #34 |
| deficiency protein | #34 |
| statin association | #35 |
| embolism | #35 |
| risk members | #35 |
| activation coagulation | #35 |
| 36 95 | #35 |
| surgery hip | #35 |
| enoxaparin prevention | #35 |
| anticoagulants benzimidazoles | #35 |
| prevention model | #35 |
| weekly subcutaneous | #35 |
| radiologists diagnosis | #35 |
| patients efficiency | #35 |
| rviia | #35 |
| neoplasms venous | #35 |
| lung scanning | #35 |
| pph blood loss | #35 |
| peripheral endovascular | #36 |
| factors travel | #36 |
| dose reduction patients | #36 |
| venous thromboembolic disease | #36 |
| studies echocardiography | #36 |
| novoseven | #36 |
| inherited risk factors | #36 |
| treatment acute vte | #36 |
| iii antithrombin | #36 |
| 287 patients | #36 |
| venous thromboembolism dabigatran | #36 |
| fibrinolytic activation | #36 |
| hellp patients | #36 |
| 4139 | #36 |
| regular monitoring | #36 |
| fibrinogen depletion | #36 |
| 1698 | #36 |
| riskbenefit | #36 |
| catheterrelated infection | #36 |
| thrombophilia venous | #36 |
| levels coagulation | #36 |
| viii levels | #36 |
| acute symptomatic | #36 |
| recombinant hirudin | #37 |
| pad studies | #37 |
| anticoagulant action | #37 |
| cumulative incidence vte | #37 |
| risk factors pts | #37 |
| genotype 95 | #37 |
| prophylactic heparin | #37 |
| magellan | #37 |
| factors thrombophilia | #37 |
| ototoxicity nephrotoxicity | #37 |
| excluding | #37 |
| thrombosis humans | #37 |
| outcome composite | #37 |
| venography | #37 |
| screening occult | #37 |
| lwmh | #37 |
| ctpa patients | #37 |
| suspected venous | #37 |
| risk venous thrombosis | #37 |
| vte increased | #37 |
| anticoagulants prevention | #37 |
| bagsvaerd | #37 |
| perelated mortality | #37 |
| tat complexes | #37 |
| warfarin 95 | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| sensitivity biomarkers | #38 |
| coagulation protein | #38 |
| fetal loss women | #38 |
| congenital deficiencies | #38 |
| doac lmwh | #38 |
| restenosis reocclusion | #38 |
| vte cancer patients | #38 |
| submassive pulmonary | #38 |
| rivaroxaban placebo | #38 |
| patients ddimer levels | #38 |
| 10 total | #38 |
| 2835 | #38 |
| age recurrence | #38 |
| 3306 | #38 |
| vte bleeding | #38 |
| recurrence day | #38 |
| catheterrelated thrombosis | #38 |
| anticoagulants female humans | #38 |
| nonmajor bleeding | #38 |
| submassive | #39 |
| enoxaparin placebo | #39 |
| subcutaneous intention | #39 |
| continued treatment | #39 |
| low molecular weight | #39 |
| incidence cancer | #39 |
| superficial vein thrombosis | #39 |
| heparins lmwhs | #39 |
| compression stocking | #39 |
| incidence patients | #39 |
| children familial hypercholesterolemia | #39 |
| septic syndrome | #39 |
| embolus | #39 |
| fibrin fibrinogen | #39 |
| specificity patients | #39 |
| time compression | #39 |
| systemic inflammatory responses | #39 |
| 277 patients | #39 |
| diagnostic prediction | #39 |
| doacs | #39 |
| common femoral vein | #40 |
| anticoagulant therapy | #40 |
| dalteparin treatment | #40 |
| patients normal | #40 |
| bleeding | #40 |
| standardized definition | #40 |
| anticoagulation therapy patients | #40 |
| pemb | #40 |
| episode venous thromboembolism | #40 |
| international clinical | #40 |
| therapeutic dosages | #40 |
| grade 1a patients | #40 |
| tfmp | #40 |
| thrombinantithrombin complexes | #40 |
| day 6 months | #40 |
| clotting activation | #40 |
| endotoxininduced | #40 |
| arterial vascular | #40 |
| activatable fibrinolysis | #40 |
| ambulatory cancer | #40 |
| fviiic | #40 |
| lung scintigraphy | #41 |
| 95 genotype | #41 |
| endotoxin induced | #41 |
| 7268 | #41 |
| risk recurrent vte | #41 |
| placebo 6 months | #41 |
| anticoagulated patients | #41 |
| triage tests | #41 |
| lowmolecularweight heparins | #41 |
| submassive pulmonary embolism | #41 |
| cancer lmwh | #41 |
| pentasaccharides | #41 |
| heparin therapy | #41 |
| calf vein thrombosis | #41 |
| dabigatran etexilate | #41 |
| patients silent | #42 |
| cell extravasation | #42 |
| patients prospective | #42 |
| netilmicin | #42 |
| 8101 | #42 |
| type graft | #42 |
| neoplasms thrombosis | #42 |
| thrombosis administration | #42 |
| patients vasopressors | #42 |
| prophylaxis venous | #42 |
| major contributor | #42 |
| stroke thrombosis | #42 |
| standardization committee | #42 |
| anticoagulation risk | #42 |
| venous thrombosis thrombophilia | #43 |
| heparin risk | #43 |
| rtap | #43 |
| monthly incidence | #43 |
| vkas patients | #43 |
| cancer adjusted | #43 |
| probability patients | #43 |
| patients vte risk | #43 |
| draft document | #43 |
| 543 patients | #43 |
| warfarin anticoagulants | #43 |
| initial treatment | #43 |
| ischemic events | #43 |
| post‐thrombotic syndrome | #43 |
| fetal loss | #43 |
| venous thromboembolism vte | #43 |
| restoration euthyroidism | #44 |
| expert physicians | #44 |
| role coagulation | #44 |
| 95 pulmonary embolism | #44 |
| recurrent vte 95 | #44 |
| 10–14 | #44 |
| efficiency models | #44 |
| experimental venous thrombosis | #44 |
| patients tinzaparin | #44 |
| indications patients | #44 |
| enoxaparin risk | #44 |
| factors thromboembolism | #44 |
| 20 30 | #44 |
| mild hyperhomocysteinaemia | #44 |
| edoxaban therapy | #44 |
| protein sepsis | #44 |
| uedvt patients | #44 |
| rate venous | #44 |
| nonvka oral anticoagulants | #44 |
| dose adjusted | #45 |
| coumarin therapy | #45 |
| treated warfarin | #45 |
| patients bnp | #45 |
| revascularisation procedures | #45 |
| fondaparinux patients | #45 |
| venous thrombotic | #45 |
| years algorithm | #45 |
| oral direct | #45 |
| dvt patients | #45 |
| dose lmwh | #45 |
| coagulation activation | #45 |
| 95 warfarin | #45 |
| wells score | #45 |
| pioped | #46 |
| percent confidence | #46 |
| day levels | #46 |
| stroke risk assessment | #46 |
| prothrombin fragment f1 | #46 |
| bleeding rivaroxaban | #46 |
| standard therapy | #46 |
| ssc isth | #46 |
| ruling | #46 |
| management venous | #46 |
| patients unprovoked vte | #46 |
| extended duration | #46 |
| hospital outpatients | #46 |
| abtpo | #46 |
| treatment model | #46 |
| major bleeding placebo | #46 |
| healthcare settings | #46 |
| daily rivaroxaban | #46 |
| roccurve | #47 |
| episode vte | #47 |
| plasma ddimer levels | #47 |
| male methimazole | #47 |
| ambulatory anticoagulants | #47 |
| iiia receptors | #47 |
| outcome vitamin | #47 |
| central venous lines | #47 |
| mutation pregnancy | #47 |
| mechanical prophylaxis | #47 |
| new oral anticoagulant | #47 |
| boehringer ingelheim | #47 |
| bristol myers squibb | #47 |
| risk recurrent | #48 |
| travel risk | #48 |
| small studies | #48 |
| rivaroxaban compared | #48 |
| intermediate risk risk | #48 |
| thrombotic burden | #48 |
| factors rivaroxaban | #48 |
| subcommittee | #48 |
| patients acute dvt | #48 |
| recurrence venous thromboembolism | #48 |
| elevated plasma levels | #48 |
| fondaparinux heparin | #48 |
| thromboprophylactic | #48 |
| diagnosis physicians | #48 |
| daiichi | #48 |
| patients pulmonary | #48 |
| enoxaparin | #49 |
| vte diagnosis | #49 |
| lowmolecularweight heparin lmwh | #49 |
| calf vein | #49 |
| rivaroxaban prevention | #49 |
| levels protein | #49 |
| factor viii deficiency | #49 |
| women aspirin | #49 |
| vitamink antagonists | #50 |
| treatment threshold | #50 |
| dvt diagnosis | #50 |
| acute respiratory insufficiency | #50 |
| thromboembolism aged | #50 |
| transient risk factor | #50 |
| atria patients | #50 |
| prospective diagnostic | #50 |
| cardiac surgery mortality | #50 |
| etexilate | #50 |
| buller | #50 |
| nonselective betablockers | #50 |
| outpatient therapy | #50 |
| intensity treatment | #50 |
| incidence venous thromboembolism | #50 |
| strategies treatment | #51 |
| patients 11 | #51 |
| discrimination model | #51 |
| previous survey | #51 |
| normal perfusion | #51 |
| acenocoumarol | #51 |
| tomography pulmonary | #51 |
| 95 apixaban | #51 |
| global disease | #51 |
| protein deficiencies | #51 |
| factor vte | #51 |
| effects coagulation | #51 |
| vte major bleeding | #52 |
| unnecessarily | #52 |
| 3 month | #52 |
| risk venous thromboembolism | #52 |
| lung scans | #52 |
| doacs vka | #52 |
| inhibitors heparin | #52 |
| lmwh fondaparinux | #52 |
| 1·12 | #52 |
| pdvt | #52 |
| patients comorbid conditions | #52 |
| free thyroxine ft4 | #52 |
| hematologic malignancies patients | #52 |
| apixaban vte | #52 |
| svt patients | #52 |
| cross study | #53 |
| absolute risks | #53 |
| preference patients | #53 |
| patients initially | #53 |
| thromboembolism prevention | #53 |
| 1522 | #53 |
| thrombophilic factors | #53 |
| postthrombotic syndrome | #53 |
| hemostatic balance | #53 |
| versus enoxaparin | #53 |
| suspected venous thromboembolism | #53 |
| 40 daily | #53 |
| 479 patients | #53 |
| reported incidence | #53 |
| warfarintreated patients | #53 |
| acquired risk factors | #54 |
| thromboembolism death | #54 |
| prethrombotic | #54 |
| endocrine disorders | #54 |
| bled score | #54 |
| 034 | #54 |
| male pulmonary embolism | #54 |
| vte mortality | #54 |
| patients obese | #54 |
| patients incidence | #54 |
| familial thrombophilia | #54 |
| chads2 cha2ds2vasc | #54 |
| major bleeds | #54 |
| 378 patients | #54 |
| 2537 | #54 |
| pai1 levels patients | #54 |
| antithrombotic drug | #54 |
| unfractionated heparin | #55 |
| anticoagulants arthroplasty replacement | #55 |
| treatment thresholds | #55 |
| insurances | #55 |
| long term risk | #55 |
| biological pan | #55 |
| compared lmwh | #55 |
| rivaroxaban | #55 |
| unfractionated heparin ufh | #55 |
| legs patients | #55 |
| dosereduction | #55 |
| nondeficient | #55 |
| proximal extent | #55 |
| methods randomized | #55 |
| risk major bleeding | #56 |
| deficiency prevalence | #56 |
| venous outflow obstruction | #56 |
| weight heparins | #56 |
| inr values | #56 |
| reduced capacity | #56 |
| level mortality | #56 |
| vte death | #56 |
| tromboembólica | #56 |
| vitamin warfarin | #56 |
| physicians guidelines | #56 |
| time event | #56 |
| seventh accp conference | #56 |
| preeclampsia hellp syndrome | #56 |
| 20210a | #56 |
| enoxaparin patients | #56 |
| enoxaparin rivaroxaban | #56 |
| major bleeding apixaban | #56 |
| vasopressors | #56 |
| risk factors vte | #57 |
| subsegmental pulmonary | #57 |
| ctscan | #57 |
| inhibitors female humans | #57 |
| calf dvt | #57 |
| levels survival | #57 |
| clinical models | #57 |
| antithrombin iii heparin | #57 |
| malignancy mortality | #58 |
| spiral computed | #58 |
| doacs patients | #58 |
| pharmo | #58 |
| fibrinolysis humans | #58 |
| thrombin activatable | #58 |
| unfractionated heparin patients | #58 |
| ruled | #58 |
| lowmolecular weight heparin | #58 |
| inhibitors female | #58 |
| incidence symptomatic | #59 |
| risk vte | #59 |
| safety warfarin | #59 |
| direct oral | #59 |
| factor generation | #59 |
| mutation prothrombin | #59 |
| heterozygous factor | #59 |
| thrombosis aged | #59 |
| clot lysis time | #59 |
| aventis | #59 |
| acute venous thromboembolism | #59 |
| bias trial | #59 |
| risk periods | #59 |
| risk factors sensitivity | #59 |
| warfarin treatment | #59 |
| anticoagulants treatment | #60 |
| hemorrhage humans | #60 |
| prevalence pulmonary | #60 |
| acute pulmonary embolism | #60 |
| women difference | #60 |
| pulmonary embolism 95 | #60 |
| target inr | #60 |
| awareness risk factors | #60 |
| constans | #60 |
| pediatric venous thromboembolism | #60 |
| fixeddose | #60 |
| 079 95 | #60 |
| atrial fibrillation metaanalysis | #60 |
| long‐term treatment | #61 |
| free thyroxine | #61 |
| month surgery | #61 |
| benzimidazoles dabigatran | #61 |
| dvt 95 | #61 |
| tests prevalence | #61 |
| perfusion ventilation | #61 |
| hypocoagulable | #61 |
| amuse | #61 |
| rosendaal | #61 |
| 3633 | #61 |
| cdr score | #61 |
| association protein | #61 |
| informatizado | #62 |
| human endotoxemia | #62 |
| general practitioners patients | #62 |
| post thrombotic | #62 |
| patients administration | #62 |
| 273 patients | #62 |
| procoagulant state | #62 |
| 250 patients | #62 |
| activated partial | #62 |
| combined contraceptives oral | #62 |
| ttr patients | #62 |
| protein fibrinogen | #62 |
| management anticoagulation | #63 |
| smoking smoking cessation | #63 |
| women mutations | #63 |
| symptoms dvt | #63 |
| revised geneva score | #63 |
| common odds ratio | #63 |
| vte thromboprophylaxis | #63 |
| cvrs | #63 |
| treatment network | #63 |
| physicians predictive | #63 |
| quantitative test | #63 |
| injection endotoxin | #63 |
| venous thromboembolisms | #63 |
| rivaroxaban lmwh | #63 |
| factor leiden risk | #63 |
| 33 women | #63 |
| dvts | #64 |
| prior vte | #64 |
| patients aortic valve | #64 |
| postthrombotic | #64 |
| oral thrombin | #64 |
| vkas treatment | #64 |
| decision rules | #64 |
| heparin fondaparinux | #64 |
| thrombophilic risk | #64 |
| bleeding events patients | #64 |
| blinded trial | #64 |
| cancer noncancer patients | #64 |
| superficial vein | #64 |
| acute pulmonary | #64 |
| factor inhibitors | #64 |
| selfadjustment | #64 |
| ultrasonograms | #65 |
| accuracy diagnostic tests | #65 |
| stroke thromboembolism | #65 |
| prothrombin g20210a mutation | #65 |
| fvl vte | #65 |
| prevalence abnormalities | #65 |
| treatment pad | #65 |
| risk factor thrombosis | #66 |
| statin therapy risk | #66 |
| newer anticoagulants | #66 |
| elfa | #66 |
| axa | #66 |
| death classification | #66 |
| female heparin | #66 |
| 95 bleeding | #66 |
| 0 points | #66 |
| dvt sensitivity | #66 |
| rapid triage | #66 |
| standard therapy patients | #67 |
| patients tertiles | #67 |
| atrial fibrillation stroke | #67 |
| apixaban | #67 |
| rate major | #67 |
| 1127 | #67 |
| patients factor | #67 |
| perioperative blood | #68 |
| academic medical centre | #68 |
| 05 95 | #68 |
| 1894 | #68 |
| fibrinolytic | #68 |
| coagulation fibrinolysis | #68 |
| patients benefits | #68 |
| ranging study | #68 |
| 20210g | #68 |
| patients bnp levels | #68 |
| 3594 | #68 |
| suspected | #69 |
| recurrent thrombosis patients | #69 |
| heparin ufh | #69 |
| ionis | #69 |
| justify | #69 |
| thrombosis blood | #69 |
| postphlebitic | #69 |
| enfermedad tromboembólica | #69 |
| certoparin | #69 |
| plasma interleukin | #69 |
| patients protein | #70 |
| mantelhaenszel | #70 |
| ischemic events patients | #70 |
| test patients | #70 |
| aged predictive | #70 |
| fixed dose | #70 |
| 8190 | #70 |
| major bleeding complications | #70 |
| cutoff levels | #70 |
| elevated cardiac | #70 |
| α2ap | #70 |
| withhold | #70 |
| thrombosis recurrence | #70 |
| rivaroxaban treatment | #70 |
| vwfrco | #70 |
| gramnegative sepsis | #70 |
| levels vwf | #71 |
| topic costs | #71 |
| tests prospective | #71 |
| vte vka | #71 |
| clopidogrel placebo | #71 |
| plasminogen plg | #71 |
| asymptomatic atherosclerosis | #71 |
| thromboprophylaxis | #71 |
| unfractionated | #71 |
| diagnostic sensitivity specificity | #71 |
| pooled rate | #72 |
| hf studies | #72 |
| trifurcation | #72 |
| antithrombin iii iii | #72 |
| complications hematologic | #72 |
| versus vitamin | #72 |
| new anticoagulant | #72 |
| patients lmwh | #72 |
| ddimer values | #72 |
| activation prothrombin | #72 |
| overt hypothyroidism | #72 |
| elevated factor | #72 |
| viia factor | #72 |
| reversal agent | #73 |
| 12 months 95 | #73 |
| prolongations | #73 |
| noacs | #73 |
| soluble fibrin | #73 |
| tomography spiral | #73 |
| analysis diagnostic | #73 |
| ingelheim | #73 |
| ddimer measurement | #73 |
| experimental metastasis | #74 |
| longterm risk | #74 |
| prethrombotic state | #74 |
| dvt study | #74 |
| 1732 | #74 |
| 2550 | #74 |
| proteins patients | #74 |
| carriers | #74 |
| 5395 | #74 |
| soluble thrombomodulin | #74 |
| study selection | #74 |
| female hemorrhage | #74 |
| suspected dvt | #74 |
| 2124 | #74 |
| incidence bleeding events | #75 |
| thrombolytic therapy patients | #75 |
| 1334 | #75 |
| carotid femoral arteries | #75 |
| 8492 | #75 |
| postoperative dvt | #75 |
| 2904 | #75 |
| retrospective follow | #75 |
| selective factor | #75 |
| tests primary | #76 |
| factor xii deficiency | #76 |
| angiography ctpa | #76 |
| early time | #76 |
| risk thrombosis | #76 |
| oral combined contraceptives | #76 |
| extended anticoagulation | #76 |
| combined contraceptives | #76 |
| duration thromboprophylaxis | #76 |
| p023 | #77 |
| individual patient | #77 |
| thrombosis pregnancy | #77 |
| social aspects | #77 |
| boehringer | #77 |
| patients secondary | #77 |
| women thrombophilia | #78 |
| arterial wall thickness | #78 |
| arterial thromboembolism | #78 |
| 20 daily | #78 |
| ipg | #78 |
| female fibrinolysis | #78 |
| unprovoked | #78 |
| elevated dimer | #78 |
| vkas | #79 |
| efficacy agents | #79 |
| suspected acute | #79 |
| humans pulmonary | #79 |
| limulus test | #79 |
| time therapeutic | #79 |
| 2486 | #79 |
| vte fvl | #79 |
| topic heparin | #79 |
| factor adult | #79 |
| sspe patients | #80 |
| vte rate | #80 |
| subhazard ratio | #80 |
| validation models | #80 |
| patient data | #80 |
| thromboembolism incidence | #80 |
| alife | #80 |
| 95 05 | #80 |
| heterozygous deficiency | #80 |
| bleeding mortality | #80 |
| daily bid | #80 |
| suspected cancer | #80 |
| knee arthroplasty patients | #81 |
| vascular events | #81 |
| lmwh vte | #81 |
| weitz | #81 |
| prothrombin complex concentrate | #81 |
| topic risk | #81 |
| test evaluation | #81 |
| outpatient basis | #81 |
| systemic inflammatory | #81 |
| walking distance | #81 |
| heparin prevention | #82 |
| 3month followup | #82 |
| clinical sign | #82 |
| placebo women | #82 |
| common practice | #82 |
| thrombosis thrombophilia | #82 |
| crnmb | #82 |
| thrombolytic drugs | #82 |
| posthoc analysis | #82 |
| 50 micrograms | #82 |
| symptomatic carriers | #82 |
| thrombosis incidence | #82 |
| timeperiods | #82 |
| prospective validation | #82 |
| mammography patients | #82 |
| dimer patients | #83 |
| bleeding women | #83 |
| 2213 | #83 |
| bistro | #83 |
| patients thrombi | #83 |
| elective coronary | #83 |
| 287 | #83 |
| inhibitor dabigatran | #83 |
| inherited thrombophilia | #84 |
| screening humans | #84 |
| diagnostic outcome | #84 |
| heparin treatment | #84 |
| healthcare setting | #84 |
| normotensive patients | #84 |
| inhibitor rivaroxaban | #84 |
| duration therapy | #84 |
| prophylactic dose | #84 |
| asymptomatic dvt | #85 |
| antithrombin iii protein | #85 |
| endotoxins | #85 |
| normal levels | #85 |
| thrombosis svt | #85 |
| anticoagulants antiphospholipid | #85 |
| peripheral vascular diseases | #85 |
| venous thrombosis patients | #85 |
| 10⁶ | #86 |
| dabigatran vka | #86 |
| venovenous hemofiltration | #86 |
| elevated ddimer levels | #86 |
| 4576 | #86 |
| major bleeding warfarin | #86 |
| 75 microg | #86 |
| rhapc | #86 |
| contact activation | #87 |
| acute venous | #87 |
| clinical impact | #87 |
| post‐hoc analysis | #87 |
| avws | #87 |
| ≤50 | #87 |
| obstetric patients | #87 |
| patients 28 | #87 |
| vidas | #87 |
| 95 100 | #87 |
| internist | #88 |
| treatment incidence | #88 |
| cdr | #88 |
| lmwhs | #88 |
| venographic | #88 |
| activation factor | #88 |
| 3319 | #88 |
| treatment statins | #88 |
| washout period | #88 |
| 4 points | #88 |
| aged multicenter | #88 |
| reversal strategies | #89 |
| vte venous thromboembolism | #89 |
| anticoagulants dabigatran | #89 |
| severe hf | #89 |
| adequate treatment | #89 |
| smoking incidence | #89 |
| rates major bleeding | #89 |
| ddimer | #89 |
| unexplained recurrent | #89 |
| tests test | #89 |
| cytokine release | #89 |
| beta blockers | #89 |
| stroke bleeding | #89 |
| costs patient | #89 |
| matisse | #89 |
| ventilation lung | #89 |
| safety noacs | #89 |
| new patients | #90 |
| thrombophilic risk factors | #90 |
| primary thromboprophylaxis | #90 |
| popliteal vein | #90 |
| venous thrombosis risk | #90 |
| vka dabigatran | #90 |
| 2293 | #90 |
| outweighs | #90 |
| fibrinolytic factors | #90 |
| pediatric venous | #90 |
| agents hemorrhage | #91 |
| inconvenience | #91 |
| perfusion ratio | #91 |
| cdrs | #91 |
| thrombosis women | #91 |
| anticoagulants doacs | #91 |
| thromboembolism pregnancy | #91 |
| 60 95 | #91 |
| pyridines pyridones | #91 |
| 20210 | #91 |
| combined clinical | #92 |
| single intravenous | #92 |
| thrombotic disease | #92 |
| prophylaxis incidence | #92 |
| compression patients | #93 |
| rivaroxaban edoxaban | #93 |
| 95 years | #93 |
| scenario analyses | #93 |
| incidence knee | #93 |
| anticoagulation reversal | #93 |
| direct thrombin inhibitors | #93 |
| test result | #94 |
| vte surgery | #94 |
| heparins | #94 |
| children vte | #94 |
| 1027 | #94 |
| hf severity | #94 |
| patients symptomatic | #94 |
| 125 patients | #94 |
| atherogenic lipid | #94 |
| direct oral anticoagulant | #95 |
| viia rfviia | #95 |
| european consensus statement | #95 |
| 2 levels | #95 |
| 6 12 months | #96 |
| randomised crossover study | #96 |
| fondaparinux treatment | #96 |
| efficacy rivaroxaban | #96 |
| symptomatic vte | #96 |
| risk symptomatic | #96 |
| xii deficiency | #96 |
| ddimer level | #96 |
| haemophilia patients | #97 |
| tpa release | #97 |
| invasive testing | #97 |
| abnormal perfusion | #97 |
| pyrazoles pyridones | #97 |
| symptomatic pulmonary embolism | #97 |
| difference rates | #97 |
| fibrin generation | #97 |
| doacs risk | #97 |
| studies evaluated | #97 |
| activated protein apc | #98 |
| major bleed | #98 |
| 2875 | #98 |
| pregnancy postpartum period | #98 |
| simplify | #98 |
| supervised exercise therapy | #98 |
| hypercoagulable | #98 |
| essential thrombocythaemia | #98 |
| 16slice | #98 |
| perfusion scintigraphy | #99 |
| lmwh warfarin | #99 |
| hirudin | #99 |
| probast | #99 |
| risk arterial | #99 |
| acute dvt | #99 |
| 2·0 | #99 |
| unselected | #99 |
| gbd 2010 | #100 |
| doubleblind trial | #100 |
| patient groups | #100 |
| warfarin patients | #100 |
| 3 trials | #100 |
| 1116 | #100 |
| previews | #100 |
| increasing levels | #100 |
| fatty foods | #100 |
| prevention recurrent | #100 |
| aptts | #101 |
| factor viia | #101 |
| morpholines | #101 |
| factor vii factor | #101 |
| 265 patients | #102 |
| venous thromboembolism women | #102 |
| enoxaparin fondaparinux | #102 |
| alternative diagnosis | #102 |
| 40 microg | #102 |
| low pretest probability | #102 |
| pts patients | #102 |
| pregnancy puerperium | #103 |
| 338 | #103 |
| adjudicated | #103 |
| cteph patients | #103 |
| therapeutic consequences | #103 |
| arthroscopic anterior | #103 |
| endogenous thrombin | #103 |
| doppler method | #103 |
| antithrombin iii | #104 |
| separate analyses | #104 |
| apparent increase | #104 |
| diagnostic imaging humans | #104 |
| recurrence women | #104 |
| oral factor | #104 |
| fibrin degradation products | #104 |
| assay variation | #104 |
| absolute increase | #104 |
| term treatment | #104 |
| heparin pregnancy | #104 |
| partial restoration | #104 |
| 7 children | #105 |
| embryo loss | #105 |
| 1089 | #105 |
| conventional therapy patients | #105 |
| chest ray | #106 |
| thrombosis age | #106 |
| hospitalized patients hf | #106 |
| essentials | #106 |
| elevated levels | #106 |
| 2479 | #106 |
| blind double | #106 |
| thromboprophylaxis patients | #106 |
| thrombophilia | #106 |
| fibrinolytic systems | #106 |
| 314 | #106 |
| study total | #106 |
| thromboembolic | #107 |
| survival cancer patients | #107 |
| ddimer levels | #107 |
| topic recurrence | #107 |
| vte risk | #107 |
| definition classification | #107 |
| simplified version | #107 |
| cardiovascular death stroke | #108 |
| post thrombotic syndrome | #108 |
| noncancer patients | #108 |
| specific subgroups | #108 |
| human volunteers | #108 |
| patients cancer | #108 |
| grade 1c | #108 |
| anticoagulants cohort | #109 |
| factor mutation | #109 |
| 500μg | #109 |
| synthetic pentasaccharide | #109 |
| 1235 | #109 |
| thrombin antithrombin | #109 |
| viia | #109 |
| routine coagulation | #109 |
| evaluation studies | #109 |
| embolism treatment | #109 |
| 039 | #109 |
| vka doac | #110 |
| antiplasmin | #110 |
| primary safety | #110 |
| subsequent pregnancy | #110 |
| embolism quality | #110 |
| cancer activity | #110 |
| thrombosis treated | #110 |
| inferiority trial | #110 |
| obstetric complications | #111 |
| negative predictive 100 | #111 |
| siset | #111 |
| anticoagulants biomarkers | #111 |
| humans intermittent | #111 |
| comparison control | #111 |
| predefined | #111 |
| treatment risk factors | #111 |
| risk rivaroxaban | #112 |
| publication anticoagulants | #112 |
| efficacy prevention | #112 |
| epidemiology risk factors | #112 |
| recurrence treatment | #112 |
| topic guidelines | #112 |
| chromogenic | #112 |
| patients ventricular dysfunction | #112 |
| rivaroxaban enoxaparin | #112 |
| thromboembolic diseases | #112 |
| patients 70 | #112 |
| emergency situations | #112 |
| lmwh risk | #113 |
| patients nephrotoxicity | #113 |
| inappropriate treatment | #113 |
| metabolic response | #113 |
| nonionic contrast | #113 |
| heterozygous carriers | #113 |
| 0·0 | #114 |
| cancerassociated vte | #114 |
| postphlebitic syndrome | #114 |
| dialysers | #114 |
| study centre | #114 |
| total knee replacement | #114 |
| patients intermediate | #114 |
| positive predictive values | #115 |
| fibrinogen vwf | #115 |
| 393 | #115 |
| global public | #115 |
| hyperhomocysteinaemia | #115 |
| patients recurrent | #115 |
| vte data | #116 |
| major bleeding 95 | #116 |
| topic dabigatran | #116 |
| heparin warfarin | #116 |
| computed tomography patients | #116 |
| agents heparin | #116 |
| reference standard | #116 |
| effects tnf | #116 |
| anticoagulants arthroplasty | #116 |
| life treatment | #116 |
| women severe preeclampsia | #116 |
| women caesarean | #117 |
| arthroscopies | #117 |
| protein resistance | #117 |
| vte complications | #117 |
| protein inhibitor pci | #117 |
| 2460 | #117 |
| vte children | #117 |
| fibrinolytic parameters | #117 |
| arterial thrombosis patients | #118 |
| 4118 | #118 |
| patients extensive | #118 |
| proximal dvt | #118 |
| 2744 | #118 |
| autopsyconfirmed | #118 |
| patients doac | #119 |
| compared warfarin | #119 |
| humans leg | #119 |
| incidence pulmonary embolism | #119 |
| compression stockings | #119 |
| previous vte | #120 |
| rivaroxaban patients | #120 |
| healthy humans | #120 |
| mortality diseases | #120 |
| dabigatran factor | #120 |
| lactoferrin leukocyte | #120 |
| months follow | #120 |
| acquired deficiency | #120 |
| risk thromboembolism | #120 |
| thrombosis study | #120 |
| thrombocytopenia thrombosis | #121 |
| patients prostatic cancer | #121 |
| studies venous | #122 |
| anti factor | #122 |
| oral hormonal | #122 |
| patients 6 | #122 |
| fatal pulmonary embolism | #122 |
| placebo standard | #123 |
| 100 patients | #123 |
| early dynamics | #123 |
| factor xia | #123 |
| heparin | #123 |
| venous thromboembolism pregnancy | #123 |
| minor bleeding | #123 |
| acute infection | #123 |
| heparin hirudin | #123 |
| statin risk | #124 |
| association level | #124 |
| ft4 levels | #124 |
| thrombophilia pregnancy | #124 |
| treatment data | #124 |
| vte lmwh | #124 |
| atherogenic lipid profile | #124 |
| bayer | #125 |
| skin perfusion | #125 |
| treatment indication | #125 |
| elevated liver enzymes | #125 |
| intravenous heparin | #125 |
| diseases mortality | #125 |
| thromboembolism recurrence | #125 |
| incidence thrombosis | #125 |
| fibrinolysis inhibitor | #125 |
| nonsignificantly | #125 |
| puerperal disorders | #125 |
| peripheral arterial disease | #125 |
| doacs treatment | #126 |
| upper extremity | #126 |
| distal dvt | #126 |
| patients ventilation | #127 |
| patients permanent | #127 |
| marder | #127 |
| thromboprophylaxis lmwh | #127 |
| unacceptably | #127 |
| performance scores | #127 |
| occurrence vte | #127 |
| development vte | #128 |
| resistance apc | #128 |
| venous thromboembolism risk | #128 |
| 50 age | #128 |
| treatment months | #128 |
| direct factor | #128 |
| prevention | #128 |
| patients conventional therapy | #128 |
| elevated biomarkers | #129 |
| ctrough | #129 |
| 060 | #129 |
| riete registry | #129 |
| 1041 | #129 |
| mortality cancer patients | #129 |
| day 10 | #130 |
| 220 | #130 |
| internists | #130 |
| plaster cast | #130 |
| patients episode | #130 |
| hospital discharge records | #130 |
| anticoagulants antithrombins | #130 |
| 194 patients | #130 |
| linear interpolation | #131 |
| pooled incidence | #131 |
| tests specificity | #131 |
| obviating | #131 |
| long‐term clinical outcomes | #131 |
| 05 patients | #131 |
| hypocoagulability | #132 |
| hoc analysis | #132 |
| postpartum period women | #132 |
| rivaroxaban versus | #132 |
| avidin | #133 |
| cha2ds2vasc | #133 |
| 80 anticoagulants | #133 |
| direct inhibitors | #133 |
| started | #133 |
| fxa inhibitors | #133 |
| enoxaparin treatment | #133 |
| risk pad | #134 |
| selectin levels | #134 |
| embolism acute | #134 |
| instituted | #134 |
| rco vwf | #134 |
| pulmonary angiography patients | #134 |
| prevalence dvt | #135 |
| activator plasminogen | #135 |
| anticoagulant prophylaxis | #135 |
| bnp concentration | #135 |
| 0056 | #136 |
| apixaban edoxaban | #136 |
| months anticoagulation | #136 |
| severe pph | #136 |
| east asian patients | #136 |
| followup patients | #136 |
| thrombotic syndrome | #136 |
| clinical prediction | #136 |
| sequential application | #137 |
| 99 patients | #137 |
| factor prothrombin | #137 |
| acquired thrombophilia | #137 |
| phase 3 trials | #137 |
| point‐of‐care | #137 |
| 2283 | #137 |
| diagnostic work | #137 |
| intravascular coagulation dic | #138 |
| enhanced factor | #138 |
| antidote | #138 |
| complete inhibition | #138 |
| studies mortality | #138 |
| bleeding warfarin | #138 |
| national guidelines | #138 |
| 2465 | #139 |
| patients comparison | #139 |
| oral anticoagulant treatment | #139 |
| direct inhibitor | #139 |
| factor viii factor | #139 |
| reproducibility risk | #139 |
| risk fatal | #139 |
| 95 major bleeding | #139 |
| 3 weeks | #139 |
| 12 95 | #140 |
| 80 cohort | #140 |
| distal deep | #140 |
| dvt incidence | #140 |
| human activated | #140 |
| 20 iu | #140 |
| vwf rco | #140 |
| ottawa | #140 |
| 0114 | #140 |
| antidotes | #141 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| active malignancy | #143 |
| jugular veins | #143 |
| escherichia humans | #143 |
| ischaemic events | #143 |
| treatment pulmonary | #143 |
| points 95 | #143 |
| warfarin administration | #143 |
| geneva | #143 |
| doac treatment | #144 |
| topic practice patterns | #144 |
| management vte | #144 |
| fatal pulmonary | #144 |
| pregnancy female humans | #144 |
| compared treatment | #144 |
| postoperative venous | #144 |
| dose rivaroxaban | #145 |
| filters venous | #145 |
| hyperthyroxinemia | #145 |
| serial testing | #145 |
| referred patients | #145 |
| thrombosis model | #145 |
| patient populations | #145 |
| derived microvesicles | #146 |
| protein factor | #146 |
| months treatment | #146 |
| death cancer patients | #146 |
| personal fees | #147 |
| tissue factor pathway | #147 |
| 2076 | #148 |
| acute medical illness | #148 |
| antithrombotic drugs | #148 |
| intention treat | #148 |
| 10 years patients | #148 |
| embolism diagnosis | #148 |
| partial thromboplastin | #148 |
| long‐acting | #148 |
| rebuttal | #148 |
| procoagulant | #149 |
| relevant publications | #149 |
| vte hospitalization | #149 |
| individual patient data | #149 |
| diagnostic score | #149 |
| 0·45 | #149 |
| risk subgroups | #149 |
| thrombocyte | #149 |
| dimer level | #150 |
| humans injections | #151 |
| coagulation dic | #151 |
| additional imaging | #151 |
| enoxaparin unfractionated heparin | #151 |
| patients primary outcome | #152 |
| continuous venovenous | #152 |
| bleeding patients | #152 |
| patient eligibility | #152 |
| longterm treatment | #152 |
| hypercoagulable state | #153 |
| point systems | #153 |
| cardiopulmonary bypass surgery | #153 |
| thrombosis prevention | #153 |
| extracorporeal circuit | #153 |
| bleeding scores | #154 |
| dimer levels | #154 |
| angioplasty patients | #154 |
| active cancer | #154 |
| direct thrombin | #154 |
| thrombosis factor | #154 |
| activity mortality | #154 |
| states venous | #155 |
| tomography patients | #155 |
| warfarin apixaban | #155 |
| curve sensitivity | #155 |
| thromboembolic event | #155 |
| fiia | #155 |
| drug factor | #155 |
| recurrent symptoms | #156 |
| fvl | #156 |
| 09 | #156 |
| vte treatment | #156 |
| coagulant activity | #156 |
| enoxaparin dose | #156 |
| daily oral | #156 |
| patients gastrointestinal | #156 |
| stockings | #156 |
| cross‐sectional survey | #157 |
| increased thrombin | #157 |
| hemodynamically | #157 |
| prophylaxis patients | #157 |
| months chemotherapy | #158 |
| underlying malignancy | #158 |
| duration anticoagulation | #158 |
| dfl | #158 |
| 97 | #158 |
| 2126 | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| 120 minutes | #160 |
| 145 patients | #160 |
| guidelines prevention | #160 |
| children fh | #160 |
| thrombotic disorders | #160 |
| plasma dimer | #160 |
| antithrombotic efficacy | #160 |
| schering | #160 |
| antagonists patients | #161 |
| prophylactics | #161 |
| pvo | #161 |
| 2206 | #162 |
| incidence vte | #162 |
| women time | #162 |
| patients imaging | #162 |
| lysine analogues | #162 |
| increased plasma levels | #163 |
| lmwh therapy | #163 |
| factors bleeding | #163 |
| coagulation blood | #163 |
| 198 patients | #163 |
| imaging test | #163 |
| rates vte | #163 |
| venous thrombus | #163 |
| strain gauge | #163 |
| age comorbidity | #164 |
| 028 | #164 |
| observer variability | #164 |
| justified | #164 |
| inborn humans | #164 |
| subhazard | #165 |
| relatives patients | #165 |
| patients enoxaparin | #165 |
| mutation factor | #165 |
| management venous thromboembolism | #166 |
| phlebography | #166 |
| stockings compression | #166 |
| pravastatin therapy | #166 |
| strategies patients | #166 |
| viii factor | #166 |
| microvascular thrombosis | #166 |
| recurrent thrombosis | #167 |
| 3658 | #167 |
| thrombin venous | #167 |
| ankle brachial abi | #167 |
| current clinical practice | #168 |
| syndrome pts | #168 |
| recurrent acute | #168 |
| cstatistics | #168 |
| cvcs | #168 |
| warfarin | #168 |
| double heterozygosity | #168 |
| treatment 3 months | #168 |
| fold increased | #169 |
| 3 12 | #169 |
| patients infections | #169 |
| postthrombotic syndrome pts | #169 |
| risk profile | #169 |
| preexistent | #169 |
| therapeutic range | #169 |
| cart patients | #170 |
| heavy menstrual bleeding | #170 |
| interobserver agreement | #170 |
| thrombosis cancer | #170 |
| postoperative blood loss | #170 |
| venous thrombotic events | #171 |
| aged algorithms | #171 |
| recombinant factor | #171 |
| adamts‐13 | #171 |
| 57 years | #171 |
| lmw heparin | #172 |
| clinical trials patients | #172 |
| vaginal bleeding | #172 |
| patients blood transfusion | #172 |
| pulmonology | #172 |
| risk factors patients | #172 |
| antifibrinolytic | #172 |
| bleeds | #173 |
| inr | #173 |
| hospitalized medical patients | #173 |
| pulmonary | #173 |
| patients initial | #174 |
| laboratory monitoring | #174 |
| bleeding tendency | #174 |
| arterial occlusions | #174 |
| clinically bleeding | #174 |
| vte common | #175 |
| arterial venous | #175 |
| data control | #175 |
| reocclusion | #175 |
| fragment 1 | #175 |
| prothrombin | #177 |
| picotamide | #177 |
| mitsubishi | #177 |
| 122 | #178 |
| aspirin ticlopidine | #178 |
| short‐ | #178 |
| hyperthyroidism hypothyroidism | #178 |
| intention analysis | #178 |
| concomitance | #179 |
| vte event | #179 |
| baseline day | #179 |
| noninferior | #179 |
| oral female humans | #179 |
| isth | #180 |
| patients deficiency | #180 |
| additional risk factors | #180 |
| ventilation perfusion | #180 |
| thromboplastin time | #180 |
| referral bias | #180 |
| aged partial | #181 |
| testing patients | #182 |
| acute episode | #182 |
| antithrombin | #182 |
| painkillers | #182 |
| hyperhomocysteinemic | #183 |
| 2–4 | #183 |
| patients major | #183 |
| biological variation | #183 |
| antithrombin iii atiii | #184 |
| prognosis pulmonary | #184 |
| treat analysis | #184 |
| 4150 | #184 |
| n110 | #184 |
| coagulation factors | #184 |
| pregnancy vte | #184 |
| thromboinflammation | #184 |
| incidental | #184 |
| subsequent diagnosis | #184 |
| risk bleeding | #184 |
| deficient patients | #185 |
| vte age | #185 |
| brain natriuretic | #186 |
| anticoagulated | #186 |
| symptomatic | #186 |
| studies heparin | #186 |
| hemostatic effects | #186 |
| patients intensive units | #186 |
| patients thromboprophylaxis | #186 |
| live birth rate | #186 |
| patients haemophilia | #187 |
| safety apixaban | #187 |
| cutoff level | #187 |
| risk composite | #187 |
| antifibrinolytic agents | #187 |
| humans international | #188 |
| ratio inr | #188 |
| prevalence cancer | #188 |
| 926 | #188 |
| doacs vkas | #188 |
| spontaneous rupture | #188 |
| absolute rate | #188 |
| clinical validity | #189 |
| heparin administration | #189 |
| fibrinolysis | #189 |
| viia female | #189 |
| blood loss patients | #189 |
| 64slice | #189 |
| riete | #189 |
| willebrand factor antigen | #189 |
| patients netherlands | #189 |
| ischemic event | #190 |
| current views | #190 |
| anticoagulant drugs | #190 |
| thrombosis patients | #190 |
| ccus | #190 |
| score patients | #191 |
| attending physicians | #191 |
| gogh | #191 |
| 07 | #191 |
| venous outflow | #191 |
| acute thrombosis | #191 |
| stroke systemic | #192 |
| 1495 | #192 |
| 058 | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| heparin patients | #194 |
| blood coagulation | #194 |
| 070 | #194 |
| anticoagulation | #194 |
| prothrombin activation | #194 |
| recurrent ischemic events | #195 |
| antixa levels | #195 |
| target range | #195 |
| 65 months | #195 |
| risk major | #195 |
| antagonist treatment | #195 |
| abnormal test | #196 |
| complications cardiovascular | #196 |
| 29 95 | #196 |
| coagulation status | #196 |
| difference treatment | #198 |
| vwf adamts13 | #198 |
| ate | #198 |
| sew2871 | #198 |
| treatment groups patients | #198 |
| vii rfviia | #198 |
| cachectin | #199 |
| patient diagnosis | #199 |
| coagulation monitoring | #199 |
| obese controls | #200 |
| incidence cardiovascular events | #200 |
| screening patients | #200 |
| patients 12 months | #200 |
| thromboembolic disease | #201 |
| validation sets | #201 |
| thrombin factor | #201 |
| patients abnormal | #201 |
| vte incidence | #201 |
| arterial thrombosis | #202 |
| 17 95 | #202 |
| johnson | #202 |
| peritoneovenous | #202 |
| heparin dose | #203 |
| invitees | #203 |
| worldwide survey | #203 |
| symptomatic pad | #203 |
| induced activation | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| thrombophilia risk | #205 |
| stroke systemic embolism | #205 |
| 0 95 | #205 |
| extended thromboprophylaxis | #205 |
| low incidence | #205 |
| period time | #205 |
| data synthesis | #206 |
| fgt | #206 |
| varese | #206 |
| patients anticoagulant therapy | #206 |
| venous ultrasonography | #206 |
| platelet activation patients | #207 |
| cardiologist | #207 |
| objectively | #207 |
| death female humans | #207 |
| fviii | #207 |
| imt patients | #207 |
| 06 | #207 |
| systematic review studies | #207 |
| methods consecutive | #207 |
| algorithms anticoagulants | #207 |
| desogestrel | #207 |
| patients hypothyroidism | #208 |
| thrombocythaemia | #208 |
| bleeding compared | #208 |
| free protein | #209 |
| deficiency risk | #209 |
| women frequency | #210 |
| hirudins | #210 |
| tgt | #210 |
| antixa activity | #210 |
| ioxaglate | #211 |
| toxaemia | #211 |
| systemic embolism patients | #211 |
| stocking | #211 |
| anticoagulation management | #212 |
| atrial fibrillation study | #212 |
| heparitin sulfate | #213 |
| plasminogen activator activity | #213 |
| topic practice | #214 |
| correct interpretation | #214 |
| dabigatran dose | #214 |
| studies rivaroxaban | #215 |
| current developments | #215 |
| factors vte | #215 |
| standard duration | #215 |
| thrombin inhibition | #215 |
| deamino | #216 |
| betatg | #216 |
| community hospital | #216 |
| duplex venous | #216 |
| warfarin stroke | #216 |
| diagnostic algorithm | #217 |
| mildest | #217 |
| undergoing total | #217 |
| obviates | #217 |
| studies difference | #217 |
| cstatistic | #218 |
| plasminogen activator inhibitor | #218 |
| conclusive evidence | #218 |
| g20210a | #218 |
| npv 100 | #218 |
| deamino arginine | #219 |
| cancer | #219 |
| 077 95 | #219 |
| patients cart | #219 |
| vii factor | #220 |
| hip replacement surgery | #220 |
| viii female | #220 |
| techniques female | #220 |
| data extraction | #220 |
| postoperative vte | #221 |
| preventive measures | #221 |
| hmvec | #221 |
| healthy human subjects | #221 |
| heparin humans | #221 |
| apc resistance | #222 |
| vte events | #222 |
| proximally | #222 |
| engl | #223 |
| 1 january | #223 |
| substantial proportion | #223 |
| pulmonologists | #223 |
| 1541 | #223 |
| thromboendarterectomy | #224 |
| topic factor | #224 |
| protein pathway | #224 |
| subsequent cancer | #224 |
| neoplasms prospective | #225 |
| balloon coronary anticoagulants | #225 |
| org | #225 |
| kruskalwallis | #225 |
| thrombosis warfarin | #225 |
| inr monitoring | #226 |
| 16 95 | #226 |
| extremity amputation | #226 |
| vascular events patients | #226 |
| 0·67 | #226 |
| tests diagnosis | #227 |
| acute medical | #227 |
| 35 ± | #227 |
| haemostasis | #227 |
| mild hyperhomocysteinemia | #228 |
| ipe | #228 |
| cgp | #229 |
| scant | #229 |
| dalteparin | #229 |
| residual thrombus | #229 |
| advocated | #230 |
| 037 | #230 |
| thiazoles | #231 |
| ft4 | #231 |
| habitual abortion | #231 |
| patients discontinuation | #231 |
| equinox | #231 |
| urosepsis | #231 |
| 6 studies | #231 |
| resource utilisation | #231 |
| major orthopaedic surgery | #231 |
| severe preeclampsia | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| endogenous thrombin potential | #233 |
| surgical embolectomy | #233 |
| dimer | #233 |
| anticoagulant effects | #233 |
| cancer prevalence | #233 |
| humans netherlands | #233 |
| recurrence risk factors | #233 |
| effective alternative | #234 |
| doac | #235 |
| prothrombotic state | #235 |
| graduated compression | #235 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| humans meta | #236 |
| myocardial infarction 95 | #237 |
| oral anticoagulants | #237 |
| treatment continuation | #237 |
| predictive tests | #238 |
| 6500 | #238 |
| 009 | #238 |
| patients vkas | #238 |
| crossover study | #239 |
| factor viii fviii | #239 |
| anticoagulants aspirin | #239 |
| rational approach | #239 |
| factor tnf | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| aspirin heparin | #241 |
| hip knee arthroplasty | #241 |
| 045 | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| patients intermittent claudication | #243 |
| pivotal trials | #243 |
| prothrombin fragment | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| thrombogenesis | #246 |
| vte cases | #246 |
| children neonates | #246 |
| casecontrol | #246 |
| warfarin aged | #247 |
| antithrombotic | #247 |
| 23 95 | #247 |
| lipoproteina levels | #247 |
| anti activity | #248 |
| coronary anticoagulants | #248 |
| treatment compared | #248 |
| committees | #248 |
| patients solid tumours | #248 |
| diagnostic models | #249 |
| bleeding rates | #249 |
| multiple comorbidities | #249 |
| score risk | #249 |
| protein risk | #250 |
| fv leiden | #250 |
| ischemic strokes | #250 |
| ioxaglic | #250 |
| finalized | #251 |
| patients contraindications | #251 |
| microthrombosis | #251 |
| 8595 | #251 |
| vkas doacs | #252 |
| simplification | #252 |
| somit | #252 |
| thrombin thrombosis | #253 |
| incidence | #253 |
| agents anticoagulants | #254 |
| treatment duration | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| medea | #256 |
| activation humans | #256 |
| haul | #256 |
| clinical utility | #257 |
| bleeding risk | #257 |
| continuous intravenous | #257 |
| q24h | #257 |
| cost‐effectiveness | #257 |
| activity assay | #257 |
| fibrin degradation | #258 |
| ctpa | #258 |
| patient subgroups | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| dvt risk | #260 |
| sspe | #260 |
| heparin dosing | #261 |
| thrombus size | #261 |
| toxicosis | #261 |
| noncarriers | #261 |
| patients hospitalization | #262 |
| risk pulmonary | #263 |
| optimal duration | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| statins risk | #268 |
| endotoxaemia | #268 |
| randomised cross | #269 |
| lysis time | #269 |
| propeptide | #269 |
| relation time | #269 |
| versus aspirin | #269 |
| malignancy patients | #269 |
| discontinuing | #270 |
| single test | #270 |
| exclusion | #270 |
| protein patients | #270 |
| 3·0 | #271 |
| protein apc | #271 |
| hormonal replacement therapy | #271 |
| thrombosis inflammation | #271 |
| platelet serotonin | #271 |
| orthopaedic patients | #271 |
| bleeding patient | #272 |
| clopidogrel ticlopidine | #272 |
| groups levels | #272 |
| patients combination | #272 |
| vte recurrence | #272 |
| ankle brachial | #273 |
| efficacy analysis | #273 |
| risk levels | #274 |
| cleavage sites | #274 |
| months 12 | #274 |
| prevalence pad | #274 |
| parenteral nutrition patients | #275 |
| performance score | #275 |
| international normalized | #275 |
| antithrombotic agent | #276 |
| fourth quartile | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| normalized ratio | #278 |
| imaging sensitivity | #278 |
| dose reduction | #278 |
| blood test | #279 |
| rco | #279 |
| aptt | #279 |
| propositi | #280 |
| exclusion criteria | #280 |
| partial thromboplastin time | #280 |
| obviate | #280 |
| hospitalized medical | #280 |
| intracranial hemorrhage patients | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| diagnostic sensitivity | #283 |
| neutrophil degranulation | #283 |
| puerperal | #283 |
| presentation patients | #283 |
| thyroid diseases | #283 |
| animals anticoagulants | #284 |
| favor | #284 |
| departments | #284 |
| noninferiority margin | #284 |
| test characteristics | #284 |
| outpatient treatment | #284 |
| major orthopaedic | #285 |
| patients apixaban | #286 |
| 2630 | #286 |
| plasma bnp | #286 |
| gentamicin treatment | #286 |
| clinically | #287 |
| patients pancreatic cancer | #287 |
| levels measured | #287 |
| disseminated intravascular | #287 |
| subdistribution | #287 |
| 227 | #288 |
| oral combined | #288 |
| md patients | #288 |
| premature atherosclerosis | #288 |
| vte women | #289 |
| vte rates | #289 |
| substantiation | #289 |
| cvt patients | #289 |
| clot lysis | #289 |
| thrombin time | #290 |
| 0·50 | #290 |
| n59 | #290 |
| extracted data | #291 |
| current clinical | #291 |
| oral contraceptives | #291 |
| carriers mutation | #291 |
| 016 | #291 |
| 1603 | #292 |
| activator inhibitor | #292 |
| willebrand disease vwd | #292 |
| 2 studies | #292 |
| pentasaccharide | #293 |
| plasmin activity | #293 |
| 1000 personyears | #293 |
| patients dabigatran | #293 |
| adverse outcome patients | #293 |
| cardiac troponin ctnt | #294 |
| patients rivaroxaban | #294 |
| tissuetype plasminogen activator | #294 |
| lower extremities | #294 |
| extremity dvt | #295 |
| scenario analysis | #295 |
| 1025 | #295 |
| peripheral vascular | #296 |
| coagulation factor viii | #296 |
| classified | #296 |
| routine monitoring | #297 |
| observer agreement | #297 |
| specificity npv | #298 |
| episode patients | #298 |
| recurrent miscarriage | #298 |
| thrombocytes | #298 |
| patients inr | #299 |
| inferiority | #300 |
| heparitin | #301 |
| 041 | #301 |
| aged neoplasms | #302 |
| 155 patients | #302 |
| subclinical thyroid dysfunction | #302 |
| toxemia | #302 |
| thromboglobulin | #302 |
| 1214 | #304 |
| absolute difference | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| hematologic pregnancy | #310 |
| thrombotic | #310 |
| surgery day | #310 |
| vte pregnancy | #310 |
| 105 patients | #311 |
| percentage points | #311 |
| antithrombins blood | #311 |
| clinical presentation | #311 |
| patients 100 | #311 |
| leg male | #312 |
| 598 | #312 |
| negative reactions | #313 |
| vte 95 | #313 |
| hereditary thrombophilia | #313 |
| obesity risk factor | #313 |
| diagnosis | #314 |
| funding | #315 |
| postpartum haemorrhage | #315 |
| heparin aspirin | #315 |
| cardiologists | #315 |
| puerperium | #315 |
| apixaban versus | #316 |
| therapeutic dose | #316 |
| patients followup | #317 |
| adjudicators | #317 |
| 0·92 | #318 |
| deciding | #318 |
| safety outcomes | #319 |
| failure rates | #319 |
| decision model | #319 |
| bnp levels | #320 |
| patients pregnancy | #320 |
| combined administration | #320 |
| 1731 | #320 |
| influenza infections | #320 |
| catheter thrombosis | #320 |
| ventricular dysfunction patients | #321 |
| difference risk | #322 |
| additional data | #322 |
| patients noacs | #322 |
| intermediate phenotype | #322 |
| peripheral arterial | #324 |
| glaxosmithkline | #324 |
| inrs | #324 |
| mortality odds ratio | #325 |
| convincing evidence | #325 |
| mechanical heart valves | #326 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| pulmonary embolus | #326 |
| clinical | #327 |
| surgery trauma | #327 |
| association vte | #329 |
| incidence bleeding | #331 |
| vitamin administration | #331 |
| pregnancy outcome women | #331 |
| thrombotic event | #331 |
| new oral | #332 |
| embase databases | #333 |
| analysis trials | #333 |
| 95 percent | #333 |
| n69 | #333 |
| incidences | #334 |
| 95 confidence limits | #334 |
| complicate | #334 |
| minor effects | #334 |
| rationale design | #335 |
| fibrillation benzimidazoles | #335 |
| patients healthy volunteers | #335 |
| central venous catheter | #336 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| 035 | #337 |
| 065 | #337 |
| total hip replacement | #337 |
| plethysmographic | #337 |
| recurrent | #337 |
| 2 points | #337 |
| fatal bleeding | #338 |
| outpatient management | #338 |
| coagulation abnormalities | #338 |
| aged netherlands | #338 |
| placebo trials | #339 |
| noacs warfarin | #339 |
| prospective clinical study | #339 |
| 024 | #340 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| activatable | #341 |
| 217 | #341 |
| coagulation markers | #341 |
| noac patients | #342 |
| knee arthroscopy | #342 |
| pretest | #344 |
| patients covid19 infection | #344 |
| antithrombotic strategies | #345 |
| splanchnic vein thrombosis | #345 |
| vte prevention | #345 |
| rfviia | #345 |
| embolisms | #346 |
| diagnosis vte | #346 |
| patients thrombosis | #347 |
| 073 | #347 |
| activated protein resistance | #347 |
| 044 | #348 |
| cochrane central | #348 |
| chads2 | #349 |
| bsf | #349 |
| 2575 | #349 |
| tafia | #350 |
| trousseau | #350 |
| randomized studies | #350 |
| brain predictive | #350 |
| 013 | #351 |
| factor viii | #351 |
| versus warfarin | #351 |
| dermatan sulphate | #352 |
| factor activation | #352 |
| anticoagulants noacs | #352 |
| selection bias | #352 |
| 5075 | #353 |
| relative efficacy | #353 |
| vein | #353 |
| 1590 | #353 |
| oral anticoagulant therapy | #353 |
| aged pulmonary | #354 |
| international normalized ratio | #354 |
| studies diagnostic accuracy | #355 |
| patients gp | #355 |
| protein deficiency | #356 |
| intestinal microbiome | #357 |
| tests prospective studies | #357 |
| post hoc | #357 |
| categorised | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| consensus agreement | #362 |
| treatment risk | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| bleeding rate | #366 |
| topic female | #366 |
| prediction models | #367 |
| infrainguinal | #368 |
| time recurrence | #368 |
| patients 3 | #368 |
| thrombin inhibitor | #369 |
| influenza infection | #370 |
| 6week | #370 |
| patients acl reconstruction | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 803 | #372 |
| 055 | #372 |
| recombinant activated | #373 |
| aprotinin blood | #373 |
| patients svt | #373 |
| knee surgery | #373 |
| clinical suspicion | #373 |
| patients scores | #374 |
| helical computed tomography | #374 |
| human cytomegalovirus infection | #374 |
| subcutaneous | #375 |
| hmb | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| tafi | #381 |
| ethinyloestradiol | #381 |
| antitnf | #382 |
| prefilter | #383 |
| standardized questionnaire | #384 |
| 0·8 | #384 |
| reassessed | #384 |
| multivariate regression analysis | #384 |
| thromboembolic complications | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| conference proceedings | #386 |
| surrogate outcome | #386 |
| bleeding events | #386 |
| antithrombins | #387 |
| sensitivity npv | #387 |
| cumulative incidences | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| safety rivaroxaban | #389 |
| referred | #389 |
| systemic embolism | #389 |
| 880 | #389 |
| vitt | #390 |
| tinzaparin | #390 |
| apixaban warfarin | #390 |
| abi | #391 |
| biosis | #391 |
| increased bleeding | #391 |
| postop | #391 |
| comparison patients | #391 |
| drug prescription | #391 |
| topic female humans | #392 |
| time presentation | #392 |
| patients chest | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| background patients | #394 |
| clinical score | #394 |
| injections intravenous | #394 |
| pulmonary emboli | #394 |
| 007 | #395 |
| popliteal | #396 |
| bleeding event | #396 |
| 95 12 | #396 |
| factors factor | #397 |
| embolic events | #397 |
| hirudins humans | #397 |
| replacement surgery | #397 |
| 665 | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| risk factors asthma | #400 |
| patients risk | #400 |
| echography | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| controversy | #403 |
| dabigatran | #403 |
| increased risk vte | #403 |
| massive pulmonary embolism | #405 |
| thrombolytic agents | #406 |
| treatment patient | #406 |
| 2215 | #406 |
| 075 | #406 |
| factor levels | #408 |
| oral anticoagulant | #408 |
| biologic effects | #410 |
| patients assigned | #411 |
| safety combination | #411 |
| noacs patients | #411 |
| fviii levels | #411 |
| transfusion patients | #412 |
| 20 microg | #412 |
| major risk factor | #412 |
| coagulation patients | #414 |
| euthyroidism | #414 |
| maastricht | #414 |
| hypocortisolism | #415 |
| xii | #415 |
| aged odds | #415 |
| deserve | #416 |
| pai1 levels | #416 |
| dose heparin | #416 |
| intravascular coagulation | #416 |
| 95 10 | #417 |
| data risk | #417 |
| comparable | #417 |
| pretest probability | #418 |
| 95 | #418 |
| carotid femoral | #418 |
| risk factors thrombosis | #419 |
| dermatan | #419 |
| 269 | #419 |
| ototoxicity | #420 |
| xia | #420 |
| fibrillation risk | #421 |
| fibrillation clinical | #422 |
| tests radiography | #422 |
| 2850 | #422 |
| 1989 | #422 |
| fibrinolysin | #423 |
| subanalysis | #424 |
| fviia | #424 |
| prevalence patients | #425 |
| adjunct | #426 |
| cancer cohort | #426 |
| fii | #426 |
| randomised double | #426 |
| activated factor | #427 |
| consecutive | #427 |
| daily practice | #428 |
| excessive bleeding | #428 |
| plg | #428 |
| conferences | #428 |
| prolactin levels | #429 |
| idiopathic myelofibrosis | #429 |
| daily clinical practice | #429 |
| patients testing | #429 |
| undergoing elective | #429 |
| 1904 | #430 |
| rule | #431 |
| heparinoids | #431 |
| bleeding complications | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| firstdegree relatives patients | #436 |
| blood cultures | #436 |
| bolus injection | #437 |
| 059 | #437 |
| prostatic cancer | #439 |
| dose adjustment | #439 |
| composite point | #439 |
| women compared | #439 |
| proven | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| 074 | #442 |
| rate vte | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| 58 | #449 |
| hellp | #449 |
| utrecht | #449 |
| patients parenteral nutrition | #449 |
| 3 12 months | #450 |
| prevalence distribution | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| fatal disease | #453 |
| thrombin generation | #453 |
| aspirin risk | #453 |
| noninvasive tests | #453 |
| placebo day | #454 |
| factor xii | #454 |
| portal blood | #454 |
| 30 40 | #454 |
| 026 | #455 |
| 12week | #455 |
| microthrombi | #455 |
| fviii vwf | #456 |
| dichotomized | #456 |
| squibb | #457 |
| dicumarol | #457 |
| onwards | #457 |
| iii complexes | #458 |
| hazard ratio 95 | #458 |
| anti levels | #458 |
| recommend | #460 |
| plasma lipoprotein | #460 |
| svt | #460 |
| factor fxa | #461 |
| gastrointestinal cancer | #461 |
| curve biomarkers | #462 |
| expert consensus document | #462 |
| hip arthroplasty replacement | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| gp iib | #464 |
| patients values | #464 |
| studies ultrasonography | #464 |
| month follow | #465 |
| diabetes stroke | #466 |
| cancerassociated thrombosis | #466 |
| thrombin formation | #467 |
| accuracy detection | #467 |
| patients nsaids | #468 |
| prophylaxis | #468 |
| intimamedia thickness | #468 |
| bmi≥30 | #469 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| inr patients | #470 |
| roc analysis | #470 |
| 077 | #470 |
| hemihepatectomy | #470 |
| test probability | #470 |
| placebo recipients | #471 |
| hypercoagulability | #472 |
| prophylactic anticoagulation | #472 |
| case control study | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| patients heparin | #475 |
| plethysmograph | #475 |
| 15 95 | #475 |
| intermittent pneumatic | #475 |
| endotoxemia | #475 |
| heterozygote humans | #475 |
| atria | #477 |
| haemophiliacs | #479 |
| 08 | #479 |
| patients score | #479 |
| versus standard | #480 |
| acutely | #481 |
| hit patients | #481 |
| thrombosis cvt | #481 |
| transportability | #482 |
| advisory | #482 |
| 1162 | #482 |
| postoperative blood | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| composite scores | #487 |
| secondary prophylaxis | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| pan troglodytes | #493 |
| p00007 | #493 |
| residual risk | #493 |
| hemophilic | #493 |
| treatment period | #493 |
| new therapy | #493 |
| vcf | #494 |
| activated protein | #495 |
| dose oral | #496 |
| favour | #496 |
| heterozygote | #496 |
| replacement hip arthroplasty | #496 |
| topic risk factors | #497 |
| 271 | #497 |
| risk factors stroke | #498 |
| willebrand disease | #498 |
| blockages | #498 |
| discriminative ability | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| deficiencies | #503 |
| subcategories | #503 |
| ft4 tsh | #503 |
| rapid decrease | #504 |
| patients referred | #505 |
| nondiagnostic | #505 |
| complications pulmonary | #505 |
| 1107 | #505 |
| 310 | #506 |
| net clinical | #506 |
| nonionic | #507 |
| day surgery | #507 |
| oftentimes | #507 |
| inhibitors rivaroxaban | #508 |
| contraceptives | #509 |
| 13 95 | #509 |
| aminocaproates | #509 |
| guidelines diagnosis | #509 |
| coagulation tests | #509 |
| new oral anticoagulants | #510 |
| thrombosis animals | #510 |
| angiography patients | #510 |
| degradation products | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| highintensity | #514 |
| interim analysis | #514 |
| 056 | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| bleeding outcomes | #518 |
| sensitivity diagnosis | #518 |
| protein antithrombin | #518 |
| thrombotic diseases | #518 |
| thrombophilia thrombosis | #518 |
| treatment cancer patients | #519 |
| groups treatment | #519 |
| study sensitivity | #520 |
| duration intensity | #521 |
| 8090 | #521 |
| 1599 | #521 |
| warfarin therapy | #524 |
| general practitioner | #525 |
| fixed doses | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| convincing | #529 |
| 923 | #529 |
| 051 | #529 |
| 378 | #529 |
| fatal | #530 |
| health female | #530 |
| humans postoperative | #531 |
| betaalanine | #531 |
| thrombosis hemostasis | #531 |
| medically patients | #531 |
| ≥50 years | #532 |
| 068 | #532 |
| intensive units icu | #532 |
| thrombosis risk | #532 |
| factor thrombin | #534 |
| therapy cancer | #534 |
| 730 | #536 |
| factor pathway | #537 |
| 449 | #538 |
| humans neoplasms | #538 |
| patients idiopathic | #538 |
| concise | #539 |
| comprehensive search | #539 |
| ddavp | #539 |
| cbo | #539 |
| diagnostic accuracy studies | #540 |
| diagnosis acute | #540 |
| clinical review | #540 |
| conventional treatment | #543 |
| vascular obstruction | #543 |
| thrombotic risk | #543 |
| 234 | #543 |
| patients eligible | #543 |
| bleeding episodes | #543 |
| pad abi | #544 |
| coagulative | #544 |
| 00 | #544 |
| jak2 mutation | #544 |
| prospective cohort study | #545 |
| hellp syndrome | #545 |
| perc | #545 |
| v617f | #545 |
| association statin | #546 |
| screening strategies | #546 |
| prothrombin complex | #547 |
| bureau | #547 |
| primary | #548 |
| 95 difference | #549 |
| overt | #549 |
| adequate | #549 |
| 1103 | #550 |
| reviewers | #550 |
| platelet inhibitors | #550 |
| percent patients | #550 |
| conduction anesthesia | #550 |
| cancer type | #550 |
| day patients | #552 |
| amsterdam | #552 |
| careful | #552 |
| studies sensitivity | #552 |
| 500 patients | #552 |
| management bleeding | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| vivo treatment | #558 |
| 66 patients | #558 |
| factor vii | #558 |
| orthopedic surgery | #559 |
| bleeding time | #559 |
| limulus | #561 |
| patients transfusion | #563 |
| female humans tests | #563 |
| risk development | #563 |
| board directors | #563 |
| appears | #564 |
| hip replacement | #564 |
| anamnesis | #564 |
| increasing risk | #565 |
| hyperfibrinolysis | #565 |
| cardiac troponins | #566 |
| withholding | #566 |
| solid tumours | #566 |
| patients 2 years | #568 |
| n46 | #568 |
| roc curves | #568 |
| levothyroxine | #571 |
| alpha1antitrypsin | #571 |
| aggravation | #572 |
| ctnt | #573 |
| menstrual bleeding | #574 |
| revascularization procedures | #574 |
| cutoff point | #574 |
| major bleedings | #575 |
| women proportion | #575 |
| subcutaneously | #575 |
| progression cancer | #577 |
| patients vka | #578 |
| endothelial barrier | #578 |
| thiophenes | #579 |
| pharma | #579 |
| endotoxin | #579 |
| diagnostic tools | #580 |
| 99 | #580 |
| notice | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| unselected patients | #584 |
| dummy | #584 |
| coagulation disorders | #585 |
| 094 | #585 |
| chondroitin sulfates | #586 |
| major orthopedic surgery | #588 |
| feasibility safety | #588 |
| helminth proteins | #589 |
| beta alanine | #590 |
| malignancy | #590 |
| healthy human | #590 |
| thrombophilias | #590 |
| reversal agents | #590 |
| conventional management | #592 |
| massive pulmonary | #592 |
| doppler ultrasound | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| major hemorrhage | #597 |
| ldf | #597 |
| severe bleeding | #597 |
| replacement knee | #597 |
| patency rates | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| tests sensitivity | #600 |
| loss surgical | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| events occurred | #604 |
| comorbid conditions | #604 |
| clinical characteristics patients | #604 |
| diagnostic studies | #606 |
| 0·3 | #607 |
| initial increase | #607 |
| patients antibodies | #607 |
| activated coagulation | #607 |
| treatment acute | #608 |
| pfizer | #609 |
| arbitrage | #609 |
| tissue factor | #609 |
| airline | #610 |
| benefit risk | #610 |
| 100 years | #610 |
| patients death | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| leg | #615 |
| patients bariatric surgery | #615 |
| reluctant | #615 |
| complications risk | #616 |
| arterial disease | #617 |
| treatment rivaroxaban | #617 |
| occurred | #618 |
| stroke atrial fibrillation | #618 |
| 467 | #618 |
| compared placebo | #620 |
| fh patients | #620 |
| advisory committees | #621 |
| patients elevated | #621 |
| 1002 | #622 |
| sgs | #623 |
| thyrotoxic | #623 |
| thrombocytopenia hit | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| stopped | #626 |
| topic practice guidelines | #626 |
| stroke warfarin | #627 |
| warfarin risk | #628 |
| 66 | #628 |
| women risk factors | #628 |
| 5000 | #628 |
| physical training | #629 |
| diagnostic algorithms | #629 |
| human subjects | #629 |
| referral patients | #629 |
| sanofi | #630 |
| absolute | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| uneventful | #635 |
| outweigh | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 95 allcause mortality | #640 |
| 14 95 | #640 |
| proceedings | #641 |
| study quality | #641 |
| predictive performance | #642 |
| 3050 | #642 |
| neutrophilia | #643 |
| threatening bleeding | #643 |
| association mortality | #647 |
| primary outcome measure | #647 |
| necessitating | #648 |
| studies efficacy | #648 |
| statin treatment | #648 |
| fixed | #651 |
| thrombolysis patients | #651 |
| 036 | #651 |
| organisations | #652 |
| troglodytes | #652 |
| fxa | #653 |
| hemorrhagic stroke | #653 |
| 127 | #655 |
| patients review | #657 |
| 69 | #659 |
| coronary stent implantation | #659 |
| bleeding death | #659 |
| haematoma | #660 |
| tertiles | #661 |
| coagulation proteins | #661 |
| physical examination | #661 |
| clinical presentations | #662 |
| haemophilia | #662 |
| 95 studies | #663 |
| 1028 | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| patients completed | #667 |
| guideline adherence | #667 |
| presence patients | #667 |
| onethird | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| elevated plasma | #673 |
| patients cteph | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| inhibitor 1 | #675 |
| clotting factors | #675 |
| il6 levels | #675 |
| highincome countries | #676 |
| prothrombotic | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| patients bleeding | #692 |
| ambulatory patients | #692 |
| myocardial infarctions | #693 |
| graduated | #693 |
| activator pa | #693 |
| precise mechanisms | #694 |
| composite outcome | #694 |
| administer | #694 |
| intracranial bleeding | #694 |
| 1718 | #695 |
| stroke prevention patients | #696 |
| moyamoya | #696 |
| combined oral contraceptives | #696 |
| difference 95 | #698 |
| participant data | #698 |
| ratio male | #698 |
| episode | #700 |
| compression devices | #700 |
| therapeutic management | #702 |
| diagnostic errors | #702 |
| prothrombin gene | #702 |
| surgery risk | #703 |
| veins venous | #703 |
| patients confirmed | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| directors | #709 |
| clinical expression | #709 |
| starters | #711 |
| medical patients | #712 |
| gastrointestinal bleeding | #712 |
| gynaecology | #712 |
| 048 | #712 |
| radionuclide imaging | #713 |
| 1098 | #714 |
| rate death | #714 |
| neurosurgical patients | #714 |
| intravenous bolus | #715 |
| menstrual period | #716 |
| rivaroxaban stroke | #716 |
| cancer groups | #717 |
| adequately | #717 |
| 10 30 | #718 |
| solid cancer | #718 |
| falsely | #718 |
| plasminogen | #719 |
| reagent kits | #719 |
| pulmonary medicine | #720 |
| pyrazoles pyridines | #721 |
| accp | #721 |
| clinical judgment | #721 |
| nordisk | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| abnormal | #726 |
| follow period | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| diagnostic therapeutic | #728 |
| orthopaedic surgery | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| oral contraception | #733 |
| tumor necrosis factor | #733 |
| relative risk 95 | #734 |
| patients levels | #735 |
| hull | #735 |
| disease pad | #735 |
| clinical prediction rule | #736 |
| atrial fibrillation risk | #736 |
| tests retrospective studies | #736 |
| 6 12 | #739 |
| post hoc analysis | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| 040 | #742 |
| early pregnancy loss | #742 |
| topic predictive | #743 |
| betathromboglobulin | #744 |
| illness time factors | #744 |
| molecular weight | #744 |
| patients 50 years | #746 |
| 285 | #746 |
| etp | #746 |
| antithrombin activity | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| fibrin formation | #754 |
| advisable | #754 |
| primary patients | #755 |
| answer | #756 |
| hf risk | #756 |
| 95 combination | #756 |
| pneumatic compression | #756 |
| 95 risk factors | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| 85 | #759 |
| loe | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| start treatment | #764 |
| cprs | #764 |
| hip surgery | #765 |
| aspirin clopidogrel | #767 |
| risk pregnancy | #767 |
| 689 | #767 |
| 732 | #768 |
| method drug | #769 |
| 566 | #770 |
| relevant | #770 |
| groups patients | #770 |
| baseline values | #772 |
| graft patency | #772 |
| patients criteria | #773 |
| bmi patients | #774 |
| subcutaneous injections | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose intravenous | #778 |
| study groups | #778 |
| dose warfarin | #778 |
| patients 65 years | #778 |
| miscarriage | #779 |
| plasmin generation | #780 |
| thromboembolism prophylaxis | #780 |
| 066 | #780 |
| patients hyperthyroidism | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| general practitioners | #787 |
| cteph | #787 |
| topic disease models | #787 |
| 100 personyears | #787 |
| polypharmacy | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| recombinant tissue | #793 |
| mechanical heart | #793 |
| risk factors risk | #795 |
| inactivators | #795 |
| 047 | #795 |
| patient years | #796 |
| patency | #796 |
| eligible | #797 |
| netherlands | #797 |
| studies prevalence | #797 |
| lupus anticoagulant | #798 |
| femoropopliteal | #798 |
| estrogen therapy | #799 |
| theme | #799 |
| patients lower | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| subclinical | #804 |
| randomized patients | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| fibrillation blood | #806 |
| adverse outcomes patients | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| efficacy patients | #809 |
| hypertension cteph | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| health predictive | #820 |
| irrespective | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| prevention patients | #823 |
| reduction mortality | #823 |
| coc | #824 |
| single administration | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| cardioembolic stroke | #828 |
| gp | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| 93 | #833 |
| myers | #833 |
| antithrombotic treatment | #833 |
| abortion habitual | #835 |
| oral adult | #836 |
| plough | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| multidetector row | #847 |
| 072 | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| 30 patients | #853 |
| pre‐eclampsia | #853 |
| reference method | #853 |
| advanced prostate | #854 |
| clopidogrel aspirin | #855 |
| fibrin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| pyridones | #870 |
| 6 month | #870 |
| individual participant | #872 |
| longterm clinical outcomes | #872 |
| favoring | #873 |
| tasman | #873 |
| thromboembolic pulmonary | #874 |
| imaging reproducibility | #874 |
| targeted inhibition | #874 |
| titles | #875 |
| plasminogen activation | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| dabigatran rivaroxaban | #878 |
| risk thromboembolic | #878 |
| anticoagulants atrial | #879 |
| 57 | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| male mexico | #894 |
| domiciliary | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| documented | #911 |
| patients clinical trials | #911 |
| initially | #912 |
| haemostatic | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| 022 | #918 |
| thromboembolic events | #918 |
| chronic thromboembolic | #919 |
| randomeffects model | #920 |
| standard patients | #920 |
| antagonist oral | #920 |
| loss patients | #921 |
| optimal dose | #921 |
| ultrasound examination | #921 |
| estimate male | #923 |
| practise | #923 |
| study medication | #925 |
| multifactorial disease | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| treatment placebo | #934 |
| wording | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| subgroup patients | #938 |
| 60 patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| women preeclampsia | #944 |
| echocardiographically | #944 |
| stroke atrial | #944 |
| emboli | #945 |
| ssc | #946 |
| predictive values | #946 |
| anticoagulation treatment | #947 |
| extensive disease | #948 |
| knee replacement | #948 |
| diagnostic | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| registro | #956 |
| network metaanalysis | #956 |
| cancer humans | #956 |
| dic | #956 |
| reassuring | #957 |
| venous insufficiency | #957 |
| day1 | #958 |
| efficacy | #958 |
| retropubic | #961 |
| combined oral | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| reference lists | #966 |
| inhibitor1 | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| hoc | #973 |
| antiplatelet | #973 |
| risk allcause mortality | #973 |
| prevalence characteristics | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| female fibrinogen | #976 |
| vascular humans | #976 |
| fvii | #978 |
| false negative | #979 |
| onset aged aged | #980 |
| 50 100 | #980 |
| 071 | #980 |
| early gestation | #984 |
| 426 | #986 |
| randomised trials | #987 |
| prophylactic treatment | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| academic medical center | #992 |
| seminar | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| 226 | #999 |
| aged | #999 |
| justification | #1000 |
| lower extremity | #1000 |
| thromboembolic risk | #1000 |
| tissue type | #1001 |
| rivaroxaban apixaban | #1002 |
| parenteral administration | #1002 |
| eclamptic | #1003 |
| hyperprolactinaemia | #1005 |
| extended | #1005 |
| interleukin 6 | #1005 |
| pyridines | #1006 |
| orthosis | #1007 |
| 50 patients | #1007 |
| easier | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| pounds | #1018 |
| ticlopidine | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| years risk | #1023 |
| cha2ds2 vasc | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| firstdegree relatives | #1030 |
| decision analysis | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| cardiovascular event | #1033 |
| risk hemorrhage | #1033 |
| relatives | #1033 |
| 052 | #1035 |
| graft occlusion | #1037 |
| male netherlands | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| patients severe asthma | #1047 |
| vwf levels | #1047 |
| examiner | #1050 |
| patients massive | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| 221 | #1054 |
| mean±sd | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| coagulant | #1060 |
| birth rate | #1060 |
| 179 | #1060 |
| 610 | #1061 |
| pad | #1061 |
| primary data | #1062 |
| published literature | #1062 |
| false | #1064 |
| 150 | #1065 |
| prekallikrein | #1065 |
| 00008 | #1066 |
| 101 | #1066 |
| live birth | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| register controlled | #1070 |
| 95 increased risk | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| 063 | #1080 |
| advocate | #1080 |
| drawbacks | #1082 |
| longterm therapy | #1087 |
| f1 | #1087 |
| bandages | #1089 |
| stopping | #1095 |
| clarifications | #1095 |
| diagnostic utility | #1096 |
| idarucizumab | #1096 |
| mandated | #1096 |
| 1223 | #1099 |
| 083 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| peptide brain | #1107 |
| clinical protocols | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| bypass grafts | #1116 |
| haemodialysis | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| probands | #1123 |
| resistance factor | #1123 |
| new developments | #1124 |
| advised | #1125 |
| 445 | #1126 |
| new perspectives | #1126 |
| heparininduced thrombocytopenia | #1127 |
| cip | #1127 |
| patients pad | #1128 |
| discretion | #1132 |
| judged | #1132 |
| ≤10 | #1133 |
| statistic | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| superior efficacy | #1141 |
| 635 | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medical records | #1151 |
| medline | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| anticoagulation therapy | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| bristol | #1163 |
| published guidelines | #1163 |
| safety concerns | #1164 |
| intermittent | #1164 |
| stable angina | #1164 |
| hyperhomocysteinemia | #1164 |
| viii | #1164 |
| thromboembolism risk | #1165 |
| age 65 years | #1165 |
| angiogram | #1167 |
| crossover design | #1172 |
| perioperative bleeding | #1172 |
| glucocorticoid treatment | #1172 |
| atherosclerotic disease | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| macroglobulin | #1176 |
| 5 years patients | #1176 |
| analysis studies | #1178 |
| findings patients | #1178 |
| 79 | #1179 |
| conceive | #1181 |
| concealed | #1181 |
| patients obesity | #1182 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| international society | #1199 |
| mandate | #1199 |
| cardiotonic agents | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| quantitative trait locus | #1204 |
| categorized | #1204 |
| 015 | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| multicenter randomized | #1214 |
| pph | #1214 |
| 103 | #1218 |
| patient treatment | #1221 |
| warranted | #1221 |
| scores patients | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| 64 patients | #1224 |
| peak levels | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| sixfold | #1227 |
| blind | #1227 |
| metabolic syndrome patients | #1228 |
| consensus guidelines | #1228 |
| trial background | #1229 |
| peptide hydrolases | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| doubles | #1232 |
| rules | #1232 |
| aspirin | #1234 |
| postoperative hemorrhage | #1238 |
| coronary angiography patients | #1238 |
| milliliter | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| ml1 | #1252 |
| subgroups | #1252 |
| matter lesions | #1252 |
| artery pulmonary | #1254 |
| oral vitamin | #1257 |
| extensive | #1257 |
| search strategy | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| visiting | #1266 |
| entity | #1266 |
| troponins | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| intensive patients | #1274 |
| equally | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| statin users | #1281 |
| 75 years | #1281 |
| routine screening | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| janssen | #1295 |
| perfusion defects | #1295 |
| scan | #1295 |
| hemofiltration | #1297 |
| predictive | #1297 |
| insufficiently | #1298 |
| cardiovascular complications | #1299 |
| low prevalence | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| pf4 | #1303 |
| 61 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| cyproterone | #1312 |
| risk difference | #1312 |
| apoa | #1312 |
| 1st | #1312 |
| adamts13 activity | #1313 |
| tests severity | #1314 |
| 0·7 | #1314 |
| current strategies | #1314 |
| atrial fibrillation | #1316 |
| claudication | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| glycoprotein gpiib | #1325 |
| lipoproteina | #1325 |
| patients coronavirus disease | #1326 |
| vascular diseases | #1329 |
| antibodies monoclonal antibodies | #1329 |
| beneficial | #1329 |
| low moderate | #1330 |
| plasminogen activators | #1330 |
| thyroid disorders | #1330 |
| coagulation cascade | #1331 |
| 6 months patients | #1331 |
| 77 | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| venous catheters | #1342 |
| 91 | #1342 |
| likelihood ratio | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| surgical trauma | #1347 |
| antitrypsin | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| 15 patients | #1359 |
| limb salvage | #1363 |
| vwf | #1363 |
| arsenal | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| 224 | #1385 |
| noninferiority | #1385 |
| dl1 | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| antisense oligonucleotide | #1402 |
| 82 | #1402 |
| equipoise | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| 515 | #1408 |
| categories | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 6 weeks | #1419 |
| thrombotic complications | #1419 |
| 3 6 | #1419 |
| 7 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| university hospitals | #1422 |
| followup data | #1422 |
| ≥55 | #1424 |
| 061 | #1424 |
| daily | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| 096 | #1439 |
| imaging radiopharmaceuticals | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| weight bmi | #1446 |
| drug levels | #1446 |
| outcome studies | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| population patients | #1454 |
| confusion | #1454 |
| aged blood | #1455 |
| platelet factor | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| prevalences | #1473 |
| 1215 | #1473 |
| centrally | #1474 |
| probability | #1477 |
| systemic infection | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| procoagulant activity | #1495 |
| patients control | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| adverse outcome | #1514 |
| growing body | #1514 |
| proximal | #1516 |
| patients 10 | #1520 |
| ganz | #1520 |
| pregnancy postpartum | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| thrombotic events | #1527 |
| contraindicated | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| live births | #1552 |
| patients severe sepsis | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| pfa | #1564 |
| enfermedad | #1564 |
| iii topic | #1565 |
| treatment prevention | #1566 |
| topic | #1566 |
| cushings syndrome | #1568 |
| deficient | #1568 |
| hyperlipoproteinemia type | #1568 |
| 95ci | #1568 |
| aged biomarkers | #1571 |
| plasminogen activator | #1575 |
| 36 | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| thyroid dysfunction | #1586 |
| cocs | #1586 |
| study entry | #1586 |
| activation markers | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| noncancer | #1598 |
| placebo | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| general surgery | #1613 |
| 162 | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| tests reproducibility | #1616 |
| positive effects | #1616 |
| factors tomography | #1616 |
| prospective cohort studies | #1616 |
| postpartum period | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| imaging tomography | #1619 |
| cvd patients | #1619 |
| female hemostasis | #1619 |
| proportion | #1620 |
| 12month followup | #1621 |
| uncertain | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| venous disease | #1632 |
| pa patients | #1632 |
| incidentally | #1632 |
| clinical patients | #1633 |
| fresh frozen plasma | #1633 |
| study outcomes | #1639 |
| double | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| ctni | #1644 |
| stroke prevention | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| 35 years | #1652 |
| ≤4 | #1652 |
| studies data | #1653 |
| thrombin activity | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| disease adult | #1670 |
| homocysteine levels | #1670 |
| thrombi | #1674 |
| inpatient treatment | #1676 |
| daily dosing | #1676 |
| deficiency | #1677 |
| plasma level | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| steroidal anti | #1686 |
| unreliable | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| yielded | #1712 |
| 033 | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| hematologic malignancies | #1720 |
| bronchospasm | #1720 |
| female femoral | #1721 |
| diagnostic evaluation | #1721 |
| mb | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| conference | #1726 |
| 107 | #1726 |
| derived microparticles | #1729 |
| 021 | #1730 |
| volunteer | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| east asian | #1735 |
| clinical scores | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| table | #1745 |
| 691 | #1745 |
| patients ventricular | #1745 |
| profession | #1746 |
| risk cardiovascular events | #1747 |
| hyperinsulinaemia | #1747 |
| turp | #1749 |
| apc | #1749 |
| pselectin | #1750 |
| replacement | #1750 |
| homozygosity | #1750 |
| 128 | #1752 |
| intracranial hemorrhages | #1753 |
| 133 | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| treatment recommendations | #1760 |
| audiometry | #1760 |
| assessor | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| fx | #1764 |
| human insulin | #1764 |
| duplicate | #1769 |
| initial management | #1770 |
| hemorrhage | #1770 |
| arteriosclerosis | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| cardiac troponin | #1794 |
| vascular surgical | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| 95 specificity | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| conjoint | #1819 |
| economic evaluation | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| preference | #1825 |
| screening middle | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| definite | #1837 |
| compressibility | #1837 |
| kaplanmeier estimate | #1838 |
| cushing | #1838 |
| severe sepsis | #1839 |
| central venous | #1842 |
| 1 week | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| thromboses | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| tnf | #1901 |
| extremity | #1901 |
| diagnostic testing | #1901 |
| clt | #1905 |
| plaster | #1906 |
| induced thrombocytopenia | #1906 |
| hazard ratio | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| 868 | #1923 |
| stroke 95 | #1923 |
| 55 years | #1924 |
| biotin | #1924 |
| venous pressure | #1926 |
| trials patients | #1926 |
| μg | #1927 |
| intracranial hemorrhage | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| nonfatal | #1934 |
| glucocorticoid | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| femoral vein | #1950 |
| safety effectiveness | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| investigators | #1962 |
| observer | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| fibrin clot | #1973 |
| 48 hours | #1973 |
| surgical blood | #1973 |
| potent inhibitor | #1976 |
| renewed | #1976 |
| topic clinical trials | #1978 |
| 771 | #1981 |
| hyperaldosteronism | #1981 |
| specificity ultrasonography | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| treatment cancer | #1986 |
| 1·0 | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| drug drug therapy | #1994 |
| cmax | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| 3 months patients | #2000 |
| transient increase | #2000 |
| clinical severity | #2000 |
| 53 | #2003 |
| 7 patients | #2006 |
| pneumonia patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| mongrel | #2017 |
| angina unstable | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| quartiles | #2051 |
| superior vena cava | #2051 |
| inadequately | #2052 |
| 277 | #2053 |
| pregnancy trimester | #2053 |
| controversial | #2055 |
| stent implantation | #2056 |
| adherence guidelines | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| varies | #2063 |
| requested | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| mcnemar | #2074 |
| national institute | #2074 |
| 188 | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| bypasses | #2087 |
| media thickness | #2087 |
| 03 | #2089 |
| versions | #2091 |
| square distribution | #2092 |
| 114 | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| 59 | #2101 |
| desmopressin | #2101 |
| lifetime risk | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 1966 | #2109 |
| 031 | #2109 |
| substantial | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| independently | #2118 |
| unnecessary | #2118 |
| initial | #2119 |
| exists | #2119 |
| development validation | #2120 |
| 11 | #2122 |
| clinicaltrialsgov | #2122 |
| coronary stent | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| topic surveys | #2127 |
| patients cardiovascular disease | #2127 |
| chose | #2129 |
| controlled | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| congress | #2134 |
| protamines | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| live | #2145 |
| clot | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| 674 | #2183 |
| advanced cancer | #2183 |
| giant cell arteritis | #2185 |
| 2 × | #2185 |
| fifty | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| diagnosis differential | #2212 |
| neutrophil elastase | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| hyperthyroidism | #2265 |
| stroke aged | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| setting | #2284 |
| based case | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| tests | #2314 |
| metaanalysis studies | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| humans myocardial | #2324 |
| method female | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| inhibitor | #2344 |
| lacked | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| risk bias | #2375 |
| 099 | #2375 |
| patients active | #2376 |
| predictable | #2377 |
| hemostasis | #2377 |
| acute coronary syndromes | #2379 |
| enrolling | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| protein | #2413 |
| postinjection | #2413 |
| periodicals | #2413 |
| risk estimates | #2414 |
| sphingosine1 | #2415 |
| 22 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| sensitivity 100 | #2426 |
| guidelines | #2426 |
| 0048 | #2430 |
| legs | #2430 |
| 002 | #2430 |
| coagulants | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| comprised | #2469 |
| 477 | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| 648 | #2485 |
| pathway inhibitor | #2485 |
| treatment efficacy | #2489 |
| 829 | #2490 |
| 1015 | #2490 |
| chest | #2493 |
| duration | #2493 |
| 25 | #2495 |
| 616 | #2503 |
| illness tomography | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| drug female humans | #2516 |
| 479 | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| neutrophil extracellular traps | #2521 |
| 463 | #2521 |
| 152 | #2523 |
| accurate diagnosis | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 874 | #2537 |
| 164 | #2537 |
| 0046 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| hydroxyethyl | #2560 |
| hours | #2560 |
| haematology | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| 73 | #2574 |
| humans logistic | #2574 |
| kits | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| translate | #2577 |
| patients total | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| efficacious | #2585 |
| 591 | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| burden disease | #2605 |
| manifest | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| patients 2 | #2608 |
| fatal outcome | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| aviation | #2620 |
| cost analysis | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| chondroitin | #2635 |
| trials rcts | #2635 |
| coincided | #2635 |
| 10 day | #2637 |
| 345 | #2641 |
| attractive | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| c677 | #2662 |
| benzimidazoles | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| iii | #2685 |
| initial dose | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| 594 | #2691 |
| aso | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| predetermined | #2746 |
| 848 | #2746 |
| baseline characteristics | #2747 |
| patients asthma | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| 143 | #2768 |
| management acute | #2768 |
| confounded | #2769 |
| expert consensus | #2772 |
| antithyroid | #2772 |
| alpha animals | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| cirrhosis patients | #2805 |
| reaching | #2805 |
| international | #2809 |
| secondary | #2811 |
| standardized | #2811 |
| embolic | #2812 |
| 406 | #2813 |
| follow studies | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| antiplatelet drugs | #2826 |
| bid | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| recurrence rate | #2835 |
| contacting | #2835 |
| ketoprostaglandin | #2836 |
| helminth | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| post discharge | #2857 |
| new treatment | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| 21 | #2897 |
| systematic review metaanalysis | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| slight | #2903 |
| severe asthma | #2903 |
| feasible | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| leading death | #2917 |
| lowrisk patients | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| 2400 | #2934 |
| risk stratification patients | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 010 | #2960 |
| 270 | #2960 |
| 20 | #2961 |
| followup | #2962 |
| exercise therapy | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| declare | #2984 |
| lecture | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| factors surveys | #3015 |
| antigen levels | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| early recognition | #3025 |
| nested case | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 419 | #3040 |
| 50 years | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| 80 | #3063 |
| nomogram | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| 2 4 | #3076 |
| subsequently | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| angioplasty | #3088 |
| chronic renal failure | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| wallis | #3122 |
| oac | #3122 |
| lifelong | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| 082 | #3142 |
| levels risk | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| idiopathic | #3153 |
| 507 | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| pregnancy women | #3194 |
| diethylstilbestrol | #3194 |
| pacientes | #3197 |
| plasmin | #3198 |
| 945 | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| cancer types | #3219 |
| suggested | #3219 |
| intravenous infusion | #3223 |
| 153 | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| bivalirudin | #3251 |
| 198 | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| reduces | #3330 |
| 465 | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| inpatients | #3344 |
| cerebrovascular disease | #3344 |
| evaluating | #3349 |
| 362 | #3349 |
| spontaneous abortion | #3354 |
| diagnosing | #3354 |
| 273 | #3355 |
| common complication | #3356 |
| diagnosis cancer | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| concluded | #3379 |
| 301 | #3379 |
| humans lower | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| function patients | #3389 |
| calf | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| 553 | #3403 |
| acute treatment | #3403 |
| tunica | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| preventive | #3419 |
| randomisation | #3419 |
| surgical patients | #3420 |
| study risk | #3420 |
| hypothesised | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| cancer metastasis | #3485 |
| antiphospholipid | #3485 |
| increased morbidity | #3486 |
| asymptomatic | #3487 |
| lower leg | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| inhibitors | #3506 |
| treat | #3506 |
| hemorrhagic complications | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| discusses | #3522 |
| confirmed | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| societies | #3541 |
| guidance | #3541 |
| 113 | #3544 |
| gastro | #3551 |
| current practice | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| platelet function | #3619 |
| treated | #3619 |
| platelet activation | #3622 |
| interval | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| kappa | #3629 |
| q3 | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| bypass surgery | #3642 |
| undergo | #3642 |
| homozygote | #3642 |
| p006 | #3645 |
| externally | #3645 |
| occlusions | #3646 |
| 1960 | #3649 |
| 30 | #3649 |
| fibrillation | #3651 |
| interindividual variability | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| pharmacodynamics | #3725 |
| inhibitors humans | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| humans intracranial | #3739 |
| effective | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| randomised | #3754 |
| deterioration | #3754 |
| objectives | #3759 |
| 8 patients | #3762 |
| subgroup analyses | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| 517 | #3778 |
| interpretable | #3778 |
| 483 | #3782 |
| aminoglycosides | #3789 |
| thyroid hormones | #3789 |
| total knee arthroplasty | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| meeting | #3856 |
| irs | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| acquired resistance | #3860 |
| review data | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| cancer survival | #3884 |
| optimisation | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| difference | #3890 |
| 351 | #3890 |
| 184 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| 405 | #3946 |
| case fatality | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| uncontrolled | #3970 |
| risk cancer | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| flying | #3986 |
| unstable | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| introduction | #4045 |
| 296 | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| activation | #4099 |
| indications | #4099 |
| cutoff | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| 2030 | #4171 |
| patients prostate cancer | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 485 | #4212 |
| 411 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 121 | #4226 |
| 289 | #4226 |
| trough | #4229 |
| p0005 | #4230 |
| crosssectional analysis | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| cox regression | #4242 |
| patients mortality | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 102 | #4340 |
| 455 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| potential risk factors | #4350 |
| managed | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| general | #4407 |
| negative | #4407 |
| bowel diseases | #4407 |
| 71 | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| splanchnic | #4417 |
| lacking | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| proband | #4461 |
| cytomegalovirus infection | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| clinical manifestations | #4486 |
| cd18 | #4486 |
| pancreatic cancer | #4487 |
| inadequate | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| activation platelet | #4503 |
| comprises | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| calculating | #4571 |
| cerebrovascular disorders | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| eventually | #4595 |
| gradual | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4000 | #4601 |
| 4 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| vii | #4613 |
| acetylsalicylic acid | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| risks benefits | #4640 |
| hospital costs | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| day | #4680 |
| fh | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| chronic renal | #4775 |
| baseline patients | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| antiplatelet therapy | #4891 |
| total | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| tests prognosis | #4906 |
| preparations | #4906 |
| served | #4910 |
| fmd | #4913 |
| chlamydophila | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| albeit | #4982 |
| orthopedics | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| epoprostenol | #5009 |
| reminder | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| screening test | #5040 |
| 156 | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| regarded | #5089 |
| evaluable | #5089 |
| hip fractures | #5090 |
| relation | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| bay | #5124 |
| vivo studies | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| ischaemic stroke | #5130 |
| 0018 | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| predispose | #5170 |
| 11 patients | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| emergencies | #5233 |
| articles | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| 365 | #5289 |
| pooling | #5289 |
| aware | #5300 |
| thrombus | #5301 |
| 36 patients | #5301 |
| atherogenesis | #5302 |
| urokinase | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| reagent | #5341 |
| acute ischemic stroke | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| schedule drug | #5363 |
| male | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| occurrences | #5490 |
| 247 | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| patient risk | #5497 |
| 260 | #5497 |
| discomfort | #5499 |
| continuing | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| established | #5563 |
| receptor1 | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| reduce risk | #5573 |
| 46 | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| equivalent | #5598 |
| circulating levels | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| 80 years | #5644 |
| reclassification | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| semiquantitative | #5771 |
| milder | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| atrial | #5852 |
| true | #5852 |
| 088 | #5854 |
| attending | #5856 |
| women pregnancy | #5857 |
| 290 | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| reliable | #5894 |
| occurrence | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| premenopause | #5938 |
| revision | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| 43 | #5962 |
| rcts | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| generation | #6160 |
| ffa | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| mortality morbidity | #6228 |
| terminated | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| practitioners | #6273 |
| colleagues | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 135 | #6340 |
| 63 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| factor gene | #6405 |
| roche | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| accuracy | #6501 |
| peripheral artery disease | #6501 |
| incidence risk | #6502 |
| cancer cell | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| 318 | #6524 |
| triiodothyronine | #6524 |
| washout | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| highrisk patients | #6532 |
| cochrane | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| thirteen | #6540 |
| aspirin patients | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| pancreatic neoplasms | #6641 |
| genetic testing | #6641 |
| individual | #6650 |
| complications | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| recognised | #6729 |
| hazard ratios | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| 385 | #6766 |
| body temperature | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| premedication | #6803 |
| reached | #6803 |
| response relationship | #6807 |
| plasma proteins | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| disturbances | #6912 |
| adverse event | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| shock septic | #6995 |
| 222 | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| withdrawal | #7204 |
| 5year | #7204 |
| cardiovascular disease cvd | #7210 |
| acting | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| treatment children | #7250 |
| vldl | #7250 |
| hematocrit | #7255 |
| 199 | #7257 |
| retrospective cohort study | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| modest | #7290 |
| sensitivity analysis | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| pectoris | #7338 |
| ischemic stroke | #7338 |
| 1c | #7352 |
| interleukin6 | #7352 |
| standardised | #7356 |
| p0001 | #7356 |
| myocardial infarction | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| urgently | #7522 |
| angina | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| comorbid | #7578 |
| 191 | #7578 |
| cinahl | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| manufacturer | #7802 |
| 110 | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| hormone replacement | #7828 |
| 31 patients | #7828 |
| label | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| tramadol | #7878 |
| academic | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| 600 | #8051 |
| preventable | #8051 |
| medical | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| investigational | #8141 |
| imaging studies | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| parenteral nutrition | #8204 |
| confidence | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| activated | #8264 |
| 125i | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| postulated | #8338 |
| endothelium vascular | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| absence presence | #8382 |
| 2 years | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| occur | #8415 |
| 28 patients | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| procedures operative | #8463 |
| transient ischemic | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| fish oil | #8624 |
| 15 years | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| hold | #8723 |
| 1 2 | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| practical | #8756 |
| cardiovascular | #8756 |
| endovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| micrograms | #8914 |
| planned | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| signs symptoms | #8945 |
| proportional hazards | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| comprise | #9005 |
| chemoprevention | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| valve prosthesis | #9147 |
| time points | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| dyspnea | #9230 |
| pci | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| positive | #9286 |
| rabbit | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| p0004 | #9355 |
| patients negative | #9355 |
| preceded | #9376 |
| loss | #9378 |
| higher incidence | #9380 |
| 014 | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| primary point | #9638 |
| kidney failure | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| precise | #9817 |
| easily | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| craniotomy | #9839 |
| 212 | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| heterozygotes | #9871 |
| nonhuman primates | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| 2003 | #9941 |
| degradation | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| 12 hours | #9997 |
| pancreatic | #9997 |
| casecontrol studies | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| protective | #10045 |
| obstacles | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| medical therapy | #10213 |
| clinical data | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| dilution | #10336 |
| 032 | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| aorta | #10352 |
| greatly | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| p0003 | #10408 |
| outcome measures | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| circulation | #10432 |
| reductase inhibitors | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| patients age | #10461 |
| priority | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| activity levels | #10489 |
| increased prevalence | #10489 |
| style | #10491 |
| 1991 | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| ray | #10570 |
| patients moderate | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| recurrences | #10583 |
| antisense | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| discriminate | #10697 |
| term | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| ischemic | #11057 |
| neutropenia | #11057 |
| attained | #11062 |
| summarizes | #11062 |
| ethical | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| location | #11108 |
| inability | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| humans kidney | #11281 |
| cerebrovascular | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| occlusion | #11533 |
| placebo treatment | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| baseline | #11624 |
| younger patients | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| thirds | #12057 |
| dietary intake | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| causality | #12208 |
| lung | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| guide | #12540 |
| requires | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| prostatic | #12708 |
| 45 | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| pulmonary hypertension | #13563 |
| accurate | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| pelvic | #13773 |
| explanation | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| risk death | #14033 |
| members | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| focus | #14084 |
| situations | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| min1 | #14391 |
| 6 patients | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| independent predictor | #14787 |
| validity | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| disorders | #15278 |
| drug | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| effectively | #15813 |
| examination | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| severely | #15997 |
| discuss | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| lung neoplasms | #17262 |
| cooperative | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| ventricular function | #18296 |
| metastases | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| gestational | #20050 |
| 2002 | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| elisa | #20562 |
| persistent | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| operative | #21137 |
| attenuated | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| naive | #23767 |
| adverse | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| mass bmi | #27411 |
| commonly | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
レポートを実行します | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| で知られている Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| で知られている Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| で知られている Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| で知られている Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| で知られている Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| で知られている Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| で知られている Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| で知られている Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| で知られている Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| で知られている Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| で知られている Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| で知られている Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| で知られている Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| で知られている Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
のための重要な人々 Pulmonary Embolism
世界のトップコル
Harry Roger Büller:専門家の影響
その概念Harry Roger Büller直接的な影響があります:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:KOLインパクト
他の著者の仕事に関連する概念for which Harry Roger Büller 影響力があります:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
これはあなたのプロフィールですか？ あなたのプロフィールを主張します URLをコピーします プロフィールへのリンクを埋め込みます |